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Traumatic brain injury (TBI) is a devastating disease causing disability and death, and currently there 
are no effective treatments available. Therefore, there is an utmost need to improve our 
understanding of the pathophysiology of TBI and to identify potential therapies that can provide  
neuroprotection after injury. The aims of this thesis were to develop an in vivo and in vitro model of 
TBI, in which to assess the potential neuroprotective effects of an omega-3 polyunsaturated fatty acid 
(PUFAs), docosahexaenoic acid (DHA). 
Method 
The controlled cortical impact (CCI) in vivo model of TBI was optimized and performed in mice. Both a 
behavioural (Morris water maze (MWM) for cognitive deficits) and histological endpoints (astrogliosis,  
lesion size and activated microglia) were used to assess severity and neuroprotective effects of  DHA. 
An in vitro model of mechanical TBI was also set up and optimized. This model employed 3D astrocyte  
cultures obtained from GFP positive rat pups. The CCI impactor from the in vivo studies was used to 
damage the cultures, and at 24 hours, 5 days and 10 days the astrogliosis and cell number was 
measured. 
Results 
The optimization of the in vivo studies demonstrated that at impaction depth of 2.2 mm produced an 
injury that was significantly different to the sham injury, in MWM performance and increased 
astrogliosis. Interestingly, there was an increase in the amount of astrogliosis on the contralateral side 
of the brain. A second study performed using the 2.2 mm injury parameters was performed, where an 
injection of DHA was administered via the tail vein 30 min after injury. The DHA-treated group did not 
demonstrate any neuroprotection compared to the injury-only group. However, there was an increase 
in the amount of astrogliosis in the contralateral hippocampus of the DHA-treat group. 
In the fat-1 studies it was shown that older male mice performed worse in the MWM, that the fat-1 
gene did not confer neuroprotection but did lead to increased astrogliosis.  
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The in vitro study revealed that astrocytes in the lesioned ge ls demonstrated an increase in 
astrogliosis, there was also an increase in the number of cell in the cultures following the lesion. 
Conclusion 
In conclusion, the in vivo model of CCI replicated components of the human TBI including a 
behavioural deficit and pathophysiological changes. Omega-3 PUFAs failed to demonstrate functional  
neuroprotection in this model, but histologically, promoted an increase in reactive astrogliosis. The 
development of a novel in vitro model of focal injury in a 3D culture system, that elicits reactive 
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1 General introduction 
1.1 Traumatic Brain Injury 
Traumatic brain injury (TBI) describes damage caused to the brain parenchyma either from direct 
impact or as a result of indirect external forces (Werner and Engelhard, 2007). Patients can suffer from 
a wide variety of symptoms, including cognitive, motor and sensory dysfunction as well as mood, sleep 
and speech problems. The World Health Organisation (WHO) estimates that by 2020 TBI will be the 
largest cause of death worldwide (WHO, 2006). This global increase in TBI means that there is high 
demand for resources, ranging from intensive care units during the acute stage to rehabilitation during 
the recovery stage, and to social care and housing. There is a personal cost to the patients and their 
family as well as a societal cost due to the loss of future earnings to patients. TBI has recently been 
quoted to cost Europe a staggering £23.9 billion. The UK cost alone is £4.1 billion, for direct (e.g. 
hospital stay, drugs, brain scans) and indirect costs (e.g. loss of earning, loss of productivity, crime) 
associated with TBI (Gustavsson et al., 2011). 
1.1.1 Epidemiology – Public health 
TBI is the largest cause of death and disability in males under 50 years of age (Maas et al., 2008). There 
are numerous ways in which a patient will receive a head injury. The most common causes of a TBI are  
motor vehicle accidents, sporting injuries, as a result of violence or during combat within a war zone. 
These causes are the main reason for the high prevalence of TBI in the young male population. 
However, there have been changes in the epidemiology of TBI due to the ageing population. In recent 
years, there has been an increase in the percentage of TBI sufferers over the age of 60, both male  and 
female (Roozenbeek et al., 2013, Stocchetti et al., 2012). This aging population mainly suffer from TBI 
due to falls. Although there are more co-morbidities in the older age group, there is a greater direct 
and indirect cost to support a younger patient, since they will suffer from lifelong disabilities as a result 
of a TBI.  As well as a change in the age range of patient populations that suffer a TBI, there has also 
been a shift in the geographical epidemiology of TBI, linked to economic development. An increase in 
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the number of motor vehicles in the developing world has seen countries such as India experience 
increasing numbers of TBI (WHO, 2006). 
The large population of TBI patients and the substantial cost of care, both of which are set to rise in 
the coming years, make the treatment of TBI a priority. A greater understanding of the 
pathophysiology of TBI will assist in patient care and help find an effective therapy for TBI. 
1.1.2 Management of human TBI 
There is currently no successful therapy for TBI, so clinicians can only provide supportive and palliative 
care. Several factors have contributed to this absence of treatment. One of the biggest obstacles to an 
efficacious treatment is the heterogeneous nature of the disease. TBI is extremely heterogeneous 
between patients; they differ in severity, brain region affected and may present with various additional 
poly-trauma complications. There are guidelines and protocols for treatment in the immediate and 
acute phase of the injury, and for the ongoing treatment in the chronic phase of the injury (NICE, 
2014). Despite these guidelines, treatment of each patient’s injury  will need to be tailored to the 
individual’s symptoms (NICE, 2014). 
1.1.3 Early phase management 
When patients first arrive at the hospital after a serious incident a doctor will be expected to treat the 
greatest threat to life, which is not always the brain per se that is injured. This may mean that trauma 
surgeons are initially there first to prevent further blood loss, to intubate and help ventilation of  the 
lungs and to treat any internal organ damage, which may be prioritised over the TBI. Nevertheless, 
there will still be an initial evaluation of the TBI, conducted by the emergency room staff or the 
paramedics. 
The initial assessment used is scored using a neurological scale called the Glasgow Coma Scale  (GCS), 
which awards a score out of 15 that correlates with the severity of a patient’s TBI (Table 1.1). The GCS 
criteria are grouped into three categories: eye movement, verbal response and motor response. The 
patient is assessed for all three criteria and awarded a score. Scores below 8 are classified as severe 
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injuries, those between 9-12 are considered to reflect moderate TBI and those equal to or above 13 
are referred to as mild injuries.  
Table 1.1. The Glasgow Coma Scale scoring system. 
Best Eye Response 
 
Spontaneous – blinking at baseline 4 
Opens to verbal command 3 
Opens to pain 2 
None 1 
Best Verbal Response 
 
Oriented 5 
Confused, but able to answer questions 4 
Inappropriate answers, words discernible 3 
Incomprehensible speech 2 
None 1 
Best Motor Response 
 
Obeys commands to movement 6 
Purposeful movement in response to painful stimulus 5 
Withdraws from pain 4 
Abnormal (spastic) flexion 3 
Extensor (rigid) response 2 
None 1 
 
If the GCS is less than 13 on the initial assessment in the emergency room, a patient will receive a 
computerised tomography (CT) scan. The CT scan is used to assess any bleeding or swelling within the 
brain. A neurosurgeon may be called if something on the CT scan is a concern, such as a subarachnoid 
haemorrhage, haematoma or skull fracture. A neurosurgeon may also be called if the patient’s 
condition worsens, i.e. a deterioration in the GCS score since the admission or a persisting coma. As 
well as ongoing assessment of the patient using the GCS, the patient will be observed for any 
additional or changing symptoms, such as seizures or vomiting. The patient’s intracranial pressure wi l l 
also be monitored for any changes using an electronic device that is inserted between the skull and 
the brain or directly into the brain via a bolt, given that raised intracranial pressure is of one the main 
causes of death (Reilly and BUllock, 1997). Depending upon all of these factors, a patient may receive 
neurosurgery or be admitted straight on the intensive care or high dependency units within th e 
hospital, until there are signs of improvement. It is important to note that the GCS has limitations, as 
the scale can be ineffective when the patient is intoxicated, sedated or intubated. 
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1.1.4 Late phase management 
During the late phase (3 months post-injury), a patient will continue to be monitored in order to track 
the progression of the secondary injury and to monitor symptoms. Follow-up rehabilitation i s unique 
to the specific patient’s symptoms and can include one or more of the following: physiotherapy,  
occupational therapy, psychotherapy, and speech therapy. Depending on the injury , a patient may 
have to take medication for ongoing pain, spasticity, hormone replacement and psychiatric reasons 
(NHS, 2016). 
The GCS is used for the initial assessment of the level of consciousness of a TBI patient. There are more 
neurological scales, that are used to assess the ongoing symptoms during a patient’s rehabilitation and 
they can be used to measure the efficacy of new therapies. Three examples of these neurological 
scales include: The Functional Independence Measure (FIM), the Glasgow Outcome Scale (GOS) and 
the Disability Rating Scale (DRS) (Pangilinan, 2015). These tests have been shown to be useful  in the 
prediction of the long term outcome for patients, particularly the GOS, when taken at 3 months post-
injury (King et al., 2005). While being useful to monitor a patient’s progress, these tests can be 
subjective, with a patient reporting their own progress.  
Tracking the evolution of the secondary injury can be done using various imaging techniques. As 
mentioned earlier, CT scans are routinely used in the acute phase after the injury, but are also used to 
monitor the progression of the disease. However, CT scans cannot detect diffuse axonal  injury (DAI) 
(Pangilinan, 2015). Magnetic resonance imaging (MRI) is a more sensitive anatomical imaging method, 
most useful at detecting delayed haematomas and assessing damage to the deep brain structures (e.g. 
basal ganglia and thalami). However, MRI imaging is a more expensive option compared to a CT scan 
and up until 72 hours after injury is no more sensitive than a CT scan at determining anatomical 
changes in the brain after TBI. Other imaging techniques such as single photon emission computed 
tomography (SPECT) and positron emission tomography (PET)  imaging are more rarely used, but can 
be employed to analyse cerebral blood flow and DAI (Lee and Newberg, 2005). 
28 
 
After monitoring of the injury via imaging, the brain pathology can only really be fully characterised by 
a post-mortem examination of the brain. As many patients, particularly those with mild to moderate 
brain injuries, live for years after their injury, our knowledge of the immediate pathology that follows a 
TBI in the human brain is limited. To understand more about the pathology after injury , animal models 
of TBI have been developed. These models help with the investigation of the pathology post-injury and 
in the development of novel therapies for the treatment of TBI.  
1.1.5 Long-term outcomes of TBI 
As a result of a TBI, patients may suffer from persistent and long-term consequences. These may 
include physical impairments (both motor and sensory), sleep disorders, endocrinopathies, cognitive 
dysfunction, psychiatric disorders, pain, seizures and the development of neurodegenerative diseases 
such as dementia (Stocchetti and Zanier, 2016). These long-term consequences require further and 
pro-longed clinical care, observation and treatment. A potential link between TBI and the development 
of dementia, particularly Alzheimer’s disease, has been studied in mild to severe TBI patients , with 
conflicting outcomes (Dams-O'Connor et al., 2013, Rapoport et al., 2008, Lee et al., 2013). In a recent 
retrospective epidemiological study conducted by Gardner and colleagues, they found that those 
patients with a moderate to severe TBI aged 55 years or older had an increased risk of developing 
dementia when compared to non-TBI trauma patients (Gardner et al., 2014).  
In younger TBI patients, repeated exposure to head trauma can cause a progressive 
neurodegenerative disorder known as Chronic traumatic encephalopathy (CTE). This is a relati vely new 
diagnosis, first described by Dr. Bennet Omalu in 2005. His seminal paper details the histopathological  
characteristics and the premortem symptoms of a retired American football player (Omalu et al., 
2005). It suggests that there is a link between the repetitive concussions as suffered by athletes 
playing high-impact contact sports such as rugby and American football , and the development of 
neuropsychiatric symptoms including depression, psychosis, aggression and dementia (DeKosky et al . ,  
2013). The pathology of CTE patients includes diffuse neocortical Aβ plaques and neurofibrillary 
tangles, this is identical to the pathology of the neurodegenerative disease that afflicts boxers, known 
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as dementia pugilistica, the aetiology being the difference between the two (Omalu et al., 2005, 
DeKosky et al., 2013). 
1.2 Pathophysiology of TBI 
The pathophysiology of TBI can be divided into two phases: the primary injury and the secondary 
injury.  
The primary injury is defined as the damage caused during the moment of injury/impact. This is the 
direct damage to the brain parenchyma. The primary injury results in cell death that is caused by the 
impact to the brain, whether it is a shock wave, direct mechanical contact with an object or damage to 
the skull impacting upon the brain tissue. The primary injury phase causes immediate death of the cells 
and tissue beneath the site of impact, which can be associated with skull fractures, haematomas, 
haemorrhage and blood brain barrier (BBB) breakdown. 
The initial cell death leads to a cascade of biochemical, molecular and cellular mechanisms that lead to 
the expansion of the primary area of injury. This evolution of the primary injury site is known as the 
secondary injury and occurs in the minutes, weeks and years following the TBI. This secondary injury is 
the cause of many of the behavioural symptoms suffered by patients and is also the main target for 
potential TBI therapy. The secondary injury phase encompasses numerous different and complex 
processes including: glutamate excitotoxicity, lipid peroxidation, oxidative stress, changes  in 
intracranial pressure, apoptosis, further necrosis, neuronal and axonal damage, activation of the gl ial  
cells and release of inflammatory mediators (Fig.1.1) (Werner and Engelhard, 2007). 
One main focus area for TBI research is to target these processes individually or together as a way of  
limiting the expansion of the secondary injury, thereby limiting the symptoms suffered by the TBI 
patient. There is currently no way of targeting the death caused by the primary injury, which can only 




Figure 1.1 Schematic showing the evolution of the primary injury to the secondary injury following TBI. Adapted from (Reifschneider et 





1.2.1 Biochemical alterations 
1.2.1.1 Glutamate excitotoxicity and intracellular calcium overload 
The process of glutamate excitotoxicity occurs almost immediately after the primary injury has been 
sustained. There are 3 main reasons for the large amounts of excitatory amino acid glutamate to be 
released into the extracellular space after TBI. Firstly, the destruction of cell membranes during the 
primary mechanical damage causes the intracellular glutamate to be released into the extracellular 
space. Secondly, large membrane depolarizations, caused by injury, increase the vesicular re lease of  
glutamate and, thirdly, post-injury energy diminution causes the glutamate transporters of the 
astrocytes to fail, thereby resulting in high levels of glutamate to be left in the synaptic cleft (Walker 
and Tesco, 2013, Yi and Hazell, 2006).  
Glutamate excitotoxicity leads to an increase in intracellular Ca2+, neuronal injury and ultimately 
neuronal cell death. Glutamate activates ionotropic glutamatergic receptors, which leads to an inf lux  
of Na+ and Ca2+ ions; this leads to membrane depolarization and subsequent opening of voltage - 
dependent calcium channels and N-methyl-D-aspartate (NMDA) receptors (Mark et al., 2001). Further 
Ca2+ influx leads to mitochondrial dysfunction, oxidative stress and apoptosis (Walker and Tesco, 
2013). 
1.2.1.2 Oxidative stress and free radical production 
Oxidative stress describes the harm caused by free radicals, which can include damage to the cell 
membrane, proteins and DNA, as well as lipid peroxidation and inhibition of the mitochondrial 
electron transport chain (Abdul-Muneer et al., 2015). Free radicals are molecules with unpaired 
electrons. These unpaired electrons make them highly reactive and, in an attempt to gain an electron, 
they cause damage. There are two main families of free radicals: reactive oxygen species (ROS: e.g . 
superoxide, hydroxyl radical and hydrogen peroxide) and reactive nitrogen species (RNS: e.g. 
peroxynitrite and nitrogen dioxide) (Abdul-Muneer et al., 2015). In normal brain function these free 
radicals are largely neutralised by the endogenous antioxidant system (e.g. superoxide dismutase and 
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glutathione peroxidase). TBI causes an increase in intracellular Ca2+ which activates numerous enzymes 
including phospholipase A2 and nitric oxide synthase (NOS), which in turn increases the production of  
ROS and RNS (Lewén et al., 2000). This large production of free radicals causes the antioxidant system 
to become overwhelmed, causing damage and contributing to the secondary injury pathophysiology. 
1.2.1.3 Lipid peroxidation 
Lipid peroxidation describes the oxidative damage caused to polyunsaturated fatty acids (PUFA ) such 
as linoleic acid (LA), eicosapentaenoic (EPA) acid and docosahexaenoic acid (DHA) as a result of  attack 
by free radicals. Lipid peroxidation is initiated by a ROS-induced hydrogen atom (H+) which gains an 
electron from the PUFA, turning it into a lipid radical which goes on to turn adjacent lipids into lipid 
radicals, thereby propagating a chain reaction of lipid peroxidation (Bains and Hall, 2012). The 
termination step in lipid peroxidation occurs when there is a depletion of substrates and the lipid 
radical reacts with another lipid radical or radical scavenger system (Bains and Hall, 2012). The damage 
to cellular membrane lipids can cause the cell membrane to become irrevocably damaged and the 
products of lipid peroxidation can lead to cell death. 
 
1.2.1.4 Mitochondrial dysfunction 
Oxidative stress and the accumulation of Ca2+ after TBI lead to mitochondrial dysfunction and 
subsequently a reduction in adenosine triphosphate (ATP) production. The excessive influx of Ca 2+ 
triggered by glutamate excitotoxicity overwhelms the Ca2+ buffering performed by the Na+-Ca2+ 
exchanger of the mitochondria. This leads to loss of the mitochondrial membrane potential, an 
increase in ROS production and consequent oxidative damage, to which mitochondrial DNA is 
particularly vulnerable (Prins et al., 2013, Walker and Tesco, 2013, Cheng et al., 2012). Mitochondrial 
dysfunction, in particular permeabilization of the mitochondrial membrane , can trigger cell death 
mechanisms, both necrosis and apoptosis. Mitochondria can trigger the apoptotic pathway e i ther by 
releasing cytochrome c into the cytosol, which causes caspase activation and therefore apoptosis, or in 
a caspase-independent manner, through the release of apoptosis-inducing factor (AIF)  (Cheng et al . ,  
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2012, Lemasters et al., 1998, Lewén et al., 2001). In addition, mitochondrial dysfunction can indirectly 
amplify the extrinsic apoptotic pathway. This extrinsic pathway is discussed in section 1.2.2.2. 
Oxidative stress can cause mitochondrial dysfunction in several ways through the action of ROS . They 
can inhibit the electron transport chain and decrease energy production, cause mutations within the 
mitochondrial DNA, instigate lipid peroxidation on the inner membrane and promote the caspase-
dependent apoptotic pathway (Murphy, 2009). In turn mitochondrial dysfunction can contribute to 
oxidative stress by producing ROS. This leads to a cycle of mitochondrial dysfunctio n and ROS 
production that ultimately ends up in cell death (Starkov, 2008, Lin and Beal, 2006). 
1.2.1.5 Oedema and changes in intracranial pressure 
Brain oedema plays a significant role in the secondary injury of TBI. Two types of oedema have been 
characterized within the brain: vasogenic oedema and cellular oedema (Kempski, 2001, Unterberg et 
al., 2004). Vasogenic oedema refers to the accumulation of water in the extracellular spaces due to the 
breakdown of the BBB. Cellular brain oedema describes the accumulation of intracellular water, which 
occurs due to the failure of cellular membrane ion pumps, causing osmotic movement of water into 
cells. Both vasogenic and cellular oedema lead to an increase in brain volume, thereby increasing ICP. 
Increased ICP adds to the deleterious effect of the secondary injury by reducing cerebral  blood f low, 
causing further hypoxia, which in turn leads to impaired neuronal function and potentially neur onal 
cell death (Michinaga and Koyama, 2015).  
Marmarou and colleagues have shown with MRI that the oedema in patients with severe head trauma 
is predominantly intracellular in nature, but have concluded that both extra- and intracellular oedema 
can lead to increased ICP (Marmarou et al., 2006, Marmarou et al., 2000). Raised ICP is the most 
common cause of death in patients with severe TBI  and monitoring of ICP is part of standard aftercare  
for TBI patients (Romner and Grände, 2013). Currently, oedema in the clinic is treated using osmotic 
diuretics including mannitol or hypertonic saline. These work by drawing fluid into the intravascular 
space via the osmotic gradient, however, due to the systemic nature of these drugs they have several  
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serious side effects including systemic hypotension and renal failure (Walcott et al., 2012). This has led 
to investigations for novel targets to treat oedema.  
Several molecules are involved in the pathogenesis of TBI-induced oedema, including factors that 
affect cellular or BBB permeability such as vascular endothelial growth factors (VEGFs), water channel  
proteins called aquaporins (AQPs) and ion channels including the cation channel SUR1/TRPM4 which is 
upregulated after TBI, leading to cellular oedema (Walcott et al., 2012, Michinaga and Koyama, 2015, 
Zweckberger et al., 2014). Targeting these molecules to treat oedema has been shown to be 
efficacious in animal models of ischaemia and TBI (Michinaga and Koyama, 2015). Antagonism of VEGF 
reduced oedema in mice that received an ischaemia/reperfusion injury , as assessed by MRI (van 
Bruggen et al., 1999). The predominant AQP channel in the brain is the subtype AQP4, found largely on 
the astrocytic endfeet. Igarashi and colleagues found that mice pre -treated with a AQP4 inhibitor 
exhibited less oedema following a focal ischaemia (Igarashi et al., 2011). Thirdly, an existing anti-
diabetic drug, a sulfonylurea inhibitor called glibenclamide, inhibits SUR1, which may inhibi t ce l lular 
oedema (Zweckberger et al., 2014). This range of targets reflects the complex nature by which oedema 
is caused following a TBI. 
 
1.2.2 Cellular alterations 
1.2.2.1 Blood brain barrier disruption 
Mechanical damage to the BBB occurs in the primary injury phase, and disruption of the BBB 
contributes to the secondary injury pathophysiology. The BBB is made up of cerebrovascular 
endothelial cells, joined together by tight junctions, whose role is to safeguard the brain by restricting 
the molecules that can and cannot enter the brain, creating a highly selective and specialised 
environment for normal brain function. However, disruption to the BBB following TBI causes the 
immediate increase in the permeability of this barrier, and otherwise excluded blood borne molecules 
can enter the brain in a uncontrolled manner  (Chodobski et al., 2011). In addition to increasing the 
permeability of the BBB, disruption to the brain vasculature initiates the coagulation cascade, causing 
the aggregation of platelets and clotting factors within the vessels surrounding the contusion area and 
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reducing the pericontusional blood flow (Stein et al., 2002). This reduced cerebral blood flow in the 
pericontusional area mimics that seen in stroke patients; this ischaemia contributes to the secondary 
injury pathology (von Oettingen et al., 2002). 
The disruption of the BBB can both contribute to the secondary injury and be further increased by the 
action of other secondary injury mechanisms such as glutamate excitotoxicity and oxidative stress. 
Glutamate excitotoxicity (as discussed in section 1.2.1.1) describes the rapid release of the 
neurotransmitter glutamate into the extracellular space after TBI. The metabotropic glutamate 
receptors (mGluRs); mGluR1, mGluR4 and mGluR5 have been shown to be expressed by human 
cerebrovascular endothelial cells and activation of these mGluRs by mGluR group I or III agonists 
increased the permeability of these endothelial cells in vitro (Collard et al., 2002). Glutamate 
excitotoxicity can indirectly propagate the damage to the BBB by inducing oxidative stress, through 
activation of NMDA receptors, thereby causing an increase in intracellular Ca2+ and subsequent 
production of large numbers of free radicals (Mark et al., 2001, Lewén et al., 2000). Dempsey and 
colleagues showed that NMDA receptor antagonists reduced the permeability of the BBB in rats at 6 
hours after TBI (Dempsey et al., 2000). Oxidative stress can cause further damage to the BBB. ROS such 
as superoxide ions and hydrogen peroxide, have been shown to increase the permeability of 
endothelial cells (Schreibelt et al., 2007, Pun et al., 2009). This continued disruption to BBB contributes 
to the secondary injury pathophysiology and further expansion of the primary contusion area.      
1.2.2.2 Necrosis and apoptosis 
There are two main types of cell death that occur following a TBI: necrosis and apoptosi s. Necrosis 
describes the rapid and uncontrolled cell death that occurs following a severe focal mechanical injury, 
ischaemia and glutamate excitotoxicity (Werner and Engelhard, 2007). Cells undergoing necrosis lose  
membrane integrity and the nucleus shrinks. The cell membrane ruptures and provokes an 
inflammatory response whereby the cell detritus is cleared. In contrast, apoptosis is a programmed cell 
death mechanism and is highly regulated. The hallmark changes that occur in a cell when undergoing 
apoptosis include membrane budding, chromatin condensation and nuclear fragmentation (Stoica and 
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Faden, 2010). Apoptosis can be initiated by extrinsic pathways, including activation of tumour necrosis 
factor (TNF) and Fas receptors or by intrinsic pathways that involve permeabilization of the 
mitochondrial outer membrane and subsequent release of cytochrome c into the cytosol  (Stoica and 
Faden, 2010, Lewén et al., 2001). Both the intrinsic and extrinsic pathways lead to the activation of the 
cysteine acid-protease caspase 3. It is the caspase-dependent cleavage of specific substrates that 
induces apoptosis (Yakovlev and Faden, 2001). Necrosis is the predominant mechanism of  ce l l death 
immediately following a TBI. Apoptosis follows during the secondary injury and causes the death of 
neurones and glial cells in the perilesional area (Walker and Tesco, 2013, Raghupathi et al., 2000).  
 
1.2.2.3 Neuronal and axonal damage 
In the primary injury, neurones are damaged through direct severing of the axon or through shearing 
forces that cause the axons to stretch. These initial injuries progress during the secondary injury phase 
and can result in further neuronal damage and extensive lesions within the brain. Severing the axon 
immediately halts axonal transport and causes release of all intracellular contents into the 
extracellular space: a main consequence of this is glutamate excitotoxicity (see section 1.2.1.1). Diffuse 
axonal injury (DAI) is a term used to describe the human widespread axonal injury following TBI, 
whereby vulnerable axons, most often the white matter tracts, undergo stretch injury and eventual 
degeneration (Johnson et al., 2013b). The term Traumatic axonal injury (TAI) is used to describe this 
same phenomenon within in vitro or in vivo models of stretch injury (Hill et al., 2016). DAI i s typical ly 
associated with diffuse TBI causes, such as acceleration/deceleration injuries or rotational injuries . 
Both of these occur as a result of motor vehicle accidents or blast trauma. It has been suggested that 
DAI is directly responsible for the loss of consciousness or coma seen in TBI patients (Gennarelli et al . ,  
1982). 
The shearing force can cause axons to stretch, become undulated and misaligned due to  microtubules 
becoming disorganised and buckling (Tang-Schomer et al., 2010). This leads to an impediment of 
axonal transport, subsequent axonal swelling, secondary disconnection and finally to Wallerian 
degeneration (Povlishock, 1992, Johnson et al., 2013b). Besides the initial shearing or mechanical 
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forces, secondary injury cascades can also cause damage to the neurones. The secondary cascades 
that can have a detrimental effect on neurones include mitochondrial dysfunction, oxidative stress and 
lipid peroxidation, inflammation and glial cell activation.  
DAI can occur even in mild TBI, but can only be diagnosed with post-mortem histology. The novel 
neuroimaging technique, diffusion tensor imaging (DTI), may make it possible to examine the extent of 
DAI in a TBI patient. DTI is a type of MRI that measures changes in the speed or direction of the 
diffusion of water molecules within the white matter tracts. DTI measures can provide information on 
tract disorganisation, axonal swelling, loss of neurones, quality of downstream nerve terminals, so 
therefore provide information on connectivity changes in TBI (Irimia et al., 2012, Johnson et al., 
2013b). If combined with MRI, these measures could provide information on the functional 
connectivity of the large networks within the brain, such as those that support cognition, thereby 
allowing for more accurate diagnosis and outcome prediction following TBI (Ham and Sharp, 2012). 
1.2.2.4 Cytoskeletal disruption 
The cytoskeleton is a complex network of proteins that provide the cell with structural support, 
organisation of intracellular contents, and helps to establish the cell’s morphology (Fletcher and 
Mullins, 2010). Underpinning the axonal injury as described above (see section 1.2.2.3) is the 
degeneration of important components required in the axonal cytoskeleton. Cytoskeleton disruption 
following TBI does not exclusively affect neuronal cells but can also affects the glial cells. As 
cytoskeletal proteins are usually absent from the extracellular space, their presence in plasma or 
cerebrospinal fluid (CSF) has been identified as a potential biomarker for TBI.  
The main cytoskeletal proteins in neuronal cells include neurofilaments and microtubules. 
Neurofilaments are a type of intermediate filament that provide structure and stability to the axons of  
neurones, they are heteropolymers that are made from three polarized sidearm subunits attached to a 
central unit that helps to keep the neurofilaments equally spaced apart (Fournier et al., 2015). This 
equal spacing is reduced following neurotrauma, when they become ‘compacted’, due to either 
altered phosphorylation or proteolysis of the sidearm subunits, which has been suggeste d to lead to 
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collapse of the neurofilament network (Pettus and Povlishock, 1996, Siedler et al., 2014). Microtubules 
on the other hand, are involved in the transport of proteins along the length of the axon, they are 
larger in diameter than neurofilaments and more rigid (Fletcher and Mullins, 2010). Under shearing 
forces (section 1.2.2.3), microtubules breakage causes undulations in the axon and eventual 
disassembly of the microtubules (Tang-Schomer et al., 2010).  Disruption of the neurofilament and 
microtubule networks has been linked to the continued, secondary axotomy in the white matter 
tracts, which is part of the DAI cascade (Fournier et al., 2015). 
The intermediate filaments in other CNS cell types are also affected by TBI and change during the 
secondary injury phase. One example that we will focus on within this thesis is the intermediate 
filament glial fibrillary acidic protein (GFAP), which is found predominantly in the glial cell type, 
astrocytes.  Following injury astrocytes exhibit a change in their morphology, they undergo 
hypertrophy as well as proliferation, and in doing so they increase the amount GFAP they express 
(Yang and Wang, 2015). This phenomenon is known as ‘reactive astrogliosis’ and is described in more 
detail in chapter 6.  
1.2.2.5 Glial cell activation 
The glial cells in the brain are more numerous than neuronal cells. The main glial cell populations 
include oligodendrocytes, microglia and astrocytes. These glial cells have several roles in brain function 
including trophic support, mediation of inflammation, myelination and maintenance of the 
extracellular environment. These glial cells present with particular pathophysiological changes 
following TBI, which are summarised below. 
1.2.2.6 Oligodendrocyte pathology 
Oligodendrocytes are the cells within the CNS that are responsible for the myelination of  axons. TBI 
induces apoptosis of oligodendrocytes, which subsequently leads to a decrease in myelination and 
therefore a reduction in axonal saltatory conduction. This demyelination can also leave axons exposed 
to harmful effects of the secondary injury, as well as producing symptoms in TBI patients similar to 
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those seen in demyelinating diseases such as multiple sclerosis (MS), including problems with learning 
and cognition (Fields, 2008).  
Damage to the oligodendrocytes occurs as a result of several of the secondary injury cascades 
including hypoxia, oxidative stress, excitotoxicity and energy deprivation due to mitochondrial 
dysfunction (Dewar et al., 2003, Underhill and Goldberg, 2007, Lyons and Kettenmann, 1998) . 
Oligodendrocytes are prone to the apoptotic cell death pathway. In a study conducted by Lotocki  and 
colleagues,  the apoptotic marker caspase-3 was present in oligodendrocytes in rats as early as 6 hours 
after injury (Lotocki et al., 2011). It has also been suggested that within the glial cell populations, 
oligodendrocytes are most vulnerable to cell death following TBI, as opposed to astrocytes and 
microglia (Lyons and Kettenmann, 1998). 
 
1.2.2.7 Microglial activation 
Microglia are the resident immune cells of the brain and share characteristics with other immune cell s 
of the body, including phagocytosis of foreign bodies and cellular debris, as well as having antigen-
presenting capabilities (Hickey and Kimura, 1988). The microglia are the main instigators of the 
inflammatory cascades that occur after a TBI. Following TBI microglia become ‘activated’ and in doing 
so change from a ramified morphology to a hypertrophic or bushy morphology (Tambuyzer et al., 
2009).  
Microglia in the mature brain become ‘activated’ in response to many molecules or changes in the 
extracellular environment, often signals that suggest the CNS is under threat from an invading 
pathogen or that the brain tissue has become damaged. Microglia are able to become ‘activated’ by a 
wide array of signals, due to the wide range of receptors that they express. These include pathogen 
recognition receptors such as toll-like receptors (TLRs) and NOD-like receptors (NLRs), which recognise 
pathogen-associated molecular patterns (PAMPs) and detect the endogenously produced damage-
induced molecular patterns (DAMPs), also known as alarmins, that are released by damaged and 
stressed cells (Hanisch and Kettenmann, 2007, Loane and Kumar, 2016). Other factors such as ATP, 
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glutamate and cytokines are released by cells damaged due to TBI can also ‘activate’ microglia 
(Domercq et al., 2013). 
 
Figure 1.2 Schematic representation of the activation of microglial cells in response to neuronal 
injury, and the different microglial phenotypes. Damage-induced molecular patterns (DAMP); Tumour 
necrosis factor-α (TNF-α); Interleukin-6 (IL-6); Interleukin-12 (IL-12); inducible Nitric oxide synthase 
(iNOS); Transforming growth factor-β (TGF-β);Interleukin-10 (IL-10). (Loane and Kumar, 2016) 
 
Similarly to other glial cell types in the brain, there are different phenotypes of microglia. These 
become apparent upon activation, when they will adopt either an ‘M1-like’ or ‘M2-like’ phenotype 
(Fig. 1.2). These various phenotypes are believed to have opposing roles in the aftermath of a TBI 
(Karve et al., 2016). The ‘M1’ microglia phenotype is considered to have detrimental effects on the 
surrounding tissue, as they produce pro-inflammatory cytokines such as interleukin-12 (IL-12), express 
inducible NOS (iNOS) and have reduced phagocytosing abilities. In contrast, the ‘M2’ phenotype is 
traditionally seen as the neuroprotective phenotype, due to its production of anti-inflammatory 
cytokines (IL-10) and growth factors (e.g. tumour growth factor -β; TGF-β) (Wang et al., 2013). There i s 
evidence to suggest that the ‘M2-like’ microglia may even promote regeneration and repair within the 
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CNS, by promoting neurogenesis of neural stem cells (NSCs) and remyelination (Butovsky et al . ,  2006, 
Miron et al., 2013). Despite the ‘M2-like’ phenotype exhibiting beneficial effects, it i s not always the 
dominant microglial phenotype in the lesion site following TBI. At different time-points post-TBI,  the 
predominant microglia phenotype varies. There is evidence to suggest that there is an initial increase 
in the ‘M2’ phenotype with a peak at 5-7 days, followed by a dominant ‘M1’ phenotype in the longer 
term (Karve et al., 2016, Jin et al., 2012). The ‘M1-like’ phenotype has been shown to be dominant in 
patients in the months and years following TBI (Johnson et al., 2013a).  
1.2.2.8 Astrogliosis 
Astrocytes have a marked reaction following TBI. This response is referred to as ‘reactive astrogl iosis’  
and reflects changes to the astrocyte morphology, increased proliferation and increased expression of  
the intermediate filament glial fibrillary acidic protein (GFAP) (Sofroniew and Vinters, 2010).  
Astrocytes also migrate towards the lesion site after TBI and are the main cell type to contribute to the 
formation of the glial scar. The glial scar describes a thick border of cells that surrounds the lesion si te  
and acts as a physical barrier, which may although protect the surrounding healthy tissue from the 
damaged necrotic tissue of the primary injury site, but can also act as a barrier to regenerating 
neurones after injury (Sofroniew, 2009). Similar to the microglia, reactive astrocytes are capable of 
having both detrimental and protective roles following a TBI (Laird et al., 2008, Karve et al., 2016). The 
roles of astrocytes following TBI are covered in greater detail in the introduction to chapter 6.   
1.2.2.9 Inflammatory mediators 
Several mediators of inflammation are involved in the secondary injury pathophysiology, including 
cytokines, chemokines and growth factors, which are released by numerous cell types. Two pro—
inflammatory cytokines that are increased after TBI include IL-1β and tumour necrosis factor-α (TNF-α) 
(Abdul-Muneer et al., 2015). IL-1β and TNF-α both contribute to the progression of the tissue damage 
and encourage the recruitment of immune cells and infiltration of peripheral leukocytes, including 
macrophages and T-cell lymphocytes (Lucas et al., 2006, Werner and Engelhard, 2007).  In normal 
brain function TNF-α has important roles in ionic homeostasis and synaptic plasticity. Following TBI 
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there is an increase in the activity of TNF-α, which has been associated with tissue damage and 
neurobehavioral deficits (Longhi et al., 2013, Feuerstein et al., 1994). 
1.3 Potential therapies for TBI 
Currently, there are very few treatment options for TBI patients. With the increasing patient 
population, the substantial cost both socially and economically, there has been a real effort to f ind a 
therapy suitable for the treatment of TBI. A summary of potentially neuroprotective therapeutic 
strategies are presented in Table 1.2. 
1.3.1 Surgery 
Neurosurgical interventions can be one of the first courses of action that may minimise the damage to 
the brain during the secondary injury phase. Surgical interventions are most commonly used to 
monitor or reduce increased ICP. Increased ICP can be caused by hematomas and haemorrhages, 
which can be removed or drained surgically. If the brain tissue has become swollen and increased ICP 
has not been brought under control through alternative therapies, a decompressive craniectomy or 
hemicraniectomy may be performed (Haddad and Arabi, 2012). All the surgical efforts to reduce the 
ICP can help to reduce the negative contribution raised ICP has to the secondary injury cascade, and 
therefore improve the outcome of the patient. However, a study conducted by Cooper and colleagues 
showed that although patients who had undergone decompressive craniectomy surgery saw a 
reduction in ICP, they also scored much lower on the GOS at 6 months (Cooper et al., 2011). 
1.3.2 Neuroprotective strategies  
As discussed in section 1.2, the brain tissue destroyed by the primary injury cannot be rescued. 
However, the multiple secondary injury mechanisms detailed above provide several therapeutic 
targets for the treatment of TBI. Through the prevention of the progression of some of these 
secondary mechanisms, the expansion of the primary injury area can be limited or halted and this 
could lead to a decrease in neurobehavioral symptoms in TBI patients. This strategy of targeting the 
secondary injury mechanisms, can be referred to as neuroprotection. Neuroprotective strategies can 
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be defined as any therapeutic that results in the salvage, recovery or regeneration of the nervous 
system, its cells, structure and function (Vajda, 2002).    
The strategy of neuroprotection is the basis of several therapies that have been used and clinically 
tested for the treatment of several neurodegenerative diseases such as Parkinson’s disease, 
Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In the case of TBI, there are several 
secondary injury mechanisms that if halted may be able to confer neuroprotection. There have been 
many therapeutics designed to have neuroprotective effects following TBI, but very few have made i t 
to clinical trials and currently none have demonstrated significant efficacy in improving neurological  
outcomes following TBI. Several factors may contribute to this lack of success, including clinical trial 
design, the heterogeneity of the TBI patient population and treatment protocols. Also it is worth 
noting that there are multiple contributors to the secondary injury, which might suggest that 
therapeutically targeting just one mechanism may not be enough to confer significant beneficial 
outcomes.  
1.3.2.1 Osmotherapy 
Potential neuroprotective agents targeted at specific secondary injury mechanisms are described here 
and summarised in Table 1.2. Many therapies have been used to target increased ICP, including 
neurosurgery (e.g.decompressive craniectomy). However, neurosurgery is dangerous and is only used 
in patients where death is imminent (Haddad and Arabi, 2012). Raised ICP can cause compression and 
even occlusion of cerebral blood vessels. This can lead to a reduction of cerebral blood flow, which can 
cause hypoxia, neuronal dysfunction and eventually cell death (Michinaga and Koyama, 2015). 
Osmotically active substances have been used to target increased ICP. Osmotherapy works by 
increasing the osmolality of the serum, by introducing a hyperosmolar substance such as hypertonic 
saline (HTS) or mannitol intravenously. These substances cause water from the cells of the brain to 
pass into the vasculature along the osmotic gradient, thereby reducing the fluid in the brain and 
decreasing the ICP.  
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HTS has a high concentration of salt, whereas mannitol is a sugar alcohol solution. Both have been 
shown to reduce ICP following TBI, with neither substance being more efficacious than the other (Ichai  
et al., 2009, Jagannatha et al., 2016, Boone et al., 2015). However, despite these agents reducing ICP, 
neither have been able to improve neurological outcome or reduce mortality in TBI patients in the long 
term (Wakai et al., 2007, Burgess et al., 2016, Walcott et al., 2012, Boone et al., 2015).  
1.3.2.2 Free-radical scavengers 
Targeting free radical species is another strategy by which neuroprotection could be obtained 
following TBI. Free radicals contain an unpaired electron that can cause oxidative stress leading to lipid 
peroxidation and mitochondrial dysfunction. In normal brain function there are molecules that target 
free radicals in order to control the oxidative stress level, but this system is overwhelmed in  TBI. By 
therapeutically increasing the amount of free radical scavenging within the brain, oxidative stress 
could be reduced and the impact of the secondary injury minimised. Polyethylene glycol -conjugated 
superoxide dismutase (PEG-SOD), is an example of such therapy. PEG-SOD converts the oxygen free 
radical, superoxide ion (O2-) into an oxygen molecule (H2O) or hydrogen peroxide (H2O2), thereby 
limiting oxidative stress (Broxton and Culotta, 2016). PEG-SOD was taken to phase II and phase III 
clinical trials, but failed to demonstrate any statistically significant benefit, in improving outcome or 
preventing mortality following TBI (Muizelaar et al., 1993, Narayan et al., 2002). 
1.3.2.3 Glutamate receptor antagonists 
Within minutes of the primary injury, glutamate excitotoxicity is triggered, and this secondary injury 
event goes on to trigger several other cascades and eventually leads to cell death. Therefore, 
antagonists targeting post-synaptic glutamate receptors may be able to suppress the damage caused 
by excessive glutamate release. The NMDA receptor is a glutamate receptor and ion channel, when 
activated by glutamate and glycine binding, the ion channel opens to allow positive ions (e.g. Ca2+ ions) 
into the post-synaptic neurone and thereby propagate excitotoxicity. Dexanabinol is a non-competitive 
NMDA glutamate receptor antagonist, that prevents the NMDA-R ion channel from opening in 
response to glutamate binding, thereby preventing the influx of Ca2+ ions and depolarisation 
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(Feigenbaum et al., 1989). Dexanabinol has been taken to clinical trials for the treatment of TBI. In a 
phase II clinical trial, dexanabinol appeared to reduce the amount of time severe TBI patients 
experienced increased ICP and showed a trend at improving neurological outcome, using the GCS at 3 
and 6 months post-injury (Knoller et al., 2002). However, in a large multicentre phase III cl inical trial , 
no difference in ICP or neurological outcome (as measured by the GOS at 6 months) was seen in 
patients with severe TBI (Maas et al., 2006). 
1.3.2.4 Calcium channel blockers 
One of the main consequences of glutamate excitotoxicity is a large influx of Ca2+ ions into cells. As 
discussed above, the antagonists of the NMDA-R prevent the influx of Ca2+ by preventing activation of  
the ion channel by glutamate. Calcium channel blockers are an alternative to glutamate receptor 
antagonists. Two drugs that block calcium channels are ziconotide (SNX-111) an N-type calcium 
channel blocker) and nimodipine (an L-type calcium channel blocker), both of which have been trialled 
as neuroprotective agents in TBI. 
In experimental head injury in rats, ziconotide reduced mitochondrial dysfunction and appeared to 
have a wide time-window for administration, 15 minutes to 6 hours post-injury (Verweij et al . ,  2000) . 
However, a clinical trial of 160 patients had to be terminated due to the high incidence of mortali ty in 
the ziconotide-treated group when compared to the placebo group, due to the side effect of 
hypotension in these patients (Xiong et al., 2009).  
Nimodipine is an antagonist for the L-type calcium channel blocker that originally appeared to 
demonstrate some improvement in patients with subarachnoid haemorrhage in three randomised 
controlled trials, as reported by a large Cochrane review (Towart and Kazda, 1979, Langham et al., 
2003). Also, results from the Head Injury Trial-3 (HIT-3) trial conducted in 123 patients suggested that 
nimodipine treatment significantly lowered the risk of mortality and disability (Narayan et al . ,  2002) . 
However, the combined results of the clinical trials HIT-1, HIT-2 and HIT-4, showed that nimodipine 
failed to have any beneficial effect in the subgroup of TBI patients that had suffered a subarachnoid 
haemorrhage (Vergouwen et al., 2006).  
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1.3.3 Multifactorial neuroprotective strategies 
As highlighted in the previous sections, many therapeutics with a single mechanism of action against 
one component of the secondary injury cascade, have failed to be efficacious in clinical trials. For this 
reason, many other neuroprotective strategies which have several proposed mechanisms of action, 
have been trialled in TBI.  
1.3.3.1 Hypothermia 
Mild induced hypothermia (MIH) is when a patient’s body temperature is maintained at 32oC-35oC. 
Although MIH has been repeatedly tested for efficacy in TBI in the clinic to reduce ICP, meta-analysis of 
large randomised controlled trials has found that hypothermia has no effect on TBI patient outcome 
and can also cause adverse side effects (Lazaridis and Robertson, 2016, Zhang et al., 2015).  
The hypothesis that underpins hypothermia as a neuroprotective therapeutic strategy, is that many of  
the cellular and molecular cascades that are part of the secondary injury are temperature -sensitive 
(Sahuquillo and Vilalta, 2007). Hypothermia is believed to affect many of the secondary injury 
mechanisms in order to confer neuroprotection. These include reducing the metabolic rate, decreasing 
ICP, reducing oedema formation, supressing the inflammatory response, reducing glutamate 
excitotoxicity and calcium influx (Sahuquillo and Vilalta, 2007). Recently, it has been suggested that 
MIH can induce neuroprotective cold-shock proteins (Wu et al., 2016b). 
Eurotherm3235 was a large multicentre randomized controlled trial that recruited 387 patients from 
2009 through to 2014, in 47 centres, across 18 countries (Andrews et al., 2013). The study focused on 
the effect hypothermia had on reducing ICP after TBI. Preliminary data from this study, suggested that 
MIH reduced ICP in a sample of 17 patients (Flynn et al., 2015). The conclusion from the 
Eurotherm3235 trial was that ICP was reduced with hypothermia, but did not result in improved 
outcomes, when compared to patients that received standard care (Andrews et al., 2015). 
1.3.3.2 Erythropoietin (EPO) 
EPO is a hematopoietic growth factor that controls erythropoiesis and is produced endogenously by 
the kidneys (Foley, 2008). EPO is believed to have a neuroprotective effect in TBI due to its activi ty in 
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several molecular mechanisms involved in the secondary injury (Ponce et al., 2013). EPO has 
demonstrated an antioxidant effect in an in vitro model of neurodegenerative disease, as well as 
attenuating lipid peroxidation in foetal rats (Wu et al., 2007). It has also been suggested that EPO 
exhibits a neuroprotective effect by protecting against glutamate excitotoxicity and reducing oedema 
(Morishita et al., 1997, Kawakami et al., 2000, Gatto et al., 2015).  
EPO has demonstrated efficacy in animal models of TBI, including an improvement in the novel object 
recognition (NOR) cognitive behavioural test in rats after traumatic axonal and hypoxic injury 
(Hellewell et al., 2013). Schober and colleagues also found improvement with EPO treatment in a rat 
model of CCI, whereby EPO-treated rat pups had improved cognition and improved neuronal survival 
and inhibition of caspase-dependent apoptosis (Schober et al., 2014). 
A recent retrospective study investigating the effect of an erythropoiesis stimulating agent (ESA)  that 
acts like EPO, found that treatment with ESA was associated with improved in-hospital survival in 
severe TBI patients (Talving et al., 2010). However, two clinical trials designed to test the efficacy of 
EPO in the treatment of TBI failed to show any efficacy, with the larger of the trials (EPO-TBI) being 
conducted in 27 centres, over 7 countries in 596 patients (Robertson et al., 2014, Nichol et al., 2015a). 
1.3.3.3 Progesterone 
As with hypothermia and EPO, progesterone has been tested as a therapeutic for TBI due to its 
multifactorial targets for neuroprotection. Progesterone is a hormone involved in the regulation of the 
menstrual cycle and pregnancy, that like EPO, is produced endogenously. The basis for the 
administration of the female sex hormone progesterone stems from observations that females recover 
better after experimental TBI (Stein, 2011, Stein, 2015). There is controversy in the literature whether 
gender has an impact on the outcome of TBI (Roof et al., 1993, Groswasser et al., 1998, Farace and 
Alves, 2000). 
In models of rat TBI, progesterone treatment appeared to reduce glutamate excitotoxicity, lipid 
peroxidation and inflammation (Roof et al., 1996, Roof et al., 1997, Shear et al., 2002, Stein, 2011). It is 
also suggested to reduce oedema through changes in the expression of cell membrane water channels, 
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specifically the aquaporin 4 channel (AQP4) (Guo et al., 2006). A functional study has shown that 
progesterone improves rats’ performance in the Morris water maze test following  TBI (Shear et al., 
2002). Importantly, progesterone has also shown efficacy in TBI models of larger species, as wel l as in 
other injury models, resulting in progesterone being taken to clinical trials in human TBI patients 
(Stein, 2011).  
In a phase II clinical trial of 100 patients, entitled ProTECT, TBI patients that received the progesterone 
treatment had a reduced mortality rate at 30 days, with moderate TBI patients more likely to have a 
moderate to good outcome, as measured by the GOS-E (Wright et al., 2007). Based on the data from 
this trial and other phase II trials, in which progesterone treatment had a positive impact on TBI 
patient outcome, phase III clinical trials on progesterone treatment went forward despite having 
incomplete understanding of progesterone’s mechanism of action (Xiao et al., 2008, Vandromme et 
al., 2008). Two large multicentre phase III clinical trials went forward with optimistic hopes for the 
efficacy of progesterone treatment. However, the SyNAPSe phase III trial which was completed in 2014 
failed to show that progesterone treatment had any impact on patients’ GOS-E score 6 months post-
injury (Skolnick et al., 2014). Another larger phase III clinical trial that was conducted in paral le l  with 
the SyNAPSe trial, entitled ProTECT III, was terminated on the basis of not exhibiting any positive 
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(Langham et al., 2003, 
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Results of large scale CRASH 
trial demonstrated that 
treatment with 
corticosteroids led to a 
higher risk of death. 
(Edwards et al., 2005) 
Mannitol Reduces ICP 
Reduces 
Inflammation 
Randomised trials have given 
insufficient data on the  
effectiveness of pre-hospital 
mannitol treatment. 
(Wakai et al., 2007) 
Hypertonic saline Reduces ICP Randomised trials show no 
differences in mortality, 
neurological outcomes, and 
ICP reduction with 
hypertonic saline. 
(Burgess et al., 2016) 
Decompressive 
craniotomy (DC) 
Reduces ICP A phase III randomised trial 
DECRA showed that DC 
decreased intracranial 
pressure but was associated 
with more unfavourable 
outcomes. 
(Cooper et al., 2011) 
Dexanabinol NMDA receptor 
antagonist 
A phase III randomised trial 
showed dexanabinol to be 
safe but not efficacious in 
TBI. 
(Maas et al., 2006) 
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In two large phase III trials 
(SyNAPSe and PROTECT III) 
progesterone treatment did 
not provide any benefit on 
the neurological recovery in 
moderate or severe TBI. 
(Skolnick et al., 2014, 
Meyfroidt and 
Taccone, 2015, 
Schumacher et al., 
2015, Wright et al., 
2014) 
 
1.3.3.4 Polyunsaturated Fatty Acids (PUFAs) 
Several of the potential therapeutics that have been taken to clinical trial s have multiple mechanisms 
of action. Another type of compound that has shown to have some therapeutic potential in 
neurological disorders and neurotrauma, whilst being safe and tolerable in humans, are the omega -3 
polyunsaturated fatty acids (Dyall and Michael-Titus, 2008). The omega-3 PUFAs are the 
neuroprotective compounds under investigation in this thesis. 
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1.4 Polyunsaturated fatty acids - General Introduction 
Fatty acids (FA) are carboxylic acids with long unbranched aliphatic tails, that can be saturated or 
unsaturated. The level of saturation and the various functional groups determine the family  to which 
each fatty acid belongs. Saturated fatty acids contain no double bonds and mono-unsaturated fatty 
acids contain one carbon-carbon double bond (Table 1.3). Fatty acids that contain more than one 
double bond are known as polyunsaturated fatty acids (Fig.1.3 and Table 1.4).  
 
Figure 1.3 Fatty acid structures. A) The saturated FA; Palmitic acid, (B) omega-9 monounsaturated FA; 
Oleic acid, (C) omega-6 poly-unsaturated FA; Arachidonic acid, (D) omega-3 poly-unsaturated FA; 
Docosahexaenoic acid. 
 
PUFAs (Table 1.4) can be further divided into sub-groups according to the position of the first double -
bond from the methyl end of the chain (Fig. 1.3). The two main groups are the omega-3 PUFAs, where 
the first carbon-carbon double bond from the methyl end of the carboxylate is found at the omega -3 







Table 1.3 Types of saturated and mono-unsaturated fatty acids 
 
Table 1.4 Nomenclature of omega-3 and omega-6 PUFAs. 
Type Common Name  Abbreviation No. of 
Carbon 
Atoms 





















Linoleic acid LA 18 2 18:2 n-6 
γ-linoleic acid GLA 18 3 18:3 n-6 
Dihomo-γ-linoleic acid DGLA 20 3 20:3 n-6 
Arachidonic acid AA 20 4 20:4 n-6 
Docosatetraenoic acid DTA 22 4 22:4 n-6  







α-linolenic acid ALA 18 3 18:3 n-3 
Stearidonic acid SDA 18 4 18: n-3 
Eicosatetraenoic acid ETA 20 4 20:4 n-3 
Eicosapentaenoic acid EPA 20 5 20:5 n-3 
Docosapentaenoic acid DPA n-3 22 5 22:5 n-3 
Docosahexaenoic acid DHA 22 6 22:6 n-3 
 
 
1.4.1 Synthesis, metabolism and transport of fatty acids 
Both the saturated and monounsaturated fatty acids can be synthesised de novo in the brain (Bazinet 
and Layé, 2014). The PUFAs, however, cannot be synthesised in the human brain due to the lack of the 
necessary desaturase enzymes, so these fatty acids have to be obtained through the diet. Omega-6 
fatty acids can be found in ready supply in vegetable oils, whereas cold-water oily fish are a rich source 
of omega-3 fatty acids. Long chain PUFAs (LC-PUFA) (20-22 carbon chain) can be obtained directly from 
the diet or can be metabolised from the shorter chain (18 carbon) PUFAs linoleic acid (LA) and α -
linolenic acid (ALA). The conversion of the 18 carbon PUFAs ALA and LA into the 20-22 carbon omega-3 
PUFAs DHA, EPA and the omega-6 PUFA AA, occurs in the liver, through a series of desaturation and 
Type Common Name  Abbreviation No. of 
Carbon 
Atoms 









  Palmitic acid PA 16 0 16:0 




















Oleic acid OA 18 1 18:1 n-9 
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elongation steps, detailed in figure 1.4 (Rapoport et al., 2007, Nakamura and Nara, 2003). Once 
synthesised in the liver long chain PUFAs (LC-PUFAs) are released into the bloodstream, from which 
uptake can occur by the CNS. LC-PUFAs can also gain access to the bloodstream via lipolysis from 
adipocytes, or from the small intestine, where dietary LC-PUFAs are absorbed. Once in the 












In order to gain access to cells, PUFAs have to un-bind (dissociate) from albumin or be separated from 
the lipoprotein via hydrolysis by lipoprotein lipases. The unbound LC-PUFAs can be absorbed into the 
outer leaflet of the plasma membrane. Following absorption, the PUFA must then traverse the plasma 
membrane (Fig. 1.5). There are 3 main ideas as to how this occurs. Firstly, by passive diffusion across 
the membrane, a process known as “flip—flop”, where upon the dissociation of the PUFA from the 
lipoprotein or albumin, it is absorbed into the outer layer and then flip-flopped to the inner membrane 
where it quickly dissociates and is then released into the cytosol. Other proposed methods of  plasma 
membrane transport suggest that the FA is helped across by membrane -associated proteins. Either 
through a transmembrane protein (acting as a channel) or by binding the FA to aid their diffusion 
through the membrane, these proteins are known as fatty-acid binding proteins (FABPs) and may 
include the protein CD36. Recent studies have suggested that CD36 may not be a FA transporter but 
instead aids in the metabolism of FA and transports cholesteryl esters instead (Xu et al., 2013). Figure 
1.5 illustrates the mechanisms by which LC-PUFAs cross the BBB to enter the brain. Recent studies 
have identified the transporter Mfsd2a as a major form of transport of DHA into the brain (Nguyen et 
al., 2014).  
After crossing the BBB (for a detailed description of the BBB and its composition see section 6.1.3.1) 
into the brain, the PUFAs can be activated by the enzyme acyl -CoA synthase to fatty acyl-CoA 
(Watkins, 2008). PUFAs then bind to cytosolic FABPs, which guide the PUFAs to different pathways, 
either for esterification or metabolism (Furuhashi et al., 2011). Activated PUFAs, esterified by acyl-
transferase become incorporated into the phospholipids of the plasma membrane; the LC-PUFAs most 
commonly involved in this way are DHA and AA (Bazinet and Layé, 2014).  Different PUFAs are 
associated with different phospholipids with varying degrees of preference; the half -lives of PUFAs are  
also dependent on the phospholipids to which they are bound (Rapoport, 2001, Rapoport, 1999) . The 
composition of the PUFAs in the phospholipid membrane is important as it can affect the signalling   
pathways  within the cell  (Graber et al., 1994). PUFAs hydrolysed from the phospholipids of the cell 
membrane by the action of phospholipases (e.g. PLA2), are then available to be converted into the 
oxygenated PUFA derivatives, called eicosanoids and docosanoids. Cyclooxygenases (COX) and 
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lipoxygenases (LOX) are responsible for converting the free LC-PUFAs    into  eicosanoids (these include 
prostaglandins, thromboxanes, lipoxins and leukotrienes) and docosanoids (neuroprotectins and 
resolvins) (Tassoni et al., 2008). 
The metabolism of PUFAs, in particularly LNA, ALA and EPA involves undergoing β-oxidation in the 
mitochondria, where they are converted to acetyl-CoA, which can then enter the tricarboxylic acid 
(TCA) cycle. Interestingly, the ATP produced by the β-oxidation of FAs is relatively small  compared to 
that generated by the oxidation of glucose. This low ATP yield and the high amount of oxidative stre ss 
caused by the process of β-oxidation may be the reason for the low level of brain FA β-oxidation 




LC-PUFA enter the plasma through dietary intake, as a result of metabolism in the liver or release from the adipose tissue (1). In the plasma some PUFAs are 
bound to albumin (2), then become unbound in order to cross the luminal plasma membrane of the endothelial cells of the blood brain barrier,  e i ther through 
passive diffusion via the ‘flip-flop’ (3) or via facilitated diffusion through a membrane fatty acid protein (FATP) (4). Other PUFAs travel to the brain in t he plasma 
as lipoproteins, such as low- density lipoprotein (LDL) (5). LDL can bind to specific LDL receptors (LDLR), which can induce endocytosis and cross the plas ma 
membrane (6). Once transferred across the plasma membrane, LDLs can by hydrolysed to release PUFAs (7). Alternatively, LDL interacts with a lipoprotein lipase 
(LPL) to produce a lysophopholipid, which can cross the plasma membrane via facilitated diffusion (8). After crossing the luminal plasma membrane the LC-PUFAs 
can become associated with fatty-acid binding proteins (FABP) (9) and cross the neuronal plasma membrane via facilitated diffusion (10)  or passive transport 
(11). Once inside the cell, LC-PUFAs can be converted into eicosanoids by the enzymes, cyclooxygenase (COX) or lipoxygenase (LOX) (12) . Other LC -PUFAs are  
activated by the enzyme acyl-CoA synthase, to become Acyl-CoA (13). From here they can enter the mitochondria and undergo β-oxidation, where i t can then 
enter the TCA cycle (14), or more commonly Acyl-CoA undergoes esterification by the enzyme acyltransferase and is then incorporated into the phospholipids 
(15). These LC-PUFAs can be released back into the free fatty acid pool by the action of phospholipases (e.g PLA 2) (16). 
Figure 1.5 Transport and processing of LC-PUFAs into the brain. 
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1.5 PUFA in the CNS 
The brain tissue has one of the highest percentages of lipids in the body, second to adipose tissue 
(Tassoni et al., 2008). PUFAs have several roles in the brain which include modulating the function of  
the neuronal membrane, providing lipid mediators for cell signalling and affecting neuroplastici ty. As 
mentioned above, PUFAs are incorporated into the phospholipids of the cell membrane. The 
composition of PUFAs within the membrane can affect the membrane fluidity, permeability and 
composition of lipid rafts (Stillwell and Wassall, 2003, Stillwell et al., 2005, Yehuda et al., 2005). The 
lipid mediators eicosanoids and docosanoids, which are produced by oxygenation of PUFAs by COX 
and LOX enzymes, can activate several signalling pathways in the brain (Dyall, 2015). Lipoxins, which 
are derived from AA as well as resolvins, which are derived from DHA, are both known to promote the 
resolution of inflammation (Farooqui et al., 2007). Neuroplasticity is affected by PUFAs hydrolysed 
from the membrane phospholipids; these can influence endocannabinoid signalling and synaptic 
plasticity. A deficiency in PUFAs in the diet has been shown to alter neuroplasticity and has been linked 
to impaired emotional behaviours (Lafourcade et al., 2011). 
1.5.1 PUFAs and CNS disease 
Dietary deficiencies in LC-PUFAs, particularly omega-3 PUFAs, have been associated with several 
diseases, including coronary heart disease, stroke, cancers (i.e. breast, colon and prostate), 
autoimmune diseases (e.g. lupus) as well as CNS disorders (i.e. Alzheimer’s disease and Parkinson’s 
disease) (Connor, 2000, Janssen and Kiliaan, 2014). Due to their multiple important roles in normal 
brain function, dietary deficiencies in PUFAs leading to a reduction in brain PUFA levels, can lead to 
neurobehavioral deficits in learning and increased risk of anxiety and depression (Larrieu et al . ,  2012, 
Lafourcade et al., 2011). This link between dietary intake of PUFAs and neurodevelopmental and 
neuropsychiatric disorders has also been seen in the clinic, including a correlation between low intake 
of omega-3 PUFAs and attention deficit hyperactivity disorder (ADHD) (Hibbeln and Davis, 2009, 
Antalis et al., 2006). Modern day Western diets include a high amount of omega-6 PUFAs, with a 
corollary decrease in the amount of omega-3 PUFAs. This has led to a suggestion that Western diets 
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are deficient in omega-3 PUFAs (Simopoulos, 2006). Therefore, those who consume this diet are at risk 
of the diseases associated with a dietary deficiency in omega-3 PUFAs, as mentioned above.  
As PUFA deficiency may contribute to many neurological diseases, it is thought that oral treatment 
with omega-3 PUFAs could be beneficial. Furthermore, acute treatment with omega-3 PUFA has also 
been reported to have therapeutic potential. Studies have shown that there may be some benefit in 
treatment with omega-3 PUFAs in Alzheimer’s disease (AD), Parkinson’s disease (PD), peripheral nerve 
injury (PNI) and spinal cord injury (SCI) (Zhao et al., 2011, de Lau et al., 2005, Gladman et al., 2012, Liu 
et al., 2015). These examples will be discussed below. 
1.5.1.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterised by the 
formation of amyloid beta plaques in the brain tissue  and intraneuronal fibrillary tangles and by 
cognitive dysfunction, predominantly memory loss. In aging the amount of omega-3 and omega-6 
PUFAs decreases and this is seen even more so in AD patients (Yehuda et al., 2002). This decrease in 
PUFAs is seen predominantly in the area of the brain responsible for learning and memory, including 
the hippocampus (Yehuda et al., 2005). In a transgenic mouse model of AD, whereby mice develop 
amyloid-beta plaques, a diet enriched in the omega-3 PUFA DHA helped to reduce beta-amyloid 
production (Lim et al., 2005). Many clinical trials have evaluated the treatment with omega-3 
supplements or diets enriched in omega-3 PUFAs. A Cochrane study published this year fai led to f ind 
any efficacy of the treatment with omega-3 supplementation in AD. However, it still remains unclear 
as to whether omega-3 supplementation may improve non-AD dementia patients (Burckhardt et al . ,  
2016).   
1.5.1.2 Parkinson’s disease (PD) 
Parkinson’s disease (PD) is a neurodegenerative  disease in which, the dopaminergic neurones of  the 
substantia nigra progressively die, causing dysfunction of the brain’s basal ganglia system and leading 
to the symptoms of PD (e.g. tremor, rigidity and bradykinesia). Models of PD in rodents or primary 
neuronal cell cultures can be created by administration of the neurotoxin methylphenylpyridinium 
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(MPP+), which can selectively damage dopaminergic neurones. In an in vitro model, the administration 
of the omega-3 DHA derivative NPD1 rescued primary neuronal  cells from MPP+ induced apoptosis 
(Calandria et al., 2015). In humans, the ‘Rotterdam study’ was a large study that aimed to see i f  there 
was a link between dietary intake of PUFAs and reduced risk of PD. The study suggested that diets rich 
in monounsaturated FA and PUFAs were associated with significantly lower risk of PD (de Lau et al., 
2005). More studies are required in order to elucidate whether omega-3 supplementation has any 
potential efficacy in the treatment of PD. 
1.5.1.3 Peripheral nerve injury  
Peripheral nerve injury (PNI) may be caused by trauma including compression, crush or transection of  
axons in the peripheral nervous system, resulting in the loss of either/or both motor and sensory 
function. Although, peripheral nerves are able to regenerate, unlike axons in the central nervous 
system (CNS), this is dependent on the distance regeneration has to occur over, as demonstrated by 
work done previously in our lab, by Gladman and colleagues (Gladman et al., 2012). In vitro  omega-3 
PUFAs have been shown to encourage neurite growth in primary neuronal cultures (Robson et al., 
2010). From our own laboratory group, in vitro and in vivo studies with the fat-1 transgenic mouse, a 
genetic mouse model that produces endogenously high levels of omega-3 PUFAs, provided evidence 
that omega-3 PUFAs aid recovery after PNI, possibly via neuroprotection (Gladman et al., 2012). 
1.5.1.4 Spinal cord injury 
The treatment of spinal cord injury (SCI) with omega-3 PUFAs has also been investigated by colleagues 
in our laboratory. SCI, much like TBI, has no adequate treatment at present, and affects millions of 
people worldwide. In our group, acute treatment with intravenous DHA injection at 30 minutes post 
injury promoted functional recovery and induced neuronal plasticity in rats with a cervical hemisection 
SCI (Liu et al., 2015). It was also previously shown that in a compression model of SCI in rats,  an acute 
intravenous dose of DHA combined with a diet enriched in DHA reduced lipid peroxidation, 
macrophage infiltration, increased neuroplasticity and improved locomotor function (Huang et al., 
2007). However, in a small randomised controlled trial, SCI patients were given oral DHA and EPA 
supplements for 14 months, a year after the initial SCI, and this supplementation failed to improve 
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their outcomes (Norouzi Javidan et al., 2014). This suggests that omega-3 PUFA treatment might be of  
benefit in SCI, if given in the acute phase. 
1.5.1.5 Traumatic brain injury  
The beneficial effects observed with omega-3 treatment in some diseases, especially in SCI, contribute 
to the hypothesis that omega-3 treatment may improve outcomes in TBI. There is also recent evidence 
that suggests low levels of omega-3 PUFAs in the diet impairs recovery from TBI (Desai et al., 2014). 
Desai and colleagues, showed that mice with a 70% deficiency in brain levels of DHA had a worse 
outcome when compared to the TBI only mice; they had reduced cognitive and motor function as wel l  
as an increased lesion size (Desai et al., 2014).  
In vitro studies (as detailed in Figure 1.5) suggest that omega-3 PUFA treatment may be beneficial  i n 
TBI, due to its effects on secondary injury pathways. The omega-3 PUFA DHA has been shown in vi tro 
to promote neuronal survival, prevent apoptosis, reduce inflammation and oxidative stress (Akbar et 
al., 2005, Chen et al., 2005, German et al., 2006, Bazan, 2005). 
Further evidence that omega-3 PUFAs may be beneficial in TBI comes from a patient case study 
published by Lewis and colleagues. The case study describes a patient that suffered a severe head 
trauma and was in a vegetative state, as a result of a motor vehicle accident. At day 10 post TBI the 
patient started to receive very high levels of the omega-3 PUFAs (EPA and DHA), through enteral 
feeding, and by day 21 the patient came off the ventilator and gradually began to show physical and 
cognitive improvements, eventually being discharged at 4 months (Lewis et al., 2013). 
The many important roles of omega-3 PUFAs in the brain, the evidence that omega-3 PUFAs may aid in 
the treatment of other neurological disorders and the neuroprotective effects omega-3 PUFAs have 
demonstrated in in vitro studies as well as in the SCI and PNI models in our laboratory, contributed to 




1.5.2 Brain phospholipids and PUFAs after TBI 
PUFAs are structural components of phospholipids and they also have signalling roles, as reviewed 
earlier. The phospholipids in the brain are altered following TBI and the changes correlate with patient 
outcome, as suggested by observations on the CSF from patients with TBI. Pasvogel and colleagues 
found that when compared to TBI patients that survived, TBI patients that died had higher 
concentrations of the phospholipids, phosphatidylethanolamine (PE) and phosphatidylcholine (PC) in 
their CSF, on day 1 after TBI, suggesting that the integrity of neuronal and glia cell membranes was 
highly disrupted after injury (Pasvogel et al., 2010). In rodent models of TBI, the composition of the 
phospholipid classes, as well as the level of individual PUFAs within plasma have been found to be 
altered. Emmerich and colleagues recently reported that at 24 hours after TBI mice had an increase in 
PE in plasma, and a reduction in all classes of phospholipids that contained the PUFAs AA and DHA, in 
the chronic stages (3, 6, 12 and 24 months) (Emmerich et al., 2016). It has also been shown that levels 
of AA and DHA are reduced in the cortex and cerebellum of injured mice, and a reduction in 
hippocampal DHA levels following TBI correlates with impaired learning ability at 3 months post injury, 
in the Barnes maze test (Abdullah et al., 2014).  
 
1.5.3 Docosahexaenoic acid 
Docosahexaenoic acid (DHA) is found in high amounts in retinal tissue, sperm cells, synaptosomes and 
cortical tissue (Stillwell and Wassall, 2003, Breckenridge et al., 1972, Neill and Masters, 1973, Tinoco, 
1982, Brenna and Diau, 2007). It is the most common long chain omega-3 PUFA found in the brain, and 
is almost 300 times more concentrated in the central nervous system than the omega-3 PUFA EPA 
(Chen et al., 2009). DHA enters the brain from plasma through mechanisms described in the general 
introduction (Fig. 1.5). Very little DHA is synthesised in the brain tissue itself via β-oxidation, therefore 
most of the DHA found in the brain comes from the diet or metabolism in the liver (Demar et al., 
2005). Plasma DHA exists as non-esterified and esterified pools, and recent pharmacokinetic studies in 




Phospholipids are the main components of the cell membranes and their composition can affect 
synaptic structure, membrane fluidity and cell signalling pathways (Wellner et al., 2011, Dyall and 
Michael-Titus, 2008). The different PUFAs in the CNS are preferentially incorporated into specific 
phospholipid classes. DHA is primarily incorporated into the phospholipid phosphatidyl ethanolamine 
(PE), less so into phosphatidyl choline (PC) and even less into the other classes of phospholipids at the 
sn-2 position (Stillwell and Wassall, 2003). DHA is more enriched in the inner leaflet of the cell 
membrane, particularly when incorporated into the phospholipid PE or phosphatidylserine (PS) 
(Stillwell and Wassall, 2003).  
The unique structure of DHA means that when it is incorporated into phospholipids, it can alter cell 
membrane properties, including permeability, fluidity and cell signalling (Stillwell et al., 2005, Sti l lwell 
and Wassall, 2003). DHA has 6 double bonds which are locked in their cis-orientation, making them 
rigid and suggesting that they have limited flexibility; however, studies employing nuclear magnetic 
resonance spectroscopy (NMR) have produced evidence that DHA has extremely high conformational  
flexibility (Feller, 2008, Everts and Davis, 2000, Gawrisch et al., 2003). In a study conducted by 
Gawrisch and colleagues, NMR data revealed that the flexibility of the DHA chain increases from the 
carbonyl head group to the terminal methyl group, as the carbon-carbon bonds act like flexible 
‘hinges’ (Gawrisch et al., 2003). When bound to membrane phospholipids, DHA is able to be in several  
different conformations by bending, tilting and folding. This extensive flexibility of the DHA chain can 
cause the phospholipid bilayers of the cell membrane to be flexible (Gawrisch et al., 2003).  
 
1.5.4 The roles of DHA in cognition 
Studies have shown that diet composition can have an impact on cognitive function. Mice fed on a diet 
with low levels of omega-3 PUFAs exhibit poorer performance in cognitive tests (Fedorova et al., 
2007). Conversely, rats fed on a diet enriched with DHA improve their performance in cognitive 
behavioural tests including the radial-arm maze (Gamoh et al., 1999, Gamoh et al., 2001). In a model 
of impact/acceleration TBI in rats, pre-injury dietary supplementation with DHA improved 
performance in the MWM test (Mills et al., 2011). 
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The effect DHA has on cognitive performance is likely to be at least partly related to the roles DHA has 
within the regions of the brain responsible for learning and memory, such as the hippocampus. DHA 
supports hippocampal function by promoting neurogenesis. The hippocampus and the subventricular 
zone (SVZ) of the lateral ventricle wall are the only areas of the human adult brain able to display 
neurogenesis continuously, whereas the olfactory bulb in lower mammals also displays co ntinuous 
neurogenesis (Eriksson et al., 1998, Ernst and Frisén, 2015). DHA promotes neurogenesis in vivo and in 
vitro, as demonstrated by the increase in the immunohistochemical marker of proliferating cells, 5-
bromo-2'-deoxyuridine (BrdU) (Kawakita et al., 2006). It is unclear how DHA promotes neurogenesis,  
but suggestions include:  (i) DHA increases the proliferative activity of neural stem cells (NSC) thereby 
increasing the number of newborn neurons, (ii) DHA encourages NSCs to exit the cell cycle to become 
differentiated neuronal cells, or (iii) DHA confers neuroprotection, thereby increasing the survival of  
newborn neurons (Kawakita et al., 2006, Insua et al., 2003, Akbar et al., 2005). The improved 
performance of aged rats in a spatial memory test was correlated with an increased level of 
neurogenesis seen in the hippocampus, and a DHA-enriched diet has been shown to up-regulate the 
expression of genes (e.g. c-fos) in the hippocampus, associated with long-term potentiation (LTP) 
(Drapeau et al., 2003, Tanabe et al., 2004). LTP is a model for the reinforcement of synapses through 
increased stimulation, which is believed to underlie synaptic plasticity and learning and memory (Bl i ss 
and Collingridge, 1993).  
DHA also contributes to hippocampal function through promotion of synaptogenesis and by 
strengthening synaptic plasticity (Su, 2010). DHA supplementation increases the level of the growth 
factor brain derived neurotrophic factor (BDNF), which plays a key role in the promotion of 
synaptogenesis (Wu et al., 2008, Cunha et al., 2010). With an increase in the number of synapses, 
there is an increase in synaptic proteins such as synapsin-1, expressed at higher levels after dietary 
DHA supplementation (Cao et al., 2009). Through the promotion of neurogenesis and synaptogenesis,  
DHA supplementation can support hippocampal-based learning and memory. 
As well as dietary supplementation, acute injection of DHA or of emulsions containing DHA has also 
been shown to confer neuroprotection. Although an acute injection cannot alter the composition of  
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the phospholipids in cell membranes, it has been shown to improve outcome in animals models of SCI, 
epilepsy and stroke (Liu et al., 2015, Trépanier et al., 2015, Williams et al., 2013, Taha et al., 2010, 
Hong et al., 2014, Hong et al., 2015). Our group has shown that an acute injection of DHA 30 minutes 
after SCI (and up to 2 hours after injury) can promote neuroplasticity, increase neuronal and gl ial  ce l l  
survival, improve locomotor function and reduce lesion size (Liu et al., 2015, King et al., 2006). In a 
model of epilepsy, the subcutaneous injection of DHA an hour before pentylenetetrazol 
(PTZ) administration, increased the latency to seizure activity in rats, and this effect correlated with an 
increase in unesterified levels of DHA in the serum, without affecting brain phospholipid DHA levels 
(Taha et al., 2010, Trépanier et al., 2012). In models of stroke, Hong and colleagues, have shown that 
an i.v. dose of DHA 3 hours post-occlusion of the middle cerebral artery (MCA) improves motor 
function, cognition and reduces tissue loss up to 3 weeks after injury, and in the acute ph ase reduces 
BBB permeability as demonstrated by decreased Evans blue extravasation (Hong et al., 2014, Hong et 
al., 2015). Omega-3 PUFAs can be incorporated into emulsions and administered via injection of  such 
emulsions. The benefit of using an emulsion for the delivery of omega-3 PUFAs is the reduction in FA 
oxidation and the slower release of the omega-3 PUFAs. Emulsions containing omega-3 PUFAs, 
particularly DHA, have also been reported to induce neuroprotection and reduction of brain tissue loss 
in a hypoxic-ischaemic injury in neonate animals (Williams et al., 2013).  
 
1.5.5 DHA and secondary injury mechanisms 
The mechanisms that contribute to the secondary injury after TBI include oxidative stress and 
neuroinflammation, which can lead to enhanced cell death via apoptosis. Neuroprotectin D1 (NPD1) i s 
a docosanoid derived from DHA and it has been shown to have anti -inflammatory, anti-oxidative  and 
anti-apoptotic effects (Bazan, 2005, Mukherjee et al., 2004, Bazan, 2009a, Bazan, 2009b). In a model of 
stroke, NPD1 infused during reperfusion down-regulated DNA damage caused by oxidative stress and 
reduced apoptosis through the regulation of pro- and anti-apoptotic proteins. NPD1 down-regulates 
the pro-apoptotic protein Bax and up-regulates the anti-apoptotic protein Bcl-2 (Bazan, 2009b) . DHA 
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supplementation has also been shown to increase superoxide dismutase (SOD) and the silent 
information regulator 2 (Sir2) after TBI, which are known to have anti -oxidant effects (Wu et al., 2011). 
Glial cell activation is an important part of the secondary injury inflammatory pathways. In our model  
of CCI, astrogliosis and microglial cell activation was induced by the injury and reflected as an up -
regulation of GFAP and increase in the number of Iba1+ cells. DHA acute treatment following SCI in our 
laboratory and in other groups has been shown to reduce glial cell activation, by reducing 
microglia/macrophage number and GFAP staining (Paterniti et al., 2014, Lim et al., 2013b).  DHA may 
modulate glial cells by reducing the amount of pro-inflammatory cytokines released from glial cells 
(e.g. TNF-α and IL-6) that would otherwise go on to further activate additional microglia and cause 
astrogliosis (Heras-Sandoval et al., 2016, Gupta et al., 2012).  
 
1.6 Failures of TBI therapies 
After the failures of the progesterone SyNAPSe and PROTECT III trials as well as the Eurotherm3235 
and EPO-TBI clinical trials, questions surrounding the reasons for these failures have been raised. The 
reasons, as suggested in a 2015 review by Stein are as follows (Stein, 2015): 
• Heterogeneous patient population – The heterogeneous nature of TBI means that recruitment 
of a uniform patient population is impossible. Between patients, the cause, location and 
severity of the injury differ. Other factors are the time to hospital, post-injury complications 
and the patients’ underlying resilience to the trauma or any pre -existing conditions. 
 
• Appropriate outcome measure – Although the GOS is the most commonly used outcome 
measure, it has been suggested that it may not be sensitive enough. Other composite scores 
used to assess outcome also rely on the patient’s own reporting which can be subjective. 
Screening for biomarkers of injury in the cerebrospinal fluid (CSF) or blood serum may be a 
more effective and sensitive outcome measure. Several potential biomarkers have been 
identified including the S100-B and glial fibrillary acidic protein (GFAP), both markers of 
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astroglial injury, as well as neurofilament light polypeptide, which is a marker of axonal 
damage (Zetterberg et al., 2013). Combining outcome scores with biomarker analysis and 
advanced brain imaging may produce a clearer assessment of patient outcome.   
 
• Ineffective dosing – Failure of these large clinical trials may be down to sub-optimal dose or 
ineffective dosing schedule. There have been very few large trials comparing single dosing to 
sustained dosing. Also there may be failure in the translation of the preclinical doses to the 
clinical trial dose (Narayan et al., 2002). It is also worth remembering that at the preclinical 
testing phase several potential treatments are given before the injury or close to the time of  
injury, which does not reflect the common clinical situation. 
 
• Inadequate pre-clinical testing – There could be several factors at the preclinical phase 
causing failures down the line in clinical trials, including false positives, anaesthesia, drug 
interactions, simplistic injury models, translation of drugs from animals to humans assuming 
trans-species validity of targets, the relevance of outcome measures and the use of genetically 
identical animals. 
 
These points further reiterate the complexity, the heterogeneity and the difficulty of translation from 
bench to bedside of TBI. Particularly important are the potential problems with the pre-clinical testing. 
If another therapeutic strategy is to make it to a large scale clinical trial and prove to be efficacious, 
the preclinical testing needs to be of a high standard and take into considerat ion the points raised 
(Loane and Faden, 2010). The different in vitro and in vivo models of TBI used for preclinical screening 






1.7  In vitro models of TBI 
In vitro models have been developed to reflect different types of TBI. There are models that mimic 
focal lesions by causing direct injury to tissue or cells: these include transection and weight -drop 
models. There are also in vitro models designed to reflect the shearing that neuronal cells undergo in a 
diffuse injury, which include a shear strain model and a shockwave blast injury model  (Morrison et al . ,  
1998). Changes in the environment in vitro allow the study of the response to a particular 
environmental change that occurs following a TBI. Such manipulations of the environment can be the 
modification of the glucose concentration within the media to produce hypoglycaemic conditions, or 
reduction in the available oxygen within the incubator, to mimic hypoxia. These models are 
summarised in the table below (Table 1.5). 
In vitro models can be modified by the selection of the cell culture system. Immortalized cell lines, 
primary cell cultures and organotypic tissue preparations can all be subjected to any of the TBI in vitro  
models described. There are advantages and limitations to each of these culture systems, concerning 













Table 1.5. Summary of in vitro models of TBI. 




A plastic stylet or 
Barkan goniotomy knife 
is used to create a cell 




glutamate and K+ to 
mimic glutamate 
excitotoxicity and 
disruption of ion 
homeostasis.  
 
(Tecoma et al., 
1989) 
(Brizuela et al., 
2015) 
(Xu et al., 2014a) 
Weight-drop 
Similar to the in vivo 
weight drop model. A 
known weight is 
dropped onto a layer of 
cells or onto an 
organotypic tissue slice. 
 
The weight drop 
causes compression to 
the cells or tissue 
beneath it to produce 
axonal compression-
like axonal injury. 
 




Shear strain injury 
Cells grown on a 
specialised flexcell 
material. The material 
can then be 
manipulated and 
deformed to cause a 
shear injury to the cells.  
Strain injury causes 
cell rupture and 
death. Increase in 
axonal damage that 
can be changed by the 
duration and extent of 
the strain.  
(Gladman et al., 





A glucose free medium 
is used to induce an 
ischaemic reaction in 
the cells. Cells are 
incubated in a low 
oxygen incubator to 
cause hypoxia. 
Hypoglycemia causes 
neuronal cell death. 
Hypoxia causes a 
decrease in neurite 
growth and eventually 
cell death in neurones 
as well as other CNS 
cells. 
 
(Gladman et al., 
2010) 
 
Blast Injury   
Cells are placed in a 
water filled tube. A 
shock wave is generated 




causes cell death and 
indicates BBB injury in 
a culture of 
endothelial cells. 
Organotypic cultures 
also show high levels 
of cell death. 
 










Table 1.6 Summary of different cell culture systems. 
Cell culture 
system 









• Ready supply -Can 
be frozen and 
passaged 
• Robust 





• Not representative 
of CNS cells 
(Wang et 
al., 2014a) 
(Xu et al., 
2014b) 
 






• CNS specific cells 
from targeted 
tissue 
• Single cell type 




• Harvesting of cells 
can cause damage 
and be a complex 
process 
• Short-term 
experiments as they 
cannot be passaged 
• Behaviour of cells 
may change ex vivo 
(Gladman et 
al., 2010) 











• The complex tissue 




• Very short-term 
studies 
• Tissue preparations 










The benefits of in vitro models make them a useful tool for the screening of potentially 
neuroprotective therapies for TBI. They are also useful for the investigation of the cellular and 
molecular secondary injury pathways that contribute to the pathophysiology following TBI. A novel  in 
vitro model of TBI, which employs the use of a pneumatic impactor to create a focal injury in 3D tissue 











1.8 Animal modelling of TBI 
Clinical TBI is very heterogeneous, and this had led to the development of several animal models that 
reflect different aspects of human TBI symptoms and pathologies. The two types of  injury modelled 
most extensively in animals are focal and diffuse injuries (Xiong et al., 2013). Models that mimic focal  
and diffuse injuries are described below and the advantages and disadvantages of  these model s are  
detailed in Table 1.7. 
• Focal injury describes a localised impact, where direct penetration of the brain ti ssue occurs. 
This causes destruction of the skull, brain parenchyma and blood vessels at the site of impact.  
The models that result in a focal injury include the controlled cortical impact (CCI) model ,  the 
fluid percussion model and the weight drop model. The CCI model causes a direct injury to 
the brain parenchyma with a pneumatically driven rigid impactor. The fluid percussion model  
employs a high pressure fluid bolus to cause focal destruction of the brain parenchyma. This 
model also induces some diffuse damage. The weight drop model, is where a weight is 
dropped directly onto the exposed brain tissue to cause a focal injury. 
• Diffuse injury describes the damage caused to brain tissue, in particular neurons, when it is 
stretched and sheared. The animal models that mimic this type of injury include blast injury 
models, whereby animals (predominantly swine) are exposed to the shockwaves caused by an 
explosive blast. Diffuse injury can also be modelled in a closed head model of rotational 
injury, where animals receive rapid axial head rotations with a pneumatic actuator. The 
previously described weight drop model can be adapted to cause diffuse injury, if the weight 









Table 1.7 The various in vivo models of TBI. (Cernak, 2005, Xiong et al., 2013, Marklund and Hillered, 
2011) 
















• No skull fracture 




• High mortality rate 







• Severity easily 
adjusted 
• Craniotomy 








Diffuse • Produces prolonged 
unconsciousness 
• High mortality rate 
• Variability (between 
animals and centres) 











Focal • Injury parameters 
can be tightly 
controlled  
• Injury severity can 
be altered 
• Highly reproducible 
(between animals 
and centres) 
• Long lasting 
behavioural deficits 
• Low mortality rate 
• Craniotomy 
Weight drop Rat 
Mouse 
Focal • Injury severity can 
be altered 
• Behavioural deficits 
• Craniotomy 
• Parameters not so 
tightly controlled 
• Similar to the 
Marmarou model, but 
creates a localised focal 
injury 
Blast injury Swine 
Rat  
Mouse 
Diffuse • Closely mimics the 
injury mechanism in 
human TBI 








1.8.1 Species used in the animal modelling of TBI 
The TBI models that represent focal and diffuse injuries have been conducted in a wide variety of 
species. Most commonly used species are rodent, but there are several models that have been 
adapted to use larger species, such as swine and cats. All of the species used are able to mirror some 
of either the neurobehavioral consequences or pathophysiological tissue changes observed in the 
human condition (Table 1.8).  
Table 1.8 Species used in various in vivo models of TBI. 







• ↑ICP (King et al., 2010) 




• Axonal injury 
• Subarachnoid haemorrhage 
• Cortical lesion 
(Sullivan et al., 2013) 
(Manley et al., 2006) 
(Bauman et al., 2009) 
Cat Lateral fluid 
percussion 
 
• Subarachnoid haemorrhage 
• Haematomas 
(Hayes et al., 1987) 
(Carey et al., 1990) 
Rat CCI 
Fluid percussion 
Weight drop models 
Blast Injury 
• Hypotension 
• Axonal Injury 
• Cortical contusion 
• Haemorrhage 
(Dixon et al., 1991) 
(Cernak et al., 2004) 
Mouse CCI 
Fluid percussion 
Weight drop models 
• BBB breakdown 
• Cortical tissue loss 
• Axonal injury 
(Smith et al., 1995) 
(Flierl et al., 2009) 
(Carbonell et al., 1998) 
 
There are clear advantages and disadvantages to using a particular species in which to model TBI.  The 
larger species have a neuroanatomy that is more representative of the human brain. Pigs and cats, like 
humans have a gyrencephalic cortical structure and a similar white-to-grey matter ratio (Gennarelli, 
1994). Despite the clear benefits of using an animal that has neuroanatomical similarities to humans, 
there are limitations that need to be considered when using larger species. Firstly, the high cost of 
housing and maintaining larger species. Secondly, the life span of these animals make long term 
studies more time consuming, and therefore not suitable for a high-throughput screening of potential 
therapies. Thirdly, there are  more substantial ethical concerns when larger species are used 
(Marklund and Hillered, 2011). 
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Rodents are the main animals used in models of TBI. Unlike the larger species, the rodents’ 
neuroanatomy has some very obvious differences to that of a human’s neuroanatomy ( Fig. 1.6) .  The 
cortices in a rodent’s brain are lissencephalic. Also, the ratio of white-to-grey matter is very di f ferent  
(less white matter) and the olfactory bulbs make up a larger proportion of the brain than that in 
human (Gennarelli, 1994). Despite these differences, rodents are a much more viable  option for the 
initial screening of a novel therapeutics due to their relative cost, size and life span. There is one other 
main benefit to using rodent species, in particular mice, over the larger species, and that is the abi l i ty 
to manipulate the genetics of a mouse to produce a desired transgenic breed (Xiong et al., 2013). 
Transgenic mice enable a researcher to look much more in depth at the processes contributing to the 
secondary injury and at novel therapies.  
It could be suggested that the high number of studies conducted in rodents, as opposed to larger 
species, may be one of the major reasons leading to the failure of therapies for TBI. The positive 
neuroprotective effects of therapies seen in rodents may not be translational to human patients due 
to the neuroanatomical differences stated above.  
 
 









1.8.2 Rodent models of TBI 
The model of TBI that is characterised in this thesis will be in a rodent species. Three of the most 
popular models of TBI conducted in rodent species include the fluid percussion model, the Marmarou 
model (a weight-drop model) and the controlled cortical impact model (CCI). These three models are  
described in detail here. 
 
1.8.2.1  Fluid percussion model 
 
 
Figure 1.7 Equipment used in the fluid percussion model of TBI. (Xiong et al., 2013). 
 
The fluid percussion model is first mentioned in the literature in 1989 (McIntosh et al., 1989). This 
model causes both focal and diffuse injuries and has been adapted to mimic different types of  TBI,  by 
altering the location of the injury from a lateral location to the midline (Cortez et al., 1989, Thompson 
et al., 2005). The fluid percussion model employs a large piece of equipment made up of a pendulum 
and a saline reservoir (Fig. 1.7).  
The injury is caused by the release of a pendulum onto one end of a saline reservoir (fluid filled tube), 
while the other end sits next to the exposed intact dura through a craniotomy. The force of the 
pendulum impact on one end of the tube causes a pressure wave of fluid within the tube, and this 
results in a fluid bolus being forced into the brain, causing a deformation of the brain tissue (Marklund 
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and Hillered, 2011, McIntosh et al., 1989). The severity of the injury can also be altered by incre asing 
the pressure wave of the fluid within the tube via increasing the angle of the pendulum. 
Nonetheless, the design of the equipment does allow for some errors to occur. Firstly, the dropping of  
the pendulum by the tester as a means of initiating the injury is not a precise method and al lows for 
some tester error. Secondly, after the pendulum has been released and impacted the reservoir tube, it 
still has some momentum force. The tester should be aware of this and make sure to be prepared to 
catch the pendulum, before it rebounds and causes a second injury.  
1.8.2.2 Marmarou model – impact/acceleration weight drop model 
The impact-acceleration weight drop model, was presented first by Marmarou in 1994, five years after 
the fluid percussion model, and is often referred to as the Marmarou model (Foda and Marmarou, 
1994).  
 
Figure 1.8 Equipment used in the  Marmarou model of TBI.  (Xiong et al., 2013) 
 
This model creates a global diffuse injury throughout the rodent’s brain. It does this by having a weight 
falling onto a steel disc that is glued to the skull of the rodent. The head of the rodent rests on a piece 
of foam, with a defined ‘spring constant’, to allow a controlled movement of the head after impact 
(Marmarou, 1994; Morales, 2005). The injury causes widespread axonal injury, due to the steel disc 
distributing the energy of the impact over the whole brain (Morales et al., 2005). 
77 
 
This model is able to replicate the diffuse injury without causing a focal lesion, similar to the injury 
observed from a motor vehicle accident. The diffuse injury occurs because of acceleration and 
deceleration forces causing the brain to move within the skull (Foda and Marmarou, 1994). 
Consequently, the axons shear and become damaged, which leads to Wallerian degeneration and 
eventually neuronal cell death. The main advantage of this model is the ability to i solate the di ffuse 
injury and investigate the diffuse pathophysiology alone. This model is also able to achieve prolonged 
unconsciousness in rodents, an aspect of TBI that most models do not replicate (Marmarou, 1994) 
The Marmarou model, much like the fluid percussion model relies on the impact of a falling weight (or 
pendulum), so important to prevent a rebound injury. Another similarity is the complexity of the 
equipment used to initiate the injury. These problems may be overcome with the increased use of the 
equipment.  
 
1.8.2.3 Controlled cortical impact model (CCI) 
The controlled cortical impact (CCI) model is an example of a model that causes a focal injury by direct 
brain deformation (Fig. 1.9) (Lighthall, 1988). 
 
Figure 1.9 Equipment used in the controlled cortical impact model of TBI. (Xiong et al., 2013) 
 
This model was first developed in ferrets, but then later in rats and mice (Dixon et al., 1991, Smith et 
al., 1995). To deliver CCI to a rodent, a craniotomy is performed over one hemisphere. Then, a 
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pneumatically driven rigid impactor strikes the intact dura mater to cause deformation of the brain 
tissue (Marklund and Hillered, 2011). The pathophysiology following CCI has been shown to include 
brain oedema, elevated intracerebral pressure, reduced cortical perfusion, decreased cerebral  blood 
flow, as well as neuroendocrine and metabolic changes, which are hallmarks of clinical  TBI  (Baskaya, 
1997; Cherian, 1994; Bryan, 1995; Prasad, 1994).  
 
The pneumatically driven rigid impactor is operated via a computer, and the parameters can therefore 
be tightly controlled. These parameters include impactor velocity, depth of impact and dwell time 
(O'Connor et al., 2011). The ability to stringently control the various parameters limits the variabil ity 
between each injury conducted for each rodent. This high reproducibility between injuries is very 
important in the early stages of pharmacological screening in order to determine the efficacy of a new 
therapeutic agent. 
 
The equipment needed to perform this model is relatively simple and its design means that  there is no 
risk of rebound injury (O'Connor et al., 2011). This model can  offer high reproducibility of injury 
between animals and between centres due to the parameters of the injury being digitally control led. 
Despite the technical advantages of this model over the fluid percussion and Marmarou model, the CCI 
model does have some disadvantages that are worth considering. Firstly, the lesion size caused by the 
impactor is relatively large. This large lesion size is not comparable to that of the injuries seen in 
human patients that survive a TBI. Secondly, and similarly to the fluid percussion model, a cran iotomy 
needs to be performed prior to the injury. A craniotomy obviously does not reflect the  usual pathology 
of a human TBI and may attenuate secondary brain swelling if the bone flap is not replaced 
(Zweckberger, 2006; De Bonis, 2010). Nonetheless, a craniotomy does mean that there is no risk of 
skull fracture in the rodent, which would cause further damage, leading to a more heterogeneous 
injury between animals, lowering the reproducibility and negating the model’s use as a therapeutic 
screening tool. Overall, this model has high reproducibility, is good as a therapeutic screening tool and 
is technically relatively simple to operate.  
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1.8.3 Behavioural outcome measures 
The symptoms suffered by TBI patients vary depending on the type, location and severity of  th e TBI. 
After a TBI, complex cognition and personality changes may develop. Due to the significant impact that 
neurobehavioural symptoms have on a patient’s quality of life, a key outcome measure for in vivo 
models of TBI must be a deficit in relevant behavioural tests. Behavioural analysis in rodents includes 
many established tests that assess different aspects of behaviour, and monitor anxiety, learning, 
memory and motor function. The most common neurobehavioural outcome assessed in rodent 
models of TBI are cognitive and motor dysfunction. These commonly used behavioural tests are 
reviewed below and in Table 1.9. 
 
1.8.3.1 Open field 
 
The open field test measures the exploratory behaviour of a rodent within a confined space, e.g. a 
Perspex box. The behaviour of the rodent within the box can be used as an index of general locomotor 
activity and has also been interpreted to reflect the anxiety of the animal exposed to a new 
environment. The open field has been used to test these behaviours in a variety of models of 
neurological conditions, including TBI. TBI patients can experience symptoms including anxiety and 
motor dysfunction and therefore this behavioural test would be a relevant outcome measure in the 
assessment of a TBI rodent model. With reference to anxiety, rodents that spend a reduced amount of  
time in the central zone and an increased amount of time next to the walls of the open field are 
indicating anxiety-related behaviours (Jones et al., 2008). In a lateral fluid percussion model, rats that 
received a severe injury spent less time in the central zone, suggesting that they were more anxious 
than the control groups (Jones et al., 2008).  Using this test as a measure of anxiety is contested, as 
noted in a review of the literature, as mice treated with certain anxiolytic drugs did not exhibit 






Figure 1.10 Open field test. Dimensions of Perspex box  (A), behaviour of rodent during the test (B) and 
an illustrated outcome measure of the open field test (C). 
 
 
The distance travelled within the open field is an outcome measure that can be used to assess the 
locomotor activity of the rodent. After a CCI injury, mice that received a severe injury showed a 
decrease in the distance travelled and therefore exhibited reduced locomotor activity (Zhao et al., 
2012b). Reduced locomotor activity may also reflect other symptoms induced by the CCI injury, 
including anxiety, depression, habituation to the test apparatus or motor dysfunction. It would take 
further behavioural testing to decipher the precise cause of the reduced locomotor activity.  
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Table 1.9 Example of behavioural tests used as outcome measures in animal TBI models. (Armario and Nadal, 2013, Xiong et al., 2013, Schaar et al., 2010) 























































Test Paradigm Strengths of the Test Limitations of the Test 
Morris 
Water Maze 
+ + - - - - An acquisition phase of 2-4 swimming trials 
a day for 4 days, in which the animal 
should learn to locate the hidden platform. 
At 24 hours after the last acquisition trial, a 
probe trial (with the platform removed) is 
performed. 
-Gold standard test for 
memory deficits 
-Tests for deficits in the 
animal’s ability to learn 
-Tests spatial memory 
-No pre-test starvation 
-Paradigm is adaptable 
-Results can be affected by a 
number of factors including 
water temperature, home 
cage environment, testing 
room environment. 
Y-Maze + + - - - - An acquisition trial (5 – 15 minutes), in 
which one arm is blocked. After an interval 
time of up to 2 hours there is a retrieval 
trial. The animal is allowed to explore all 3 
arms of the maze. 
-Tests for deficits in the 
animal’s ability to learn 
-Tests spatial memory 
-No pre-test starvation 
-Paradigm is adaptable – 
spontaneous arm alternation. 






- - - + - - Animals are allowed to explore the open 
and enclosed arms for a 5 minute trial. 
-No pre-test starvation 
-Short testing period 
-No pre-training required 
-Results can be affected by 
exposure to previous 
behavioural tests, previous 
handling, testing environment  






+ + - - - - Animals are exposed to 2 identical objects 
within an open-field. After a 24 hour 
interval time, the animals are placed back 
in the test with 1 familiar object and 1 
unfamiliar object.  
-No pre-test starvation 
-Paradigm is adaptable 
 
-Results can be affected by 
exposure to previous 
behavioural tests, olfactory 





- - + - + - Animals are given a score on the 
completion of 10 tasks including – beam 
balance, beam walking, startle reflex, 
paresis and seeking behaviour. These tasks 
can be repeated every 24 hours. 
-No  pre-test starvation 
-Simple to administer 
-Composite score may mask 
individual deficits 
-Results can be affected by 
exposure to previous 
behavioural tests, olfactory 
stimuli, testing environment . 
Forced 
Swim Test 
- - - - - + Mice are forced to swim in a narrow 
beaker of water for 6 minutes.  
-No  pre-test starvation 
-Simple, low cost  
-Swimming performance 
between tests can be 
markedly different, due to 




- - + + - -  Animals are allowed to explore an open 
field test environment for a 5 – 30 minute 
trial. These trials can be repeated 
throughout the study. 
-No  pre-test starvation 
-Paradigm is adaptable 
-Measures multiple 
behaviours. 
-Results can be affected by 





1.8.3.2 The Y-maze 
The Y-maze has been used to test memory function by exploiting rodents’ natural exploratory 
behaviour. There are two main protocols for the Y-maze in which one of the three arms is blocked,  in 
order to create an arm within the maze that will be novel to the test rodent (Sarnyai et al., 2000). Once 
exposed to the novel arm, the amount of time the animal spends in the novel arm is indicative  of  the 
rodent’s memory function, as the rodent recognises its novelty and spends time exploring it. Mice that 
received a hippocampal lesion failed to recognise the novel arm, thereby providing evidence that the 
Y-maze is a useful test for memory (Sanderson et al., 2007). As with other cognitive behavioural tests, 
results from the Y-maze can be misinterpreted for a number of reasons, for example if the locomotor 
activity is altered, the time spent exploring the novel arm may be lessened (Sanderson et al., 2010). 
 
Figure 1.11 Y-maze test. Actual image of the apparatus in use (A), behaviour of rodent during the test 








1.8.3.3 Morris Water Maze 
The most regularly used test for learning and memory dysfunction i s the Morris water maze (MWM). 
This test has been used to evaluate memory deficits in neurodegenerative disease models such as AD 
models,  as well as for discriminating between young and aged rodents (Buccafusco JJ, 2009, D'Hooge 
and De Deyn, 2001). It has also been used to distinguish between experimental brain lesion severi ties 
in mice (Washington et al., 2012, Smith et al., 1991). 
The MWM test is a complex task that requires the rodent to employ a range of neurological processes. 
The aim of the task is to locate the hidden platform within the water tank, therefore escaping the 
water. it is the impetus to escape the water that motivates the animal to locate the platform.  During 
the acquisition phase, the rodent is required to learn to navigate its way to the platform by using the 
visual cues that surround the tank. In order to complete this task the rodent must employ place 
learning and spatial memory (Buccafusco JJ, 2009, Morris, 1984).  The brain region essential for these 
processes is the hippocampus. Bilateral and unilateral hippocampal lesions in rats and mice have 
resulted in complete or severely impaired performance in the MWM task (D'Hooge and De Deyn, 
2001, Clark et al., 2005). The hippocampus is one of the main brain regions damaged by a TBI, 
independent of the location and severity of the TBI (Kotapka et al., 1994).  
This test is useful for assessing both the animal’s ability to learn during the acqui sition phase and i ts 
memory in the probe trial. The dual outcome measures allow the evaluation of the cognitive aftermath 
of a TBI without pre-injury training and without pre-test food deprivation. Despite the multiple useful 
outcome measures this test provides, it does have limitations. These include the size of the test 
equipment, the time taken to perform this test and the substantial effect external environmental 
factors have of the performance of the animals within the test (Vorhees and Williams, 2006) . As with 
the Y-maze test, the locomotor function of the animal can impact upon the animal’s performance in 
the test. Therefore, additional outcome measures, such as average speed as well as concurrently 
running locomotor activity testing are of benefit. 
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The limitations of the MWM may not be restricted to the operation of the test, but may include the 
misinterpretation of the outcome measures.  An increased latency to the platform zone is interpreted 
as impaired memory function, and this assumes that the animal is attempting to employ a cognitive 
strategy to locate the platform and failing. However, it does not take into consideration the likelihood 
that an animal may be using a non-cognitive strategy such as thigmotaxis, that may be lengthening 
their latency time, thus leading to the mistaken assumption that these animals are memory-impaired  
(Wolfer et al., 1998). 
The MWM may have its limitations, but as one of the most frequently used and widely accepted 
cognitive tests, it is a good and accessible behavioural tool for the evaluation of memory impairment in 
in vivo models of TBI. Notwithstanding the benefits of behavioural testing for preclinical screening of  
novel therapeutics, assessment of some of the subtle changes in cognitive and psychiatric behaviour  
(e.g. speech and mood disorders) following TBI cannot be carried out. 
 
 
Figure 1.12 Morris water maze test. Actual image of apparatus in use (A) and representative trace of 









1.9 Aims  
The main aims of this thesis are as follows: 
1) To optimise and characterise a mouse model of TBI with behavioural and histological endpoints. 
2) To investigate whether treatment with the omega-3 fatty acid docosahexaenoic acid improves 
outcome in a mouse model of TBI. 
3) To investigate whether a sustained high level of endogenous omega-3 fatty acids in the transgenic 
fat-1 mouse can lead to an improved outcome after TBI. 
4) To set up and characterise an in vitro model of mechanical injury for the study of the effects of 


























2 Methods and Materials 
2.1 In vivo studies 
2.1.1 Animals 
All animal procedures were approved by the Animal Welfare and Ethics Committee of Queen Mary 
University of London, in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 
and with international guidelines on the ethical use of animals. All animals were maintained on a 12  
hour light/dark cycle with ad libitum access to food and water and at a temperature of 21  ± 1oC.  
Mice used were either male CD1 mice at 10-12 weeks old or transgenic fat-1 mice with aged and sex 
matched C57BL/6 mice as control, as indicated in the corresponding chapters.  
The original fat-1 breeders were provided by Dr J.X. Kang (Harvard University, Massachusetts, USA) 
and the colony was maintained in house by mating heterozygous fat-1 mice with wild type C57BL/6 
mice purchased from Charles River UK, Ltd (Margate, UK). Heterozygous male mice 49-53 weeks old 
(aged), male mice 10-12 weeks old (young adult) and female mice aged 10-12 weeks old (young adult)  
and wild-type littermates were used in the studies. The genotypes of these mice were verified by PCR 
analysis of ear punches, provided by Charles River Laboratories (Margate, UK).  
The phenotype of the fat-1 mice was also reliant on the mice being fed on an omega-6 PUFA rich diet 
(Kang et al., 2004). The special omega-6 PUFA rich diet was fed to both fat-1 and wild-type littermates 
(AIN-76A diet containing 10% corn oil, TestDiet UK, Product no. 1812592; Appendix 1.2) and animals 
were allowed access to the diet and water ad libitum. The diet was changed daily and stored at -20oC 
to prevent oxidation of the omega-6 PUFAs in the diet. Aged and gender matched C57BL/6 mice 
bought from Charles River Laboratories (Margate, UK) were used as controls and were fed on a 
standard diet (RM1, Special Diets Services, Lillico Biotechnology, Surrey; Appendix 1.3).  
2.1.2 Surgery 
The CCI model was chosen due to the reasons discussed in section 1.8.2.3, the model is reproducible  
between animals and centres, unlike several other TBI animal models. It was also chosen because the 
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CCI equipment in was already being employed in a contusion model of spinal cord injury with our lab 
group. 
All the controlled cortical impact (CCI) surgeries in mice were performed by  the author. Mice were 
anaesthetized with a mixture of ketamine (50 mg/kg) and medetomidine (10 mg/kg) intraperitoneally 
(i.p.) and given pre-emptively analgesia buprenorphine (0.05 mg/kg) subcutaneously (s.c.). Surgical 
anaesthesia was confirmed by loss of the tail pinch reflex and corneal reflex. Anaesthesia depth was 
monitored throughout the surgery by monitoring the respiration rate.   
Mice were placed into a stereotaxic frame and secured with mouse teeth bar and guinea pig ear bars. 
A midline incision was made to expose the skull and a 3.5 mm craniotomy was made over the right 
parietal bone (central point was at -2.0 mm bregma, 2.5 mm lateral) using a 0.5 mm diameter burr bi t 
connected to a hand held dental drill. Care was taken so that the dura mater was undisturbed during 
the drilling and the removal of the skull flap. 
The contusion was carried out using the Hatteras PinPoint controlled cortical impactor (Hatteras 
Instruments, USA) (Fig. 2.1). The parameters used were: 3.0 m/s velocity, 100 ms dwell ti me, and 20O  
angle. The injury severity (based on behavioural tests) was determined by the impact depth; 1.5 mm 
(very mild), 2.0 mm (mild), and 2.2. mm (moderate). Sham injury mice received a craniotomy only. 
After the injury, the skull bone flap was replaced, the skin sutured and the animal placed into a warm 
incubator (27-28oC) to recover. In certain studies, agents were administered intravenously ( i.v.)  at 30 
min post-injury. Approximately 45 min after the anaesthesia of the animal, atipamezole (Antisedan, 2 
mg/kg, s.c.) and sterile saline (100 ml/kg, s.c.) were administered to reverse the anaesthetic effect and 
provide rehydration, respectively. Each mouse was housed separated after surgery to prevent fighting 
and the interference with the surgery site such as removal of sutures. Post-operative care involved 
daily weight monitoring and twice daily administration of buprenorphine (0.05 mg/kg, s.c.) until there 
was weight gain.  
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2.1.3 DHA preparation and administration 
Stock solutions of the free fatty acid DHA (Sigma, Dorset, UK) were made up in ethanol under 100% 
nitrogen. Each 5 µl 1 M stock aliquots were kept in light sensitive, airtight glass containers (Agilent, 
Stockport, UK) and were stored at -20oC until required. An aliquot of the stock solution was diluted 
initially with 50 µl 100% ethanol and then to a final concentration providing the dose required (500 
nmol/kg) with sterile saline (NaCl 0.9%). DHA or vehicle (Veh) was administered intravenously via a tail  
vein 30 minutes post-injury in a volume of 5 ml/kg. The injections were administered by Mr Meirion 







Figure 2.1 Surgical setup for the controlled cortical impact injury (CCI) in mice. (A) Apparatus used to 
carry out the cortical impact using the computer controlled pneumatic device. (B) Positioning of the 
mouse during the surgery. (C) Mouse covered in a sterile plastic surgical drape with a craniotomy 
(arrow). (D) Macroimage of the unilateral CCI injury (arrow) in a mouse brain at 28 days post injury. (E)  











2.1.4 Behavioural studies 
2.1.4.1 Open field test 
The open field test was conducted on day 1, 7, 14, 21 and 28 post-injury. The mice were placed in a 50 
cm x 50 cm black box in low lighting and were allowed to explore for 5 minutes (Fig. 2.2). The base of  
the box was divided into 25 (10 cm x 10 cm) square zones. The distance travelled, the speed, time 
spent immobile and the number of line crossings made by the mice was recorded and tracked using 
the software ANYmaze (San Diego Instruments, USA). 
 
 
Figure 2.2 Open field test.  (A) Dimensions of the open field. (B) Division of the base into 10 x 10 
cm square zones (C) An example of an exploration trace created by the ANYmaze software (D) 
An example of an occupancy plot showing the frequency of the mouse at a particular region 






2.1.4.2 Y maze test 
The maze comprises of three arms (30 cm x 15 cm) at an angle of 120o from each other, with a 
different visual cue at the end of each arm. One arm was selected as the start arm and one arm was 
selected to be blocked off, to later become the novel arm. The animal was placed in the start arm and 
was allowed to explore the two open arms of the maze for 5 minutes. The animal was then removed; 2 
hours later it was placed back into the maze. During this time, all three arms were open and avai lable  
to explore for 5 minutes. It is expected that the ‘novel’ unexplored  arm would encourage longer 
exploration in healthy mice (Wright and Conrad, 2005, Sanderson et al., 2009). This ‘retention’ trial 
used the ANYmaze software (San Diego Instruments, USA) to record the amount of time the animal 
spent in the novel arm (Fig. 2.3). 
 
Figure 2.3 . Y maze test. (A) Dimensions of the Y maze. (B) A screen capture of a mouse marked with 
an orange dot, during the Y maze test (C) An example of an occupancy plot showing the frequency of  




2.1.4.3 Morris water maze test 
The protocol for the Morris water maze test (MWM) used was adapted from (Washington et al., 2012). 
It was conducted in very low lighting and mice were allowed to acclimatise to the room for 4 hours 
prior to testing. The MWM test was performed on days 15-19 and 22-26 after CCI injury (Fig. 2.4) .  The 
water maze tank was 100 cm in diameter and filled with water that was maintained at 26oC and made 
opaque using black or white water-based paint (dependent on mouse strain) (Fig. 2.5). Extra-maze 
spatial cues were hung on the walls of the tent in which the tank was located. The platform was 10 cm 
in diameter and was submerged 1 cm below the surface of the water. The initial training of  the mice 
took place on days 15-18 (initial acquisition phase) and consisted of 4 trials per day. The mice were 
placed into the tank at one of the four entry points, each entry point was located in the middle of each 
compass-related quadrant (NE, SE, SW & NW), and each of these entry points was used by each mouse 
on every day of the acquisition phase. The interval time between each trial for each mouse was 20 
minutes. The location of the platform stayed the same throughout the initial training.  The mice were 
given 90 seconds to locate the platform within the tank and remained on the platform for 10 seconds 
before they were removed. Mice that did not find the platform in the 90 seconds were placed on the 
platform for 10 seconds before being removed. The tracking software ANYmaze (San Diego 
Instruments) was used to record the latency to reach the platform. On day 19 after injury (24 hours 
after the last trial of the training phase), a probe trial was conducted in which the platform was 
removed and the animal was tracked over a 90 second trial. The latency to enter the zone where the 
platform used to be located was measured, as well as the number of times this zone was crossed and 
the time spent within the platform quadrant (NE). This training phase and probe trial was then 
repeated from day 22 onward, and the platform was repositioned in the opposite quadrant (reverse 
platform; SW) to the one in which the original platform was located. During the probe trial on day 26, 
the latency to the platform zone, the line crossings and time spent in the various quadrants were 
recorded, for both the original platform and the reverse platform zone. This protocol was shortened to 
just one week of acquisition training (day 15 – 18) and one probe trial (day 19), and no reverse 




Figure 2.4 Training and testing schedule for the Morris water maze. Studies were stopped after the 
first probe trial (day 19) and animals perfused at day 21, while some other trials continued with 




Figure 2.5 Morris water maze test. (A) Dimensions of the Morris water maze. (B) The compass-related 
quadrants and the positioning of the platform during different tests. (C) A screen capture of  a mouse 
marked with an orange dot during the Morris water maze test (D) An example of a trace showing the 
movement of the mouse heading to the platform observed during the testing period.  
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2.1.5 Tissue processing 
2.1.5.1 Tissue collection 
Mice were culled at 1, 21 or 28 days post-injury by inducing deeply anaesthesia with sodium 
pentobarbital (50 mg/kg, i.p), then were transcardially perfused with saline followed by 4% 
paraformaldehyde (in 0.1 M phosphate buffer). The entire brain was dissected out and post fixed in 4% 
paraformaldehyde at 4oC for 24 hours, then cryoprotected in 20% sucrose (in 0.01 M PBS) at 4oC until 
further processed. A 2 mm coronal segment surrounding the lesion site was dissected out of the brain 
and embedded in OCT embedding medium (VMR, Lutterworth) and stored at -80oC until further 
processing. 
For tissue collected for brain lipid analysis, the mice were deeply  anaesthetised with sodium 
pentobarbital, then transcardially perfused briefly with saline . Each brain was rapidly removed, 
separated into selected brain regions and frozen on dry ice. The brain regions were stored at -80oC 
until further processed. 
2.1.5.2 Tissue sectioning 
Serial 20 µm coronal sections throughout the lesion epicentre and the length of the hippocampus were 
cut using the cryostat and collected on Superfrost Plus glass microscope slides (VWR, Lutterworth, UK). 
The slides were allowed to dry at room temperature prior to storage in slide boxes at -20oC until 
further processed.  
2.1.5.3 Toluidine blue staining 
Selected slides were removed from the -20oC, allowed to warm up to room temperature and become 
dry. Slides received a 5 minute wash in 0.01 M PBS to remove OCT embedding medium. A solution of  
0.1% toluidine blue (Sigma, UK) in 70% ethanol was applied to the slides for 5 minutes. The slides were 




2.1.5.4 Imaging of toluidine blue 
Bright field images of the brain sections stained with toluidine blue were taken with a 4X objective 
using a stereology microscope (Fig. 2.6). Images were merged together using the ImageJ software 
(National Institutes of Health, USA). The lesion areas were measured using ImageJ software. 
 
Figure 2.6 Brain regions examined after toluidine blue staining. Areas shaded in blue were regions 




Slides with the frozen sections were removed from -20oC and allowed to return to room temperature. 
Slides were then washed 3 times in 0.01 M PBS for 5 minutes each time. During the 
immunohistochemistry protocol, positive controls of injured mouse spinal cord and negative  primary 
antibody omitted controls were analysed alongside the test mouse brain tissue, as appropriate.  
For the antigen retrieval procedure, after the initial PBS washes the slides were placed in an 80oC 
water bath for 30 minutes with antigen unmasking solution (Vector labs, H-3300) and then incubated 
with 10% goat or donkey serum for an hour at room temperature. Primary antibody diluted in 
antibody diluting buffer (ADB, comprised of 0.01M PBS, 0.2% Triton X-100 and 0.1 sodium azide) ,  was 
incubated with the tissue overnight at 4oC. The sections were washed 3 times with 0.01 M PBS for 5 
minutes each and then the corresponding secondary antibody conjugated with Alexa Fluor-488 or 
Alexa Fluor-594 (diluted in ADB; Molecular Probes, UK) was incubated with the tissue for 2 hours at 
room temperature. Washes in 0.01 M PBS were repeated three times and then sections were 
counterstained with the fluorescent nuclear dye Hoechst (0.2mg/100 ml, Sigma UK) for 5 minutes. 
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Slides were washed again and mounted in PBS glycerol (1:9) and stored at 4oC in the dark unti l  ready 
for microscope imaging. 
 
 
Figure 2.7 Schematic representation of the brain sections used for immunohistochemical analysis. 
A) Sagittal view of a mouse brain with the locations of the coronal sections used for analysis in relation 
to the bregma landmark. A representation of the coronal slices (levels), using the hippocampus as the 
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Fluorescent microscopy was conducted using the Leica epifluorescence microscope (Wetzlar, 
Germany). Regions of interest (ROI) identified using a 20X objective were chosen for analysis .  These 
included 4 from the cortex and 4 from the contralateral hippocampus, and from each of the 4 coronal  
brain levels chosen for analysis (-1.5 mm, -2 mm, -2.5 mm and -3 mm posterior from bregma) (Fig. 
2.7). Cortical images included 2 ROI from the ipsilateral cortex surrounding the lesion site and 2 ROI 
matching the location in the contralateral cortex. The ROI imaged in the contralateral hippocampus 
were in 4 distinct hippocampus locations; the dentate gyrus (DG), CA1, CA2 and CA3 regions. The 
staining in each region was measured or counted and expressed as mean ± standard error to the mean 





Figure 2.8 Schematic representation of the regions of interest (ROI) used for analysis at each coronal 
brain level. (A) -1.5 mm, (B) -2 mm, (C) -2.5 mm and (D) -3 mm, posterior from bregma. The ROI from 
the cortex include C1 and C2 from the contralateral cortex and C3 and C4 from the ipsilateral cortex, 
surrounding the lesion site (marked in red). There are 4 ROI within the contralateral hippocampus used 
for analysis; the dentate gyrus (DG), CA1, CA2 and CA3 regions. The size of the ROI was the view taken 
using a x10 objective. 
 
2.1.7 Image analysis 
2.1.7.1 Image analysis of GFAP and Iba1 
To determine the amount of reactive astrogliosis, GFAP immunoreactivity was analysed using the 
ImageJ software. In the cortical and hippocampal ROIs, a measuring frame of 250 µm x 250 µm was 
placed on the image and an appropriate threshold level  was set to allow for the finer processes of  the 
GFAP-positive astrocytes to be identified. The level of immunoreactivity was expressed as a 
percentage of the measuring frame and compared to the control group. This method was used as the 
reactive astrocytes in injured tissue can overlap considerably and therefore cell counts were not 
suitable.  
The number of Iba1-positive microglia was counted within a measuring frame of 250 µm x 250 µm that 
was placed on the ROI images. ImageJ software was then used to count the number of Iba1-positive 
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cells and expressed as the mean ± S.E.M. This method was chosen as the microglia maintained their 
individual domains and the Iba1 immunolabeling is weaker in the finer microglia processes, making 
accurate thresholding difficult. 
 
 
Figure 2.9 Quantification of GFAP immunolabelling using ImageJ analysis in mouse cortical brain 
tissue. (A) ImageJ software was used to convert images at a set threshold (B) where the processes of  
astrocytes could be detected. The level of immunoreactivity was expressed as a percentage of the 
measuring frame and compared to the control group. 
 
 
2.1.7.2 Image analysis of doublecortin staining 
Representative images of the dentate gyrus (DG) in the contralateral hippocampus were taken using 
the Leica epifluorescence microscope (Wetzlar, Germany), using a X20 objective. The number of 
Hoechst and doublecortin-positive cells along the DG were counted using a hand held ce l l  counter at 





Figure 2.10 Quantification of Iba1 and doublecortin staining. (A) Iba1-immunolabelled cells and (B) 
Doublecortin-labelled cells in the hippocampus. Labelled cells are indicated with red arrows and were 




2.1.8 Brain lipid analysis  
Lipid analysis was performed using the same method as previously reported and was performed in t he 
laboratory of Dr Simon Dyall at Roehampton university (Gladman et al., 2012, Dyall et al., 2007). 
Brain tissue (excluding cortex and hippocampus) of wild-type (WT) mice, fat-1 mice and naïve C57BL/6 
female mice was harvested at 24 hours after CCI and stored at -80oC until lipid analysis. Lipids were 
extracted from the brain tissue using the method described by Folch et al. (1957), with 0.01% w/v 2,6-
di-tert-butyl-p-cresol (butylated hydroxytoluene; BHT) added as an antioxidant (FOLCH et al . ,  1957) . 
The total phospholipids were isolated using thin layer chromatography (Manku et al., 1983). 
Transesterification of the lipids was carried out by the addition of 14% boron trifluoride in methanol at 
100oC for 20 minutes. The fatty acid composition was then measured and the individual fatty acids 
within each tissue sample were identified using gas chromatography coupled to mass spectrometry 
(Agilent 6890 gas chromatograph connected to an Agilent 5973 mass selective detector; Agilent  
Technologies) using a Supelcowax 10 capillary column (30 m x 0.25 mm x 0.25 mm; Sigma) (Dyall et al.,  
2007). Lipid identity was confirmed by retention times compared to known standards and mass 
spectra comparison to the National Institute of Standards and Technology database. Quantification 
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was performed on selected ion peak area by ChemStation software (Agilent Technologies, U.S.A). 
Corrections were made for variations in the detector response and values of detected fatty acids were 
normalised to 100% and expressed as mol%.  
 
2.2 In vitro studies 
2.2.1 Primary cortical astrocyte cultures 
All in vitro studies were carried out at the Eastman Dental Institute, University College London in 
collaboration with Dr James Phillips and with help from Dr Caitriona O’Rouke. The protocol  used was 
adapted from (East et al., 2009). 
The primary astrocyte cultures were prepared from the cortices of transgenic green fluorescent 
protein (GFP) postnatal 2 day-old rat pups. Following decapitation, the cortices were dissected out and 
the meninges and associated blood vessels removed with fine forceps. The tissue was cut up and 
placed in 250 µg/ml trypsin in 10 ml disaggregation medium [containing: 4 mM glucose (Sigma, UK), 3 
mg/ml bovine serum albumin (BSA; Sigma), 1.5 mM MgSO4 (VWR, UK) in Ca2+- and Mg 2+ -free Earle’s 
balanced salt solution (Gibco, Invitrogen, UK)] for 15 min at 37oC, and agitated. A dilute solution of 
soya bean trypsin inhibitor (21 µg/ml SBTI; Sigma) and deoxyribonuclease 1 (6 µg/ml DNase; Sigma) 
was then added and the cell suspension was centrifuged for 2 min at 250 ×g. The supernatant was 
removed and the pellet resuspended in 500 µl concentrated solution of SBTI (133 µg/ml) and DNase 
(40 µg/ml). The solution was triturated and a further 500 µl concentrated SBTI and DNase solution was 
added to the suspension. The material at the top of the suspension was removed to a separate  15 ml  
tube. This trituration procedure was repeated twice more. The resulting cell suspension was then 
underlain with 4 % w/v BSA, which was then centrifuged at 250 ×g for 5 min. The supernatant was 
gently removed and the pellet resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) 
supplemented with penicillin/streptomycin (100 U/ml and 100 µg/ml respectively; Sigma) and with 10  
% v/v foetal calf serum (FCS). This cellular suspension was dispensed into 75 cm2 flasks (Greiner, 
Stonehouse, UK) which had been pre-coated with poly-D-lysine (Sigma) at an approximate density of  
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1–2 cortices/flask containing 20 ml of DMEM. The cultures were stored in an incubator at 37oC with 5% 
CO2. 
Astrocytes were expanded in culture for 10 - 14 days to reach confluence. Once confluent, the medium 
was removed and 7 ml trypsin–EDTA solution (Sigma) was added to each flask for 15 min at 37 oC. The 
trypsin was neutralized by the addition of 13 ml DMEM (penicillin, streptomycin, 10% FCS). 
The astrocytes were placed into 3D cultures 24 hours prior to the mechanical injury.  Astrocytes 
seeded into gels at 1 million/ml (500,000 per well of a 24-well plate) were used. The preparation of the 
gels involved mixing a 10 % cell suspension in DMEM, 10 % 10x minimum essential medium (MEM; 
Sigma) and 80 % rat tail collagen (2 mg/ml in 0.6% acetic acid; First Link, UK), then neutralized using 
sodium hydroxide. Once the gel was gently mixed with the cell suspension, it was transferred into 24-
well plates (0.5 ml per well, resulting in gels approximately 3 mm thick). Gels were then placed into the 
incubator (37oC, 5% CO2) to set for 10 minutes. Once set, 1 ml of DMEM (penicillin, streptomycin, 10% 
FCS) was added to the well and gels were placed back into the incubator for 24 hours before lesion 
(Fig. 2.11). 
 
Figure 2.11 Timeline of the in vitro studies. Astrocytes were extracted 10-14 days prior to lesion and 
were placed in a 3D collagen gel 24 hours before lesion. DHA or vehicle was added to the gel  di rectly 
after the lesion. Astrocytes in 3D gels were fixed 1 day, 5 days and 10 days post lesion.  
 
 
2.2.2  Mechanical lesion of astrocyte cultures 
To administer the lesion injury to the gel, the medium was first removed from the gel and then the 
corresponding well was aligned under the Hatteras PinPoint impactor device. The impactor tip was 3 
mm in diameter and the parameters used for the impact were; velocity, 3.0 m/s; dwell time, 100 ms 
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and impact depth of 2 mm. After all the impacts had been administered, 1 ml of DMEM (penicillin, 
streptomycin, 10% FCS) was added to each gel and returned back to the incubator (Fig. 2.12). 
 
 
Figure 2.12 Mechanical injury to the 3D astrocyte gels. (A)  Schematic of the gel from above and from 
the side showing the height of the gel and the 100 µm z-stack imaged region chosen for analysis. (B) 
Schematic showing the regions of interest (ROI) imaged for analysis, perilesional ROIs (red) and away 
from lesion ROIs (green). (C) The HatterasTM PinPoint  impactor equipment and (D) the impact caused 
an indentation to the middle of the 3D gel. 
 
 
2.2.3 DHA administration to 3D cultures 
Stock solutions of the free fatty acid DHA (Sigma, Dorset, UK) were made up in ethanol under 100% 
nitrogen. The 5 µl 1 M stock aliquots were kept in light sensitive, airtight glass containers (Agilent, 
Stockport, UK) and were stored at -20oC until required. An aliquot of the stock solution was diluted to 
the final concentration (1 µM) with the DMEM (penicillin, streptomycin, 10% FCS) and added to each 




At 24 hours, 5 days and 10 days post-impact the gels were washed in 0.01 M PBS and then fixed in 4% 
paraformaldehyde for 24 hours. The gels were cut into halves for staining and image analysis. Cells 
were permeabilized with 0.5% Triton X-100 (Sigma, UK) for 30 minutes and then washed 3 times with 
0.01 M PBS, before being incubated with 5% normal goat serum in 0.01 M PBS for 30 minutes. After 
repeating the washes gels were incubated with rabbit polyclonal  antibody (1:300; DAKO) overnight at 
4oC. The next day after incubation with the primary antibody, washes were repeated and the gels were 
then incubated with the secondary antibody (1:300; Goat anti-rabbit Dylight 549; Vectorlabs, USA). 
The gels were washed and stored in 0.01 M PBS at 4oC. 
2.2.5 Imaging and analysis of 3D cultures 
Fluorescence microscopy was performed on the gels using a Leica Confocal DMIRB fluorescence 
microscope with LaserShape2000 software and Volocity analysis software. There were 3 images taken 
in the perilesional area and 3 taken away from the lesion, as shown in Fig. 2.12. Each field was 1 x 1 
mm x 100 µm (xyz), with 100 slices per stack in the Z dimension. Using the Volocity software the 
volume of GFP or GFAP staining per field was measured, the numbers of cells were counted and the 
staining per cell was calculated. The numbers of processes per cell were counted using ImageJ 
software and the distribution of the number of processes presented as a histogram. 
2.3 Statistical analysis 
All testing and analysis was performed blinded. All statistical analyses were performed using Graph Pad 
Prism 5.0 (GraphPad, USA). For the open field and the MWM acquisition trial tests, a two-way 
repeated measures ANOVA with post-hoc Bonferroni testing was used. One-way or two-way ANOVA 
testing or Kruskal-Wallis tests were used to compare experimental groups in all other behavioural tests 
and in the histological analysis. Data was presented as mean with standard error of the means (S.E.M.)  





3 Characterisation and optimisation of a mouse model of TBI  
3.1 Introduction 
There is a strong and immediate need for novel therapies in the treatment of TBI. Potential novel 
therapies for TBI need to be screened for efficacy in vivo before being brought to the clinic. At the 
beginning of this thesis work there was no established in vivo model of TBI at Queen Mary Universi ty 
of London.  
As previously discussed in the main introduction (section 1.8) there are many experimental TBI models 
which can be carried out in mice and rats, including the fluid percussion model, the weight 
drop/Marmarou model and the controlled cortical impact (CCI) injury model (Xiong et al.,  2013) . This 
chapter presents data from studies designed and performed to optimize a CCI injury in mice within our 
group. The CCI model was chosen due to it being a widely used model for creating a focal TBI in mice, 
its high reproducibility, and also because our group has already set up an established model of SCI 
contusion injury. The impactor used to set up this CCI model was the same used to cause spinal  cord 
contusion injury in rats and mice. The aim of the work presented in this chapter was to establish a 
human TBI equivalent and reproducible CCI model in mice, with behavioural endpoints and related 
histopathological changes. The optimisation of a CCI mouse model in our laboratory would then al low 
us to evaluate potential TBI therapies and their impact in terms of functional outcome and tissue 
protection.  
3.1.1 Controlled cortical impact injury model 
There are several parameters that need consideration when setting up the CCI model of injury. The 
parameters were chosen with regards to the technical specifications of the Hatteras PinPoint Impactor 
equipment and to reflect the most often used parameters in the literature, as detailed in section 2.1.2 
(Romine et al., 2014, Chen et al., 2014, Pleasant et al., 2011, Whalen et al., 1999, Smith et al., 1995,  Jin 
et al., 2012, Kabadi et al., 2012, Saatman et al., 2006, Susarla et al., 2014, Washington et al., 2012) . 
This is so that the results obtained in our CCI model could be compared to those reported by other 
groups, and thus allow us to ascertain the validity of our observations.  In particular, the impact depth 
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parameter was the independent variable (depths of 1.5 mm, 2 mm and 2.2 mm from surface of the 
brain) being assessed. It is important to establish an injury severity with defined endpoints, so that  this 
model can be used as a screening tool for novel TBI therapies. The behavioural and histological 
outcomes of these impact depths helped determine the impact depth parameter to be used in al l  the 
subsequent TBI studies shown within this thesis. 
3.1.2 Behavioural outcome measures 
One of the major symptom complaints made by TBI patients is memory loss (Paniak et al., 2002, 
Gasquoine, 1997). Memory loss is frequently assessed after CCI injury in rodents using the MWM tes t 
and this test was therefore selected to assess the memory deficits in our mice. As the MWM is most 
commonly performed two weeks after the injury was induced, we decided to employ the Y -Maze as 
another test to assess memory and learning deficits earlier in our protocol. Unlike the MWM, the Y-
Maze does not require any stress-induced motivation and could therefore assess baseline learning and 
memory function of the mice after injury. The open field test was also included in our behaviour 
testing protocol, to ensure that any deficits seen in the cognitive behaviour tests are due to poor 
cognition and not motor dysfunction. 
3.1.3 Histological endpoints 
As discussed in the introduction, there are several cellular cascades that form part of the secondary 
injury. Glial cells in particular have a pronounced response during the secondary injury. The astrocytes 
and microglia change their morphology and express injury-induced proteins that correlate with injury 
severity. A hallmark of injury-induced astrogliosis is the increase in the expression of the intermediate  
filament GFAP. This is seen in post-mortem brain tissue of TBI patients (Harish et al., 2015). Activated 
microglia can be identified by the expression of calcium-binding protein Iba1 (Ito et al., 2001).  Another 
key feature of the primary and secondary injury is cell death, which underlies tissue loss. Several 
groups have reported substantial tissue loss after CCI directly below the site of impact,  using gross 
histological assessment (Bermpohl et al., 2006, Onyszchuk et al., 2007, Zhao et al., 2012a). In order for 
our CCI model to be comparable to other studies in the literature, we focussed on the evidence  of 




The animals used in this chapter were CD1 male mice aged 10-12 weeks. The CCI injury model used to 
cause a unilateral injury is described in section 2.1.2. The behavioural tests in this chapter include the 
open field test (section 2.1.4.1), Y-maze test (section 2.1.4.2) and the MWM acquisition and probe trial  
tests (section 2.1.4.3), and the reverse MWM paradigm. The general protocol used for the execution of 
these behavioural tests is detailed in figure 3.1. After perfusion on day 28 post-injury, brain tissue was 




Figure 3.1 Timeline for the administration of the behavioural tests after surgery. Including the open 
field, Y-maze and the first MWM acquisition (day 15-18) and probe trial (day 19), and the second week 













3.3 Aims and hypotheses 
3.3.1 Aims 
The aim of the work presented in this chapter was to characterise a CCI mouse model of TBI with long -
term behavioural and histological endpoints including:  
• Transient and long lasting deficits in learning and memory as assessed by the Y-maze 
and the MWM acquisition and probe trials, respectively. 
• Persistent tissue damage and reactivity around the site of the impact; tissue loss and 
glial cell activation 
 
3.3.2 Hypothesis 
The hypothesis for this work is that CCI injury at graded depths will produce graded neurological 
deficits which can be assessed using the Y –maze test, open field test, and Morris water maze (MWM) 
test. We also hypothesized that histological changes would show a positive correlation with  the 














The results document the characterisation of a CCI mouse model of injury that produces a lesion that 
creates a sufficient, but, potentially, rescuable deficit in a memory-based behavioural test. The 
parameter that was used to alter the severity of the CCI injury was the depth of the penetration of the 
impactor tip into the brain. In the first study, we used impact depths of 1.5 mm and 2.0 mm. In the 
second study, the impact depth was increased to 2.2 mm. We also assessed the histopathological 
changes in the brain tissue of these mice at 28 days post CCI injury, using immunohistochemistry.  
3.4.1 The effect of injury severity in the open field test 
The open field test was used to assess gross locomotor function, anxiety-related behaviour 
(thigmotaxis), habituation and hyperactivity (section 1.8.3.1). To assess the potential gross and 
persistent deficits caused by a CCI injury, control and injured mice were exposed to the open fi eld test 
chamber for 5 minutes at 5 time points post-injury; 1, 7, 14, 21 and 28 days. 
The zones in which the mice spend their time during the 5 minute open field test can be indicative  of  
both anxiety-related behaviour as well as habituation to the open-field chamber. Al l 4 groups (naïve  
uninjured controls, sham-craniotomy, 1.5 mm and 2.0 mm impact depth) exhibited similar behavioural 
profiles in terms of the amount of time they spent in the outer zone against the walls of the open field 
chamber (thigmotaxis) (Fig. 3.2B), the time they spent in the inner zone (Fig. 3.2C) and the number of  
entries to the central zone during the test (Fig. 3.2D). All groups spent less time in the inner zone and 
more time in the outer zone over the course of the study.  
On day 1 post-injury the 4 groups (naïve, sham-injured, 1.5 mm and 2.0 mm CCI injured) showed no 
significant difference to each other in the distance they travelled and the number of line crossings they 
made during the five minute trial. However, at day 7 post-injury the naïve group behaviour was 
different compared to the injured groups. Between day 1 and day 7 the naïve group reduced the 
distance travelled from 28.9 ± 1.6 m to 20.1 ± 1.3 m, whereas the distance travelled by the 3 injured 
groups remained above 25 metres on both day 1 and day 7 (Fig. 3.3A). 
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The naïve group also showed a difference in the number of line crossings on day 7, when compared to 
the 3 injured groups (Fig. 3.3B). The number of line crossings the naïve group made on day 1 (234.5 ± 
18.3) and day 7 (228.8 ± 9.0) were similar, whereas the 3 injured groups increased the number of  l ine 
crossings from day 1 to day 7. The differences exhibited between the behaviour of the naïve group and 
the injured groups during the first week disappeared in the subsequent open field tests on days 14, 21 
and 28 (Fig. 3.5). 
All 4 injury groups spent less than 30 seconds immobile on day 1 post injury ( Fig. 3.6). At the end of the 
first week, the naïve group spent almost 3 fold as much time immobile when compared to th e sham, 
1.5 mm and 2.0 mm injury groups. The naïve group continued to spend the most time immobile when 




Figure 3.2. Effect of injury severity on open field performance. (A) Representative occupancy plots 
from open field testing on day 1 and day 28 from each experimental group. (B, C) The average time 
spent by each group in the outer perimeter and the inner zone. (D) The average number of entries to 






Open Field – Day 1 and Day 7 
 
Figure 3.3. Effect of injury severity on the distance travelled and line crossings in the first week. (A) 
total distance travelled and (B) the number of line crossings on days 1 and 7 of testing. On day 7 the 
naïve vs. 1.5 mm injury group showed statistically significant differences (**p<0.01) using a two way 
ANOVA with post-hoc Bonferroni testing. Mean ± S.E.M. N= 4-8 animals per group. 
 
Open Field - Total Distance Travelled 
 
Figure 3.4 The total distance travelled after injury in the open field.  (A) all 4 groups, (B) naïve vs. 
Sham, (C) naïve vs. 1.5 mm and (D) naïve vs. 2.0 mm, at day 1, 7, 14, 21 and 28 post-injury. Mean ± 






Open Field – Number of Line Crossings 
 
Figure 3.5 The number of line crossings after injury in the open field. (A) all 4 groups, (B) naïve vs. 
sham, (C) naïve vs. 1.5 mm and (D) naïve vs. 2.0 mm, at day 1, 7, 14, 21 and 28 post-injury. Mean ± 




Open Field – Time Spent Immobile 
 
Figure 3.6 The effect of injury severity on the time spent immobile within the open field test.  (A) All 
4 groups, (B) naïve vs. sham, (C) naïve vs. 1.5 mm and (D) naïve vs. 2.0 mm, at day 1, 7, 14, 21 and 28 















3.4.2 The effect of injury severity in the Y-maze test 
The Y-maze novel arm protocol was used in this study to assess memory deficits (sections 1.8.3.2, 
2.1.4.2). On day 3 and day 8 post-injury the mice received two trials, an acquisition trial and a 
retention trial with a 2 hour inter-trial time. Increased attention towards the novel arm in the 
retention trial suggests that the mice retain their memory function. 
On day 3, mice in the 1.5 mm and 2.0 mm injury groups spent less time in the novel arm than the naive 
and sham-injured groups (Fig. 3.7B). Mice exposed to the novel arm for the first time should spend 
more than a third of the retention trial time (5 minutes) in the novel arm, therefore mice spending 
longer than 100 seconds in the novel arm are exhibiting normal exploratory behaviour and reaction to 
novelty. Both the naïve and sham-injured groups spent more than 100 seconds in the novel arm: naive  
group (123.6 ± 9.7 s) and the sham-injured group (115.3 ± 10.5 s). 
At day 8 post-injury all the groups spent more than 100 seconds in the novel arm (Fig. 3.7D). The naive 
group spent the longest time in the novel arm.  The mice in the 3 injury groups spent more time in the 
novel arm at day 8 than they had during the earlier Y-maze test on day 3 (Fig. 3.8A). The 2.0 mm CCI 
group made the most entries to the novel arm during the day 3 retention trial (Fig. 3.7C). At day 8 the 
naive and 1.5 mm CCI group made more entries than the sham and 2.0 mm CCI groups. Statistical 
analysis revealed no group was significantly different compared to the others in either measurement, 









Y-Maze – Day 3 and 8 post injury 
 
Figure 3.7. Effect of injury severity on Y-maze performance. (A) Representative occupancy plots from 
the day 3 retention trials for each experimental group. (B) Time spent exploring the novel arm and (C)  
the number of entries into the novel arm during the 5 minute retention trial on day 3 post -injury. 











Y-Maze – Day 3 and Day 8 
 
Figure 3.8. Effect of injury severity on the Y-maze performance on day 3 and day 8. (A) The time 
spent in the novel arm and (B) Number of entries to the novel arm on day 3 and day 8. (C) The 
difference in time spent in the novel arm between day 3 and day 8. (D) The time spent in the novel 
arm divided by the number of entries to the novel arm, on day 3 and day 8. Mean ± S .E.M. N = 4- 8 











3.4.3 The effect of injury severity in the Morris water maze 
3.4.3.1 The effect of injury severity in the Morris water maze test acquisition trial  
The acquisition phase of the MWM is designed to test the capacity of the mice to learn.  Over the 
course of the 4 testing days during the acquisition phase, all of the groups became faster at locating 
the hidden platform and escaping the water (Fig. 3.9B). The naïve group had the steepest decrease in 
escape latency over the acquisition trial period (naive day 15 vs. day 18; ***p<0.001), suggesting that 
they had the best learning capacity.   
The naïve group (15.2 ± 5.2 s) showed a significant decrease in escape latency when compared to al l  3 
other groups (sham 32.7 ± 3.8 s, *p<0.05; 1.5 mm 38.9 ± 4.4 s, **p<0.01; 2.0 mm 48.9 ± 6.9 s, 
***p<0.001) at day 17 post-injury. 
The naïve group demonstrated a faster escape latency than the sham-injury group at day 17 (Fig. 
3.9C), and the difference was statistically significant (*p<0.05). The naïve group (12 ± 2.4 s)  sti l l  had a 
faster escape latency than the sham-injured group (26.7 ± 5.7 s) on day 18 post-injury, but the 
difference was not statistically significant. 
On day 18 post-injury the naïve group showed a significant difference in escape latency when 
compared to the 1.5 mm (*p<0.05) and 2.0 mm injury (**p<0.01) groups. The average escape latency 
of the 4 trials conducted on day 18 for the naïve group (12 ± 2.4 s) was almost 4-fold lower than that of 
the 2.0 mm injury group (44 ± 5.7 s). 
The sham-injured group did not show any significant differences compared to the 1.5 mm and 2.0 mm 






Figure 3.9. Effect of injury severity on acquisition training in the Morris water maze. The average 
escape latency of the 4 trials conducted on each day of the acquisition phase. (A) Representative 
traces from a trial on day 18 post-injury during the acquisition phase. (B) Escape latencies for all 4 
experimental groups during the acquisition phase. (C) Acquisition phase showing naïve vs. sham-injury; 
the naïve group shows a significant difference to the sham group (*p<0.05) on day 17 post-injury. (D)  
naïve vs. 1.5 mm injury group; there is a significant difference in escape latencies on day 17 and 18 
post-injury (*p<0.05, **p<0.01). (E) naïve vs. 2.0 mm injury group, with significant differences at day 
17 and 18 post-injury (**p<0.01, ***p<0.001). (F) sham-injured vs. 1.5 mm injury group and (G) sham 
vs. 2.0 mm injury group, with no significant differences between them. Repeated measures two -way 




3.4.3.2 The effect of injury severity in the Morris water maze - probe trial  
At 24 hours after the last trial of the acquisition phase, the probe trial was conducted. The platform 
was removed from the tank and the mouse was allowed to swim and explore the tank for 90 seconds. 
Mice that can recall the location of the platform from the 4 days of acquisition training are expected to 
spend more time in the target quadrant that used to contain the platform, have a short latency to the 
platform zone and revisit the platform zone more frequently. 
If a mouse spends more than a quarter of the trial time in the target quadrant, it can be proposed that 
the mouse has a preference for spending time in that quadrant, thus remembers the location of the 
platform. The naïve group was the only group to spend more than 25 % of the probe trial in the target 
quadrant, whereas the 2.0 mm group spent only 20.2 % of time in the target quadrant (Fig. 3.10B).  
The naïve, sham-injured and 1.5 mm injury group had a short latency to entry to the platform zone (Fig 
3.10C). In contrast, the mean average latency of the mice in the 2.0 mm injury group was almost 
double that seen in the 3 other groups. Despite this difference, there was no statistically significant 
difference between the 4 groups, overall.  
The number of platform crossings did not vary much between the naïve (8.3 ± 2.8), sham-injured (8.4 ± 
3.0) and 1.5 mm (7.4 ± 2.3) injured groups, whereas the 2.0 mm group (5 ± 2.4) made fewer platform 
crossings during the probe trial. The two other outcome measures which were the ‘total distance 














Figure 3.10. Effect of injury severity on the probe trial performance in the Morris water maze. (A) 
Representative track plots of a mouse from each experimental group. (B) The percentage time the 
mice spent in the target quadrant (where the platform used to be situated). (C) The latency to the zone 
where the platform used to be situated. (D) The number of crossings of the platform zone. (D)The total 
distance travelled during the probe trial. (E) The average speed during the probe trial.  Mean ± S .E.M. 





3.4.3.3 The effect of injury severity in the Morris water maze - reverse acquisition trial  
It was decided that due to the lack of significant difference between the sham group and the injury 
groups in the rate of learning in the first week of acquisition phase trial, a second week of acquisi tion 
training should be performed, as demonstrated in a protocol used by Washington and colleagues 
(Washington et al., 2012). In this second week of training the platform is moved to the quadrant 
opposite the initial location (from north-east quadrant to the south-west quadrant). This reverse 
acquisition training can be used to expose possible subtler deficits in learning between the injury 
groups.  
Using this new paradigm, the sham and the 1.5 mm injury groups showed no difference in escape 
latency in the reverse acquisition trial when compared to the naïve group (Fig. 3.11). The 2.0 mm 
injury group showed a significantly different (*p<0.05, ***p<0.001) escape latency when compared to 
the naive group on all 4 days of the acquisition phase of the reversal training (Fig. 3.11D). When 
compared to the sham-injured group, the 2.0 mm group also showed a significant deficit (*p<0.05)  in 
escape latency on the 2nd and 3rd training days of the second week reversal acquisition trial (Fig. 3.11F). 
















Reverse Acquisition Trial 
 
Figure 3.11. Effect of injury severity on the reverse acquisition training in the Morris water maze. 
The average escape latency of the 4 trials conducted on each day of the acquisition phase. (A) escape 
latencies for all 4 injury groups, (B) acquisition phase showing naïve vs. sham-injury, (C) naïve  vs. 1.5 
mm injury group, (D) naïve vs. 2.0 mm injury group, with significant differences on all trial  days post -
injury (*p<0.05,***p<0.001). (E) sham-injured vs.1.5 mm injury group and (F) sham vs. 2.0 mm injury 
group, with a significant difference between them at days 23 and 24 post-injury (*p<0.05). Repeated 
measures two way ANOVA with post-hoc Bonferroni testing used for statistical testing. Mean ± S .E.M. 




3.4.3.4 The effect of injury severity in the Morris water maze - reverse probe trial  
3.4.3.4.1 Reverse platform 
At 24 hours after the completion of the second week of the MWM, i.e. the reverse acquisition trial , a 
probe trial was conducted (Fig. 3.12). In the reversal probe trial the sham, 1.5 mm and 2.0 mm groups 
were slower at getting to the reverse platform zone than the naive group (Fig. 3.12B). The naive group 
took under half of the time (12.8 ± 5.0 s) to get to the reverse platform zone than the sham group 
(26.3 ± 6.3 s), the 1.5 mm (23.7 ± 4.6 s) and 2.0 mm (24.0 ± 6.8 s) injury groups. The naive group also 
showed a higher number of reverse platform zone crossings (6.3 ± 1.4), when compared to the sham 
group (4.7 ± 0.9), the 1.5 mm (4.6 ± 0.8) and the 2.0 mm (4.8 ± 1.0) injured groups (Fig 3.12C). 
3.4.3.4.2 Original platform 
During the day 26 probe trial, outcome measures relating to the location of the original platform (f i rst 
week of MWM testing; NW quadrant) were also measured. These included: ‘Time in the original 
platform quadrant’, ‘latency to the original platform zone’ and the ‘number of original platform zone 
crossings’ (Fig. 3.13). 
The naïve and sham control groups displayed different behaviours when compared to the 1.5 mm and 
2.0 mm injury groups with regard to the original platform measures. The naïve (33.5 ± 10.9 s) and 
sham (40.2 ± 11.2 s) groups took longer to visit the original platform zone than the 1.5 mm (14.2 ± 7.4 
s) and 2.0 mm (16.7 ± 7.6 s) injury groups. The naïve and sham groups exhibited a higher number of 
original platform zone crossings in comparison to the CCI injury groups, although the naïve group (4.75 
± 1.4) visited the zone almost twice as much as the sham group (2.6 ± 1.1). In the probe trial after the 
second week of MWM testing, neither of the 1.5 mm or 2.0 mm injury groups demonstrated any 
significant differences compared to the sham or naïve groups. 
3.4.3.4.3 Reverse Probe Trial –Reverse and Original Platform 
The naive and sham groups exhibited different behaviours compared to the 1.5 mm and 2.0 mm injury 
groups with regard to the original platform zone, during the day 26 probe trial. The naïve and sham 
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groups took longer to get to the original platform zone, but then visited the original platform more 
often and spent more time in the quadrant in which the original platform was located (Fig. 3.14).  
The two injured groups (1.5 mm and 2.0 mm) made statistically significantly (*p<0.05) fewer entries to 
the original platform zone than the reverse platform zone in the day 26 probe trial. The 1.5 mm group 
visited the reverse platform 4.6 ± 0.8 times and the original platform 1.0 ± 0.6 times. The 2.0 mm 
group visited the reverse platform 4.9 ± 1.1 times and the original platform 1.2 ± 0.7 times. This 
suggests that the injured groups had more difficulty recalling the location of the original platform.  
Reverse Probe Trial – Reverse Platform 
 
Figure 3.12 Effect of injury severity on reverse probe trial performance in the second week of Morris 
water maze testing. (A) The percentage time the mice spent in the target quadrant (whe re the 
platform used to be situated). (B) The latency to the zone where the platform used to be situated. (C)  
The number of crossings of the reverse platform zone.  No statistical differences using one -ANOVA. 
Mean ± S.E.M. N = 4-8 animals per group. 
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Reverse Probe Trial –Original Platform 
 
 
Figure 3.13.  Effect of injury severity on original platform measures during the reverse probe trial. 
(A) The percentage time the mice spent in the original platform quadrant (where the original platform 
used to be situated). (B) The latency to the original platform zone. (C) The number of crossings of  the 






Reverse Probe Trial –Reverse and Original Platform 
 
Figure 3.14 Reverse probe trial. (A) The latency to the reverse and original platform zones and (B)  the 
number of crossings of the reverse and original platform zones by all four groups during the day 26 
probe trial. The 1.5 mm (*p<0.05) and 2.0 mm (*p<0.05) injury group made statistically significantly 
fewer crossings of the original platform than the reverse platform. Two-way ANOVA with post-hoc 






3.4.4 Increase in injury severity 
The 1.5 mm and 2.0 mm injury groups showed no significant differences to the naïve and sham control  
groups in the probe trials, after the first and second week of the acquisition trials. As the most severe 
injury depth of 2.0 mm failed to show statistically significant and robust differences compared to the 
sham craniotomy group, another optimisation study was conducted with an increased impact depth of 
2.2 mm, tested against a group of sham injured animals. This study also included open field testing and 
the two-week MWM protocol including the reverse acquisition and probe trial (Fig. 3.15).  
 
Figure 3.15. Timeline for the execution of the behavioural tests after surgery. The open field and the 
first MWM acquisition (day 15-18) and probe trial (day 19), and the second week reversal MWM 




3.4.5 The effect of a 2.2 mm injury severity in the open field test 
The open field test was conducted using the same protocol as in the previous study (Fig. 3.15). The 
time spent in the outer and inner zones, the time spent immobile, total distance travelled and the 




















There was no difference between the 2.2 mm injury and sham group in the time they spent in the 
inner or outer zone (Fig. 3.17A - B). Both the sham and 2.2 mm group spent the same amount of  time 
immobile on day 1 post-injury. Over the course of the study the sham group spent an increasing 
amount of time immobile, while the time spent immobile by the 2.2 mm injury group remained 
constant (Fig. 3.18C). On day 28 post-injury the sham group (52.6 ± 7.6 s) spent almost twice as much 
time immobile as the 2.2 mm injury group (23.6 ± 5.6 s). At this time point the difference was found to 
be statistically different (*p<0.05), using a two-way ANOVA with post-hoc Bonferroni test. 
The total distance travelled (Fig. 3.18C) and the number of line crossings (Fig. 3.18D) made by mice in 
the 2.2 mm injury group and sham group showed no statistically significant differences on any of 
testing days. However, between day 1 and day 7 the 2.2 mm injury group increased the distance 
travelled and the number of line crossings made (Fig. 3.18A - B). In contrast, the sham group decreased 
the distance they travelled and the number of line crossings made between day 1 and day 7 (Fig. 3.18A 
- B).  
Sham 2.2 mm 
Figure 3.16 Effect of a 2.2 mm injury on the open field performance. Representative occupancy plots 






Figure 3.17 Open field testing of a 2.2 mm injury versus a sham injury at day 1, 7, 14, 21 and 28 post-
injury. (A)  The time spent in the outer zone and (B) the time spent in the inner zone. (C) The total time 
spent immobile; there is a significant difference between the sham and 2.2 mm injury group at day 28 
post-injury (*p<0.05), using a two-way ANOVA with post-hoc Bonferroni testing. (D) The average speed 














Figure 3.18 Open field testing of a 2.2 mm injury versus a sham injury. (A) The total distance travelled 
and (B) the number of line crossings made by the mice on day 1 and 7 i n the first week post—injury. 
(C) Total distance travelled and (D) the number of line crossings at day 1, 7, 14, 21 and 28 post- injury. 










3.4.6 The effect of a 2.2 mm injury in the Morris water maze   
3.4.6.1 The effect of a 2.2 mm injury in the Morris water maze - acquisition and probe trial 
As in the previous study, the acquisition trial of the MWM is designed to test the capacity of  the mice 
to learn. The mice in the 2.2 mm injury group had a longer escape latency time on each of the 
acquisition training days, compared to the sham group (Fig. 3.19A, B). The 2.2 mm group did reduce 
their escape latency from the first day of training (day 15) to the last day of the acquisition trial (day 
18), from 72.2 ± 7.0 s to 41.5 ± 6.0 s. Despite this reduction in escape latency, the sham group was sti l l  
statistically significantly (***p<0.001) faster at locating the platform on all four days of the acquisition 
trial. 
During the probe trial held on day 19 (Fig. 3.19C - D), the sham group first entered the platform zone 
significantly (*p<0.05) faster than the 2.2 mm injury group. The sham group also entered the platform 
zone more often than the 2.2 mm group, although there was no statistically significant dif ference vs. 




Figure 3.19. Effect of a 2.2 mm injury vs. sham control on acquisition training and probe trial in the 
first week of the Morris water maze. (A) Representative traces from a trial on day 18 post-injury 
during the acquisition training and probe trial. (B) The average escape latency of the 4 trials conducted 
on days 15 – 18 post-injury during the acquisition training.  On all days of the acquisition training the 
2.2 mm injury groups had a slower escape latency when compared to the sham group (***p<0.001). 
Statistical significance was determined using a two-way repeated measures ANOVA with post-hoc 
Bonferroni test. On day 19 a probe trial was conducted. (C) The time to the platform zone. The 2.2 mm 
injury group was slower than the sham group (*p<0.05). (D) The number of entries to the platform 
zone during the probe trial on day 19 post-injury. Mean ± S.E.M. N = 4–7 animals per group. 
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3.4.6.2 The effect of a 2.2 mm injury severity in the Morris water maze - Reverse acquisition trial 
As in the previous study, a reverse acquisition and probe trial was performed. The platform was moved 
from its original location to the quadrant opposite (from north-east quadrant to the south-west 
quadrant).  The 2.2 mm injury group had a longer escape latency when compared to the sham group, 
on every day of the reverse acquisition training (Fig. 3.20A). The difference in escape latencies was not 
as large as in the first week of acquisition training, but was still statistically significant (*p<0.05), when 
using a two-way repeated measures ANOVA with post-hoc Bonferroni test.  
3.4.6.3 The effect of a 2.2 mm injury severity in the Morris water maze - Probe trial 
A second probe trial was conducted on day 26, 24 hours after the last training trial of the acquisition 
phase. The platform was removed from the pool and outcome measures relating to the reverse 
platform zone and the original platform location were recorded during the 90 second trial (Fig. 3.20B, 
C, D & E). 
3.4.6.3.1 Reverse Platform 
In the probe trial the 2.2 mm injury group entered the reverse platform zone slower than the sham 
group (*p<0.05) (Fig. 3.20B). The sham group first entered the reverse platform zone in 5.4 ± 1.5 s, 
whereas the 2.2 mm injury group first entered the zone in 27.0 ± 8.0 s. The sham group also entered 
the reverse platform zone more frequently than the 2.2 mm injury group (4.7 ± 0.7 vs. 3.0 ± 0.9 
entries), although this difference was not statistically significant.  
3.4.6.3.2 Original Platform 
During the probe trial outcome measures relating to the original platform zone were also measured 
(Fig. 3.20D, E). The time taken for the 2.2 mm injury group and the sham group to visit the original 
platform zone was very similar and did not show any significant differences. This was also the case for 




Figure 3.20 Effect of a 2.2 mm injury vs sham control on the reverse acquisition training. The average 
escape latency of the 4 trials conducted on days 22 – 25 post-injury in the reverse paradigm. On all 
days of the reverse acquisition training the 2.2 mm injury groups had a slower escape latency when 
compared to the sham group (*p<0.05). Statistical significant was determined using a two-way 





3.4.7 The effect of injury severity on the ipsilateral hemisphere - cortex and hippocampus 
After perfusion of the mice on day 28, the brain tissue was cut into coronal sections. Sections from 4 
locations (-1.5, -2, -2.5 and -3 mm posterior to bregma) spanning the area of the lesion were analysed 
using a general histological stain (toluidine blue; a blue dye that has a high affinity for acidic cell 
components, such as nucleic acids), to assess the extent of tissue lost after injury (Fig. 3.21). 
The increased injury depth and severity resulted in an increased tissue loss at 28 day post -injury on the 
ipsilateral side of the brain compared to the contralateral side (Fig. 3.22). The size of the ipsilateral 
hemisphere, cortex and hippocampus were measured as a percentage of the equivalent contralateral 
brain region, on selected sections. All three injury groups (1.5, 2.0, 2.2 mm) lost over 20 % of the 
ipsilateral cortical area (Fig. 3.22B).  
The 1.5 mm injury group had a 20 % loss in ipsilateral cortical tissue, but no loss in ipsilateral 
hippocampal tissue. In contrast, the 2.0 mm and 2.2 mm injured groups lost over 50% of the 
hippocampus on the ipsilateral side (Fig. 3.22C). Qualitatively, the ipsilateral hippocampal tissue in the 
1.5 mm group maintained a normal structure, while the remaining hippocampal tissue in the 2 .0 mm 
and 2.2 mm injury groups had a much distorted structure, with some regions of the hippocampus 
being compressed or absent entirely (Fig. 3.21).   
The sham injury group showed no significant tissue loss in any of the three measurements, however 
toluidine blue staining revealed damage to the surface of the cortex beneath the site of the 







Figure 3.21. Brain sections stained with toluidine blue. Coronal brain sections (20 µm) posterior from the naïve, sham, 1.5 mm, 2.0 mm and 2.2 mm injury groups. 
The brain sections were taken from the following location posterior to bregma skull landmark: -1.5 mm, - 2.0 mm, -2.5 mm and - 3.0 mm. The red arrowheads 
indicate the region of craniotomy and the red arrows indicate the location of the injury site. 
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Ipsilateral hemisphere, cortex and hippocampal changes 
 
 
Figure 3.22. The effect of injury severity on the ipsilateral brain regions as compared to the 
contralateral side. (A) hemisphere, (B) cortex and (C) hippocampus. Statistical significance was found 
using one-way ANOVA and post-hoc Bonferroni testing (*p<0.05, **p<0.01, ***p<0.001). Mean ± 
S.E.M. N = 3 animals per group. 
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3.4.8 The effect of injury severity on astrocytes in the cortex and the hippocampus 
Following TBI, the glial cells, such as astrocytes and microglia in the area surrounding the lesion si te , 
can become ‘activated’ (section 1.2.2.7). When ‘activated’, these glial cells change their morphology 
and phenotype. In particular, when astrocytes become ‘activated’ they begin to undergo a process 
called ‘reactive astrogliosis’, and become hypertrophic, highly ramified and upregulate the 
intermediate filament protein GFAP (Sofroniew, 2009). Brain tissue collected from the mice was 
immunolabelled with an anti-GFAP antibody, to assess the extent of reactive astrogl iosis induced in 
the different injury groups, within the cortex and the contralateral hippocampus. The amount of GFAP 
staining was measured by the percentage increase in staining compared to the naïve control group.   
Four regions of interest (ROI) within the cortex were chosen for the analysis of the GFAP 
immunofluorescence. Two ROI from the border of the lesion site (Fig. 3.24A; C3 - C4) in the ipsilateral  
cortex were analysed and two ROI in the equivalent locations on the contralateral side (Fig. 3.24A; C1 -  
C2). The amount of GFAP immunofluorescence was calculated as a percentage increase when 
compared to the naïve group GFAP staining within the same ROI.  
Within the contralateral cortex (Fig. 3.24B), the sham, 1.5 mm and the 2.0 mm injury groups all 
showed an increase in GFAP staining compared to the equivalent area in the naïve group. The 2.2 mm 
injury group had a much higher increase (486.5 ± 155 %) in the amount of GFAP staining compared to 
the naïve group. Despite this increase there was no statistically significant difference overall.  
In the ipsilateral cortex (Fig. 3.24C) the sham group showed no increase in GFAP labelling compared to 
the naïve group. The 1.5 mm and 2.0 mm injury groups both showed an increase in GFAP staining by 3-
fold, while the 2.2 mm group showed an increase in GFAP staining of over 600 % compared to the 
naïve group. The 2.2 mm injury group showed a statistically significant (**p<0.01) difference 
compared to the sham group.  
Due to the destruction of the ipsilateral hippocampus, ROI in the contralateral hippocampus were 
analysed for GFAP staining. Four ROI in the contralateral hippocampus, including the dentate  gyrus 
(DG), and areas CA1, CA2 and CA3 were analysed (Fig 3.24A). The four ROI showed a graded 
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percentage increase in GFAP vs. the equivalent areas in the control group, correlating with the severity 
of the injury (Fig. 3.24D), sham (121.6 ± 39 %), 1.5 mm (152.3 ± 19.1 %), 2.0 mm (192.9 ± 19.1 %) and 
the 2.2 mm injury group (270.4 ± 73.8 %). The analysis of the DG ROI showed that the sham, 1.5 mm 
and 2.0 mm injury groups all displayed a similar percentage increase in GFAP labelling compared to the 
naïve group (Fig. 3.24E). However, the 2.2 mm injury group, showed a much higher increase in GFAP 
labelling compared to naïve, of almost 400%, with increased astrogliosis nearer the lesion. 
 
 
Naive Sham 1.5 mm 
2 mm 2.2 mm Glial Scar 
A B C 
D E F 
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Figure 3.23. The effect of injury severity on the GFAP expression. Immunolabelling of reactive 
astrocytes with GFAP in the ipsilateral cortex in the (A) naïve, (B) sham-injured, (C) 1.5 mm, (D) 2.0 
mm, (E) 2.2 mm injury groups in tissue adjacent to the lesion (top of image), (F) the glial  scar in a 2.0 






Figure 3.24. The effect of injury severity on the reactive astrogliosis in the cortex and hippocampus. 
(A) Schematic showing the ROI in the cortex and hippocampus that were analysed for GFAP label l ing 
(GFAP+). The percentage increase in GFAP labelling compared to the naïve  group in (B) the 
contralateral cortex, (C) the ipsilateral cortex, (D) the contralateral hippocampus and (E)  the dentate  
gyrus of the hippocampus. Statistical significance was determined using one -way ANOVA and post-hoc 






3.4.9 The effect of injury severity on the microglia in the cortex and the hippocampus 
In the same ROI, the microglia cells were labelled using an anti -Iba1 antibody. Iba1 is a calcium-binding 
protein that is up-regulated in microglia after injury and indicates activation of these cells  ( Ito et al . ,  
2001).  However, Iba1 also labels cells of monocytic lineage including infiltrating macrophages, which 
are more likely to be present in injured brain tissue due to the breakdown of the BBB. Differentiating 
between the two cell types is difficult due to them both being labelled by Iba1, as well as sharing 
similar morphology. Therefore, the number of Iba1-positive (Iba1+) cells in each ROI was counted as a 
measure of the presence of microglia/macrophages post-injury (Fig. 3.25). 
In the contralateral cortex (Fig. 3.26B) the number of Iba1+ cells was significantly increased in all of the 
injury and sham groups compared to the naïve group (naïve vs sham **p<0.01; 1.5 mm, ***p<0.001; 
2.0 mm, ***p<0.001; 2.2 mm, ***p<0.001). The 1.5 mm, 2.0 mm and 2.2 mm injury groups all showed 
a significantly (sham vs. 1.5 mm, # p<0.05; 2.0 mm, ## p<0.0.01; 2.2mm, ## p<0.0.01) increased number 
of Iba1+ cells compared to the sham group, with the 2.0 mm (61 ± 4) and 2.2 mm (60 ± 4) group 
exhibiting double the number of Iba1+ cells than the sham group (31 ± 5) group. 
In the ipsilateral cortex (Fig. 3.26C) the sham, 1.5 mm, 2.0 mm and the 2.2 mm injury groups all 
showed a significant increase in the number of Iba1+ cells compared with the naïve group (naïve vs. 
sham, ** p<0.01; 1.5 mm, *** p<0.001; 2.0 mm, *** p<0.001; 2.2 mm, *** p<0.001). The 2.2 mm 
group had a significantly higher number of Iba1+ cells (122 ± 13) than all of the other injury groups (2.2 
mm vs sham, ### p<0.001; 1.5 mm, && p<0.01; 2.0 mm, $$ p<0.01). 
In the hippocampus, the naïve group (57 ± 8) again exhibited the lowest number of Iba1+ cells, with all  
of the other injury groups showing a statistically significant (naïve vs. sham, ** p<0.01; 1.5 mm, ** 
p<0.01; 2.0mm, *** p<0.001; 2.2 mm, *** p<0.001) higher number of Iba1+ cells: sham (117 ± 2), 1.5 
mm (114 ± 8), 2.0 mm (131 ± 9) and 2.2 mm group (184 ± 8). The 2.2 mm group had a significantly 
higher number of Iba1+ cells compared to all of the other groups (2.2 mm vs. sham, ### p<0.001; 1.5 
mm, &&& p<0.001, 2.0 mm, $$ p<0.01). Within the DG ROI, the naïve group (22 ± 3) had the lowest 
number of Iba1+ cells and the 2.2 mm group (57 ± 2) had the highest number, showing significance 
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against the naïve (2.2 mm vs. naïve,*** p<0.001), sham (2.2 mm vs. sham, # p<0.05) and 2.0 mm 




Figure 3.25.  Microglia with Iba1 labelling at various injury severities. Iba1 immunolabelling in the ipsilateral 
cortex in the (A) naïve, (B) sham-injured, (C) 1.5 mm, (D) 2.0 mm, (E) 2.2 mm injury groups and (F) microglia in 
the contralateral hippocampus. Scale bar = 100 µm. 
Naive Sham 1.5 mm 
2 mm 2.2 mm 
A B C 




Figure 3.26. The effect of injury severity on the number of microglia/macrophages in the cortex and 
hippocampus.  (A) The ROI in the cortex and hippocampus that were analysed for Iba1+ cell numbers. 
The number of Iba1+ cells in the (B) contralateral cortex, (C) the ipsilateral cortex, (D) the contralateral 
hippocampus and (E) the dentate gyrus of the hippocampus. Statistical s ignificance was determined 
using one-way ANOVA and post-hoc Bonferroni testing (* p<0.05, ** p<0.01, *** p<0.001 vs. the naïve 
group; # p<0.05, ## p<0.01, ### p<0.001 vs. the sham group; & p<0.05, && p<0.01 vs. the 1.5 mm group; $$ 





The primary aim of these studies presented in this section of the thesis was to optimise  a CCI mouse 
model of TBI, with the aim to characterise a behavioural deficit that mirrors relevant human TBI 
neurological consequences, specifically the cognitive deficit of memory loss. Injury severity in patients 
has been shown to correlate with their long-term neurobehavioural outcome (Rapoport et al . ,  2002) . 
For our model to be valid as a screening tool for potential TBI therapeutics, we expected the injury 
severity to correlate with a significant and robust cognitive behavioural deficit. In our studies, the 
injury severity was increased by increasing the impact depth, thereby increasing the extent of the 
tissue damage. A variety of behavioural tests were used to identify neurobehavioural deficits. The 
MWM test distinguished more clearly between the different injury severities. The injury severity which 
caused a robust deficit in the MWM test was the 2.2 mm impact depth.  The 2.2 mm group had a 
significant deficit in the acquisition and probe trials of the MWM test when compared to the sham 
group. Histologically, there was also a graded increase in the reactive astrogliosis and microglia 
activation in the cortex and hippocampus, which correlated with injury severity.  
3.5.1 Functional outcomes 
Three behavioural tests were conducted in order to assess any severity dependent deficits in the gross 
locomotor function, the anxiety and cognitive ability of mice after TBI. The tests used were the open 
field, Y-Maze and the MWM test. 
3.5.1.1 Open field 
The primary purpose for conducting the open field test was to ensure that the locomotor function of  
the injury groups was comparable, therefore any deficits seen in the cognitive tests involving active 
motor performance (i.e. the MWM test) were due to cognitive and not motor dysfunction. The 
outcome measures ‘distance travelled’ and ‘number of line crossings’ confirmed that there was no 
difference between injury groups over the course of the studies. We did note, however, that the 
injured animals had a lower immobility score over time compared to naïve or sham injured mice – 
indicating a slight hyperactivity. The overall lack of difference in the various parameters considered, 
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between the injury groups within the open field test reflects similar results as those produced by 
Washington and colleagues, which showed that the open field test demonstrated no defi cit in mice at 
21 days after moderate CCI, using similar parameters to our study (Washington et al., 2012). 
As discussed in section 1.8.3.1, the open field test has been used to assess other behaviours, such  as 
anxiety. Spending a large amount of time in the outer zone of the open field apparatus, a phenomenon 
termed “thigmotaxis”, is suggested to be indicative of anxiety-like behaviour. There is conflicting data 
in the literature as to whether the CCI model does in fact cause a deficit in anxiety behaviour. Some 
groups suggest that CCI injury causes anxiety, a study performed by Yu and colleagues showed that 
thigmotaxis is increased in mice following a CCI injury  (Yu et al., 2012, Chauhan et al., 2010). Others 
however, demonstrate no difference in anxiety (Sierra-Mercado et al., 2015), or suggest that CCI mice 
actually exhibit reduced anxiety behaviour (Washington et al., 2012) and may thus show disinhibition. 
Due to the complexities of testing rodents for anxiety, the conflicting data may relate to the sensitivity 
of the anxiety-based behavioural assay administered (Tucker et al., 2016). Our data did not show any 
difference in anxiety behaviours as assessed using the open field test over the time scale of the 
experiment.  
 
3.5.1.2  Y-Maze 
The Y-maze test was conducted only in the first part of the study and not continued thereafter, due to 
the lack of a sufficient behavioural deficit between control and injury groups. There was some non -
significant difference observed on day 3, when the naïve and sham group spent more time  in the novel 
arm than the 1.5 mm and 2.0 mm injury groups. However, this difference in trend was not maintained 
on day 8 post-injury, suggesting that this deficit may be transient if at all significant.  
The paradigm used in this study (section 2.1.4.2) was to measure time spent within the novel arm of  
the maze in the retrieval trial. Time spent in the novel arm and the number of entries into the novel  
arm is interpreted in this paradigm as indicators that the mouse views the novel arm as ‘un -explored’ 
and therefore chooses to spend more time exploring it. However, this outcome measure may be prone 
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to misinterpretation. As previously mentioned (section 1.6.3.2), differences between the groups’ 
locomotor function could result in an invalid interpretation of the results in this test.  
 
One of the main benefits of this type of assessment is that it does not require food deprivation or 
involves stress, as observed in tests such as the dig task or the Porsolt forced swim test (Martens et al., 
2013, Can et al., 2012). The absence of any food reward or stress motivation may be affecting the 
results of this test. In some TBI patients, it is reported that cognitive symptoms such as deficits in 
decision making or memory function are only obvious in stressful situations (Gouvier et al., 1992). This 
could explain the absence of notable differences between the injury groups in the Y-Maze test when 
compared to the MWM results.   The lack of any significant deficit might also be due to the earlier time  
points at which this test was administered (day 3 and day 8). Due to the progressive nature of this 
disease, a significant deficit in cognitive function may not yet have been fully developed. However, 
Smith and colleagues were able to see a deficit between CCI-injured mice compared to sham-injured 
mice in the  MWM test only 48 hours after injury (Smith et al., 1995). This provides further support to 
the notion that a stress-inducing motivator may be needed in order to reveal a cognitive deficit. 
3.5.1.3 Early behavioural differences after TBI 
It is worth noting that despite there being an absence of differences in the Y-maze and open field test 
outcome measures over the course of the 4-week study, there is an indication that there may be some 
transient differences within the first week after injury. As previously mentioned, the 1.5 mm and 2 .0 
mm injury groups failed to spend more time in the novel arm at day 3 post-injury compared to the 
control groups. Correspondingly, within the open field test, the sham, 1.5 mm and the 2.0 mm groups 
travelled further and made more line crossings than the naïve group at day 7 post-injury. However, 
these differences disappeared after 7 days post injury. Transient deficits are not uncommon in rodent 
models of neurotrauma; for example, in SCI models rodents spontaneously recover some motor 
function early, following injury (Creed et al., 2011, Scherbel et al., 1999, Bareyre et al., 2004, You et al.,  
2003). It is also possible that the changes in these behaviours over time may not be due to any 
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transient component of the secondary injury pathology, or lag time in compensatory function, but 
could be due to habituation of the mouse to the testing environment.  
3.5.1.4 Morris water maze test 
The MWM test is used to assess hippocampal-dependent spatial learning and memory function in 
rodents. In the studies presented in this chapter, the MWM test revealed differences in memory 
function between the injury groups, and thereby helped to determine an injury severity level (2.2 mm 
impactor depth) to use in subsequent studies. Initially, a 4-day acquisition paradigm followed by a 
single probe trial was used (section 2.1.4.3). In the first study the acquisition trial revealed differences 
between the naïve group and the other injury groups (1.5 mm and 2.0 mm). However, in the first week 
probe trial (day 19) the differences in memory function between the injury groups w ere less notable. 
As previously mentioned, Washington et al. demonstrated clearer differences between the di f ferent 
severity groups when employing a second week reversal MWM test (Washington et al., 2012) . In the 
study paradigm, this is where the acquisition and probe testing protocol remain the same, but the 
location of the platform is changed. The data from our second week probe trial (day 26) supported 
what was shown by Washington and colleagues: our 1.5 mm and 2.0 mm injury groups headed 
towards the location of the original platform zone as opposed to the reverse platform zone 
(Washington et al., 2012). This might indicate that the cognitive function of the injured mice in the first 
week of acquisition training is superior to their cognitive function in the second week. This could be 
due to the progressive nature of the TBI pathology, whereby cognitive ability decline s as the impact of  
the secondary injury pathology increases. With regards to the results of the second week acquisition 
trial, the 2.0 mm group exhibited some deficit compared to the sham group, but this was not 
significant throughout the acquisition trial . The fluctuation of the 2.0 mm injury group’s cognitive 
ability may suggest that the injury in this paradigm is too mild, to see a consistent deficit. This has been 
seen in the clinic as well, where cognitive deficit in TBI patients categorised as mild or moderate is 
fluctuating (Satz et al., 1998).  In order for our CCI model to be robust, the injury group needs to have a 
reproducible and significant cognitive deficit when compared to the sham injury group. Consid ering 
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this, it was decided to repeat the study with an increased impactor depth of 2.2 mm and compare i ts 
effect to a sham-injury group only.  
It is important for the deficit to be significant against the sham group, as the sham group undergoes 
the same surgical procedures and aftercare regimen as in the impacted groups, but without the actual  
brain injury. Mice undergoing surgery receive anaesthesia such as ketamine, which has been shown to 
have neuroprotective and neuroregenerative properties that can cause beneficial outcomes in mice 
following TBI (Himmelseher and Durieux, 2005). Therefore, it is important that any influence these 
peri-operative compounds have on the baseline performance of the mice, is matched in the control 
group. Conversely, a craniotomy can have a detrimental impact on the behavioural outcome of  mice, 
as seen in the first week acquisition trial in the first study (Fig. 3.9). Therefore, it is important that any 
baseline negative effect the craniotomy has on the mice is matched by the control group.  
In the second study, during the first week of MWM testing the 2.2 mm injury group exhibited a 
significant deficit in learning in the acquisition trial, as well as a significant deficit in memory function 
in the first week probe trial, when compared to the sham group. The 2.2 mm group continued to have 
a significant deficit during the reversal MWM acquisition and probe trial . The outcomes of  the MWM 
test in this second study demonstrated that an impactor depth of 2.2 mm causes an injury level 
sufficient enough to produce significant cognitive dysfunction in the mice and is therefore an 
appropriate impact depth for our CCI mouse model of TBI.  
It was important for the continuation of this study and its relevance, that there was a deficit in the 
MWM, as it is an established behavioural test for memory function. As mentioned in the introduction 
to this chapter, memory loss is one of the main complaints of TBI patients. It is also a common test 
used when screening transgenics as a model for neurodegenerative diseases, or as a screening tool for 
therapeutics that may reverse or diminish memory loss (Bromley-Brits et al., 2011). Several lab groups 
that employ the mouse CCI model of TBI, use the MWM as a behavioural test (Washington et al., 2012, 
Xuan et al., 2014, Su et al., 2015, Kabadi et al., 2012, Zhang et al., 2012). Our MWM data shows that 
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our CCI model reproduces the changes seen by other groups in the same field of research, using the 
same model of injury. 
3.5.2 Pathophysiological changes  
It was hypothesised that the tissue loss would increase with the severity of the injury, as the impactor 
extends further into the brain tissue, thereby causing more damage. Studies have shown that the 
lesion size and tissue loss correlates with impactor depth and thereby injury severity (Saatman et al . ,  
2006). This correlation was also observed in the tissue from our studies. Neither the naïve or sham 
group exhibited any significant tissue loss. The 1.5 mm injury group exhibited some ipsilateral ti ssue 
loss, however, it still had more tissue preservation when compared to the other 2.0 mm and 2.2 mm 
groups, particularly in ipsilateral the hippocampus region. This may explain why the 1.5 mm injury 
group performed so well in the hippocampal-dependent MWM test. The 2.0 mm and 2.2 mm injury 
groups did not show any statistical significance between each other in the percentage of tissue lost 
within each of the locations (ipsilateral hemisphere, cortex and hippocampus). The 2.0 mm and 2.2 
mm injury groups did exhibit a huge loss in ipsilateral hippocampal tissue, of almost 50 %, w ith any 
remaining ipsilateral hippocampal tissue appearing misshapen or squashed. This loss, while 
considerable, was not significant enough to cause complete failure in the MWM acquisition trial . The 
data suggest that the intact contralateral hippocampus and/or the remaining ipsilateral hippocampal 
tissue are providing some compensatory effect. It is worth noting that the deficits in the MWM test 
were observed several days before this tissue was collected and that the tissue loss at the time of  the 
testing may not be as great. In future studies it may be worth sacrificing earlier to establish a pattern 
of pathophysiological changes across a time course. But the main focus of these studies was to 
observe behavioural differences. 
 
The literature does not accurately define specific impactor depths as mild, moderate or severe injuries. 
Unlike human TBI where the GCS is used to define the severity of the injury, there is no universal score 
or behavioural test that defines the severity of the injury in animals. Due  to the differences between 
laboratory set ups and protocols (e.g. impactor equipment, rodent species and strain, different 
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outcome measures) the severity of the injury may pertain to the unique set up within individual 
laboratories (Xiong et al., 2013). Therefore, it has been up to the individual laboratory to def ine a set 
of outcomes as a mild, moderate or severe injury, when optimising their model, as was carried out in 
this first chapter. Due to the inter-laboratory discrepancy, our injury (2.2 mm), which we have defined 
as ‘moderate’, may not relate to the moderate  severity of other research groups modelling TBI. 
Furthermore, it may also not be the equivalent of a moderate human TBI as defined by the GCS. The 
differences between human and rodent brains are discussed in the general introduction of this thesis; 
these differences may make the translation of TBI severity between mouse and human even more 
difficult. 
 
 In addition to the tissue loss, we hypothesized that glial cell activation would show a positive 
correlation with the injury severity. The extent of astrogl iosis has been shown to  correlate with TBI 
severity (Sofroniew, 2009). One of the main indicators of reactive astrogliosis in an up-regulation of 
the intermediate filament GFAP, and this up-regulation was positively correlated with the severity of  
the response. As hypothesised, there was an increase in the expression of GFAP with the increase in 
injury severity. Unlike the tissue loss data, there was a marked difference between the 2.0 mm and 2.2 
mm injury group, with the 2.2 mm injury group eliciting more reactive astrogliosis within the cortex 
(both ipsilateral and contralateral) and the hippocampus. This increase in reactive astrogliosis 
correlated with the poorer MWM behavioural outcomes of the 2.2 mm group. The amount of reactive  
astrogliosis may be more indicative of injury severity than the amount of tissue loss, as there is a 
clearer step-wise increase in GFAP expression. 
 
Human TBI is characterised by astrogliosis, where increased GFAP immunostaining in post -mortem 
brain tissue at the site of contusion is seen, with decreasing astrogliosis distally from the injury site 
(Harish et al., 2015, van Landeghem et al., 2006).  Due to the difficulty in obtaining human brain tissue 
for analysis of astrogliosis, GFAP has been looked at as a serum biomarker for determining injury 
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severity. Several studies have shown an increase in GFAP serum levels that corresponds to clinical 
outcome and severity of TBI (Pelinka et al., 2004, Nylén et al., 2006, Vos et al., 2010).  
 
As with the astrocytes, the microglial response was increased in the injured groups. Activated 
microglia and infiltrating macrophages identified by the expression of Iba1 were counted within the 
same ROI as the astrocyte analysis. The 2.2 mm group had the highest number of Iba1+ cells in the 
ipsilateral cortex, as well as the contralateral hippocampus. Unlike the astrocytic response, the sham, 
1.5 mm and 2.0 mm injury groups all had comparable increased numbers of Iba1+ cells in all ROI. An 
increase in microglia activation following a TBI has been seen in other CCI mouse models of TBI and 
post-mortem human TBI brain tissue, which is reflected by our results (Loane et al., 2014, Chen et al . ,  
2014). Microglia are known to migrate to the site of injury; this is reflected in our data by the increase 
in the number of Iba1+ cells in the ipsilateral ROI (Hernandez-Ontiveros et al., 2013). However, we 
should also consider that the increase in the number of Iba1+ cells could also be due to microglia 
proliferation (Gómez-Nicola et al., 2013). Interestingly, as with the astrocytic response, there was an 
increase in the number of Iba1+ cells in the contralateral ROI.  
 
3.5.3 Contralateral glial cell activation 
An unexpected outcome that was observed in the glial analysi s by immunohistochemistry was the 
increase in immunostaining of the activated glial cells in the contralateral cortex. Originally, the 
purpose of analysing the homologous contralateral cortex areas was to use them as a control  for the 
impacted ipsilateral side. However, our study shows that an ipsilateral CCI injury can cause widespread 
response throughout other brain regions. This phenomenon has been seen in the stroke literature, 
where there is increased GFAP expression in the hemisphere contralateral to the focal occlusion 
(Patience et al., 2015, Bidmon et al., 1998, Takatsuru et al., 2013). There could be several reasons for 
this increase in contralateral glial response. Firstly, the contralateral cortex may experience injury due 
to compression against the skull during the initial swelling of the ipsilateral side caused by the 
impaction (Xiong et al., 2013, Cole et al., 2011). Secondly, the glial cells on the contralateral  side may 
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have been activated through chemotaxic signalling (Domercq et al., 2013, Ohsawa et al., 2007). 
Thirdly, glial cell migration, as it has been shown that populations of astrocytes from various regions 
such as the subventricular zone, migrate towards the site of the injury (Benner et al., 2013).  Fourthly, 
they may be due to the interhemispheric functional connectivity of large brain networks, whereby 
damage caused to neurones on the ipsilateral side is communicated to the corresponding neurones on 
the contralateral side, thereby inciting glial activation (Marquez de la Plata et al., 2011, Mayer et al., 
2011). Using diffusion MRI tractography, Crofts and colleagues found that in stroke patients there was 
a decrease in connectivity  not only ipsilaterally, but also in the contralateral regions homologous to 
the lesioned ipsilateral side (Crofts et al., 2011). Furthermore, on both sides, there were also regions 
with increased connectivity. 
3.5.4 Impact of sham injury 
Interestingly, the sham group displayed deficits in behaviour and altered histology despite  not being 
exposed to the direct impact of brain injury. The craniotomy that the sham group undergoes is an 
invasive surgery that can result in a pathological response, including oedema, inflammation and 
vascular disruption  (Cole et al., 2011). The craniotomy surgery, despite appearing to cause no 
disruption to the dura macroscopically, may have caused some microscopic structural damage to the 
underlying brain tissue, as seen in the histological analysis. This damage may be the result of 
disruption of fine blood vessels and nerve fibres that connect the brain to the skull . Also, the hand held 
drill used in this method causes friction during drilling, so therefore heat could cause further damage 
to the brain tissue. Furthermore, the drilling procedure can produce fine bone powder which may 
cause irritation to the dura and provoke an inflammatory response. Another point raised in the paper 
published by Cole and colleagues, is that the swelling caused by the changed ICP due to the 
craniotomy may cause the contralateral hemisphere to undergo compression, and this may account 
for some of the contralateral glial cell activation (Cole et al., 2011). As witnessed in our model, the 
sham-injured group in the study conducted by Cole and colleagues, displayed some behavioural 
deficits compared to naïve animals, however these were not statistically significant. This suggests that 
the sham injury is in itself a unique injury to the brain, distinct from the direct injury caused by the 
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impactor to the brain tissue, which was worth noting and became the basis for using a sham group as a 
control group, rather than a naïve group. 
 
3.5.5 The CCI model 
The CCI model as described in the general introduction is a widely used model for rodent TBI due to 
the high reproducibility of the injury, low variability in injuries between samples and the relative ease 
of administration. It also mimics several key aspects of the human TBI including neurobehavioral and 
pathophysiological consequences.  
 
The data in this chapter provides evidence that this model causes cognitive dysfunction, as learning 
impairment and memory loss was seen in the MWM test, thus being relevant to some of the human 
cognitive symptoms of TBI. In our model the impact depth needed to produce a behavioural deficit 
was larger than we anticipated, as others in the literature have reported that shallower impact depths 
had elicited behavioural deficits (Washington et al., 2012, Brody et al., 2007, Xiong et al., 2008, You et 
al., 2003, Bermpohl et al., 2006, Fox et al., 1998). This difference could be due to differences in impact 
parameters (such as dwell time or velocity of impact) or as discussed earlier, could be due to the inter-
laboratory variability in injury severity definitions. Furthermore, it could be due to the control group by 
which the injured groups are compared to, in order to assess deficit significance. 
Our model was also able to replicate some of the secondary injury pathophysiology seen in other 
animal models and in human TBI, including hallmark severity-dependent astrogliosis, increased 
number of Iba1+ cells and tissue loss at the contusion site. 
 
3.5.6 Conclusion 
The aim of this first chapter was to optimize and characterize a CCI mouse model of TBI that had 
behavioural as well as histological endpoints that reflected aspects of the human pathology and was 
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similar to the CCI mouse models of other groups. The data in this chapter has met these criteria, which 
allows it to be used as a tool for exploration of novel therapeutics for neuroprotection in TBI.  
 
3.5.7 Main outcomes  
• A CCI injury of 2.2 mm impact depth causes a deficit in the learning and memory behaviour of  
mice as test by the MWM test, but no deficit in gross locomotor function. 
• This same injury caused significant ipsilateral tissue loss, astrogliosis and microglia activation.  
• Glial cell activation was observed in the contralateral cortex. 

























4 The effect of acute DHA administration in a mouse CCI 
model of TBI 
4.1 Introduction 
As discussed in the general introduction, the omega-3 PUFAs have many roles in the CNS. They may be 
potentially useful in the treatment of several CNS disorders and may confer neuroprotection in TBI .  In 
our laboratory, the acute administration of the omega-3 PUFA DHA improved functional and 
histological outcomes in a variety of SCI models in both mice and rats (Huang et al., 2007, Liu et al., 
2015, Paterniti et al., 2014, Ward et al., 2010, King et al., 2006, Lim et al., 2013b). The effect was seen 
when DHA was administered intravenously 30 minutes post injury and was further improved by a diet 
enriched by DHA (Huang et al., 2007). In these studies, administration of DHA reduced inf lammation, 
astrogliosis and the microglial/macrophage activation, as well as improved motor function after SCI. As 
SCI and TBI pathophysiology have many similarities (Rowland et al., 2008, Anderson and Hall, 1993, 
Kwon et al., 2004),  we hypothesised that DHA may be efficacious in the treatment of TBI. In this 
chapter we investigated the effect of an acute dose of DHA post-injury, on the performance of the 
animals in the MWM, and on astrocyte and microglial activation in our model of mouse CCI.   
The beneficial effect of DHA supplementation and DHA acute treatment in models of injury to the 
central nervous system, suggest that DHA may have beneficial effects following TBI, which was the 








The animals used in this chapter were CD1 male mice aged 10-12 weeks. The CCI injury model used to 
cause a unilateral injury is described in section 2.1.2. An intravenous (i.v.) injection of DHA (500 
nmol/kg) or vehicle (Veh) was given in the tail vein 30 minutes after the injury. The behavioural tests in 
this chapter include the open field test (section 2.1.4.1) and the MWM acquisition and probe trial 
(section 2.1.4.3), including the reverse MWM paradigm. The protocol used for the execution of  these 
behavioural tests is detailed in figure 4.1. After perfusion on day 28 post-injury, the brain ti ssue was 
dissected out and cut into sections which were stained using the toluidine blue method and 
immunostained for GFAP, Iba1 and doublecortin (DCX) (as described in section 1.1.6).  
 
 
Figure 4.1. Timeline for the i.v. administration of DHA and the behavioural tests after CCI. The open 
field, Y-maze and the first MWM acquisition (day 15-18) and probe trial (day 19), and the second week 




4.3 Aims and Hypothesis 
4.3.1 Aims 
The aim of the chapter was to investigate the effects of an acute treatment with DHA in a CCI mouse 
model of TBI and assess long-term behavioural and histological correlates including:  
• Learning and memory as assessed by the MWM acquisition and probe trials 
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• Persistent tissue damage and alterations under the site of the impact; tissue loss and 
glial cell activation 




Based on the results reported after acute DHA administration in various models of injury, it was 
expected that DHA treatment would reduce the lesion size, the astrogliosis and microglial activation, 















4.4 Results  
The work in this chapter documents the effect of an acute dose of DHA (500 nmol/kg, i.v.) 30 minutes 
post-injury in a CCI mouse model. We assessed the effect DHA had on learning and memory in the 
MWM. We also assessed the effect DHA had on astrogliosis, microglial activation, lesion size and 
neurogenesis in the brain tissue of these mice at 28 days post- CCI. 
4.4.1 Effect of DHA treatment in the open field 
The open field paradigm was used to measure the locomotor function of the mice, to confirm that any 
differences seen in MWM test were not due to changes in motor function. 
 The total distance travelled and the number of line crossings made by the mice during their 5 minute 
exposure to the test was measured as an indicator of their motor ability. All 3 groups travelled over 20 
metres and made over 200 line crossings during all of their tests, over the course of the study. 
However, the sham group maintained the same distance travelled and number of line crossings 
throughout the study, whereas the 2 groups that received an injury (with either vehicle treatment or 
DHA treatment) increased the distance travelled and the line crossings made over the course of the 
study. Despite there being no statistically significant differences between the groups, there were sti ll 
differences seen between the groups. On day 21, the DHA-treated group travelled 38.9 ± 7.7 m, which 
was 10 metres more than the sham group, which travelled 29.7 ± 1.9 m.  However, the vehicle-treated 
group travelled over 20 metres more than the sham group, at 53.6 ± 11.6 m. In the model 
development chapter, we had seen that the 2.2 mm injury group consistently had higher number of 
line crossings and travelled further throughout the study compared to the sham group.  Thus, overal l ,  
the injury seemed to make animals hyperactive over time (a trend we had noticed before), and this 
tendency was reduced by DHA treatment.  
There was no significant difference seen in the amount of time any of the groups spent in the middle  
or outer zones during the study. However, on day 1 post-injury, the vehicle treated (273.0 ± 3.0 s) 
group spent more time in the outer zone and less time in the inner zone when compared to the DHA -


























Figure 4.2 Effect of DHA treatment after CCI injury on the open field performance. 
Representative occupancy plots from open field testing on day 1 and day 28 
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Figure 4.3.  Effect of DHA treatment in CCI injury on the open field performance at day 1, 7, 14, 21 
and 28 of the study. (A)  The time spent in the outer zone and (B) the time spent in the inner zone. (C) 
The total distance travelled, (D) the number of line crossings and (E) the  average speed of the animals. 




4.4.2 Effect of DHA treatment in the Morris water maze 
4.4.2.1 The effect of treatment in the first week of Morris water maze – Acquisition trial  
 
The two-week MWM protocol that was used in the model development chapter was also used in this 
study, to assess learning and memory function in these mice.  The first week of acquisition testing took 
place on days 15 – day 18 post-injury, with four trials per day (Fig. 4.4A; Fig. 4.5A). The sham group in 
this study had the fastest escape latencies throughout the acquisition trial when compared to the 2 
groups that received a CCI. The sham mice reduced their average escape latency from 42.8 ± 3.4 s on 
day 15 to 16.7 ± 1.3 s on day 17, which was the third day of the acquisition trial. On the final day of the 
acquisition training (day 18), the sham group still had the fastest escape latency at 20.1 ± 2.4 s. 
Both of the CCI groups reduced their escape latencies over the 4 days of training, but showed no 
differences between them. Both the CCI + Veh (CCI + Veh vs. Sham; day 16, #p<0.05; day 17, ###p<0.00; 
day 18, #P<0.05) and CCI + DHA (CCI + DHA vs. Sham; day 15, &p<0.05; day 16, &p<0.05; day 18, 
&&p<0.01) were significantly slower at locating the platform when compared to the sham group. The 
CCI + Veh group had an average escape latency of 56.9 ± 6.9 s on day 15, that was reduced to 43.9 ± 
4.1 s on day 18. The CCI + DHA group reduced its escape latency from 60.9 ± 5.1 s on day 15, to 40.5 ± 
5.7 s on day 18. Like the sham group, the CCI + DHA group had its quickest average escape latency on 
day 17 (the third day of the acquisition training) at 31.6 ± 4.6 s; due to this latency the CCI + DHA group 











4.4.2.2 The effect of DHA treatment in the first week of the MWM - Probe trial  
On day 19 post injury, 24 h after the last trial of the first week of acquisition training, the mice were 
given a probe trial.  
In this probe trial (Fig. 4.4B), the sham group had the shortest latency time to the platform zone of 
11.2 ± 2.9 s, followed by the CCI + DHA group 26.2 ± 8.4 s and then the CCI + Veh 37.2 ± 10.5 s (Fig. 
4.5B). The difference between the latter two was not statistically significant.  
The sham group also made the most entries to the platform zone, on average 5.4 ± 0.8 entries, 
whereas the CCI + DHA group made only 3.9 ± 0.5 entries and the CCI + Veh group made 2.5 ± 0.6 
entries (Fig. 4.5C). The number of entries made by the CCI + Veh group were statistically signif icantly 
lower than the sham group (*p<0.05). The CCI + DHA group however did not show any statistically 
significant difference either to the sham or CCI + Veh groups. In both of the probe trial measures, the 
CCI + DHA group did not appear to perform as poorly as the CCI + Veh group, but still did not perform 
as well as the sham group.  
 




Figure 4.4 Effect of DHA treatment on acquisition training in the Morris water maze. Representative 









































Figure 4.5. Effect of DHA Treatment on Acquisition training and Probe trial Performance 
In the first week of the Morris Water Maze. (A) The average escape latency of the 4 
trials conducted on days 15 – 18 post-injury during the acquisition training. The CCI 
+ Veh group had statistically significantly slower escape latencies compared to the 
sham group on day 16 (## p<0.01), day 17 (### p<0.001) and day 18 (# p<0.05). The 
CCI + DHA group were also statistically slower compared to the sham group on day 
15 (& p<0.05), day 16 (& p<0.05) and day 18 (&& p<0.01). There was no statistically 
significant difference on any day of the acquisition training between the CCI + Veh 
group and the CCI + DHA group. Statistical significance was determined using a 
two-way repeated measures ANOVA with post-hoc Bonferroni test. On day 19 the 
probe trial was conducted; (B) the time taken to the platform zone and (C) the 
number of entries to the platform zone, where the CCI + Veh group made fewer 




4.4.2.3 The effect of DHA treatment in the MWM – Reverse Acquisition trial  
 
On day 22 post-injury, the MWM second week of reverse acquisition training was initiated. In the 
second week of the MWM the platform was located in the opposite quadrant to the first week of 
MWM training (from the north-east quadrant to the south-west quadrant). The mice were exposed to 
a 4-day acquisition training phase and another probe trial 24 hours later (Fig. 4.1).  
 
As seen in the model development chapter, the second week of reverse acquisition training (Fig. 4.6; 
day 22-25) did not show the same steep decrease in escape latency over the 4-days of training 
compared to that seen in the first week of training (day 15-18). This may be due to the mice becoming 
acclimatised to the MWM paradigm. 
 
During the reverse acquisition training the sham group had the statistically fastest escape latency 
compared to the two CCI groups. At the start of the reverse acquisition training the sh am group 
located the platform in 25.1 ± 2.5 s (day 22), which was reduced to 12.2 ± 1.3 s by the end of the 
training (day 25). 
The CCI groups showed no significant differences to each other during the second week reverse 
acquisition training. Both CCI + Veh group (CCI + Veh vs. Sham; day 22, ### p<0.001; day 23, ## p<0.01; 
day 24, ## p<0.01; day 25, ### p<0.001) and the CCI + DHA group (CCI + DHA vs. Sham; day 22, &&& 
p<0.001; day 23, &&& p<0.001; day 24, &&& p<0.001) had statistically significantly slower escape 
latencies when compared to the sham group. However, on the final day of training the average escape 
latency of the CCI + DHA group decreased from 42.0 ± 3.5 s to 29.6 ± 3.9 s; this sizable decrease in 
escape latency resulted in the CCI + DHA group no longer exhibiting a statistically significant difference 





4.4.2.4 The effect of DHA treatment in the Morris water maze – Reverse Probe trial  
On day 26 post-injury and 24 hours after the last trial of the second week reverse acquisition trai ning, 
a probe trial was performed. Outcome measures pertaining to the original location of the platform 
zone (north-east quadrant) and the reverse platform location (south-west quadrant) were measured. 
4.4.2.4.1 Reverse Platform 
During the probe trial on day 26, the time taken to enter the reverse platform zone was measured (Fig. 
4.7A), the sham group entered the reverse platform zone in the quickest time of 10.4 ± 7.2 s. Both the 
CCI + Veh and the CCI + DHA group took almost twice as long to enter the reverse platform zone, 24.4 
± 7.4 s and 27.5 ± 8.8 s respectively. Despite these different values, there was no statistically significant 
difference between the groups. 
The number of entries to the reverse platform zone was also measured (Fig. 4.7B), with the sham 
group making the most visits to the reverse platform zone, i.e. 5.9 ± 1.0 entries. The CCI + Veh group 
made on average 3.6 ± 0.8 entries to the reverse platform zone. The CCI + DHA group made the fewest 
entries to the reverse platform zone, 2.3 ± 0.5, which was statistically significantly lower than the sham 
group (& p<0.05), using the one-way ANOVA test with post-hoc Bonferroni testing.  
4.4.2.4.2 Original Platform 
The time taken to the original platform zone in the south-west quadrant and the number of entries to 
the original platform zone were also measured in the day 26 probe trial.  
The three groups showed no statistical difference between them, in the time taken to enter original 
platform zone (Fig. 4.7C; Sham 35.8 ± 9.9 s; CCI + Veh 41.4 ± 8.7 s; CCI + DHA 29.9 ± 7.7 s). The same 
was true for the number of entries to the original platform zone (Fig. 4.7 D; Sham 2.0 ± 0.5; CCI  + Veh 








Figure 4.6. Effect of DHA Treatment on Acquisition training in the second week of the Morris 
Water Maze. The average escape latency of the 4 trials conducted on days 22 –25 post-injury 
during the acquisition training. The CCI + Veh group had statistically significantly lower escape 
latencies compared to the sham group on day 22 ( ### p<0.001), day 23 (## p<0.01), day 24 (## 
p<0.01) and day 25 (###p<0.001). The CCI + DHA group were also slower compared to the sham 
group on day 22 (&&& p<0.001), day 23 (&&& p<0.001) and day 24 (&&& p<0.001). There were no 
statistically significant differences on any day of the acquisition training between the CCI  + Veh 
group and the CCI + DHA group. Statistical significance was determined using a two-way repeated 
measures ANOVA with post-hoc Bonferroni test. Mean ± S.E.M. N= 7-12 animals per group. 
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Figure 4.7. Effect of DHA Treatment on Probe trial Performance in the second week of the 
Morris water maze. On day 26 the probe trial was conducted; (A) the time taken to the reverse 
platform zone, (B) the number of entries to the reverse platform zone. The CCI  + DHA group 
visited the reverse platform statistically fewer times than the sham injured group ( & p<0.05), 
when using a one-way ANOVA with post-hoc Bonferroni test. (C) The time taken to the original 
platform and (D) the number of entries to the original platform zone. Mean ± S.E.M. N= 7-12 
animals per group. 
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4.4.3 The effect of DHA treatment on the ipsilateral hemisphere -cortex and hippocampus 
 
After perfusion of the mice on day 28, the brain tissue was cut into coronal sections; selected sections 
from 4 locations (-1.5, -2.0, -2.5 and -3.0 mm posterior from bregma) spanning the area of the impact 
lesion were analysed using toluidine blue staining. 
The CCI + Veh and CCI + DHA group had substantial tissue loss in all three of the measurements, 
including the ipsilateral hemisphere, ipsilateral cortex and hippocampus, when compared to the 
contralateral side (Fig. 4.8; Fig. 4.9A, B, C). The Sham group did not show any tissue loss on the 
ipsilateral side. Both the CCI + Veh and CCI + DHA showed a statistically significant loss of tissue 
compared to the Sham group in the ipsilateral hemisphere (** p<0.01), the ipsil ateral cortex 
(***p<0.001) and the ipsilateral hippocampus (***p<0.001). The DHA treatment did not prevent any 
tissue loss after CCI, and failed to show any statistically significant difference to the CCI  + Veh group. 
The ipsilateral hippocampus in both CCI groups was almost entirely absent at the 1.5 mm, -2.0 mm and  
-2.5 mm coronal levels, and was still only partially present at -3.0 mm level (Fig. 4.8). The CCI + Veh 
group had 21.9 ± 7.5% of the ipsilateral hippocampus remaining at 28 days post-injury (Fig. 4.9C). The 
CCI + DHA group had a similarly low percentage of ipsilateral hippocampus remaining, 25.6 ± 2.0 % 
(Fig. 4.9C). Overall, the analysis of the sections from injured animals revealed that the tissue was very 
fragile, and at times it was difficult to assess whether some of the missing tissue was due to the 
expansion of the injury or to the loss of tissue due to the fragility of tissue sections placed on sl ides, 
especially during the tissue processing and staining steps. 
As observed in the model development chapter, the Sham group did not lose any ipsilateral tissue, but 
did display some damage to the surface of the cortex on the ipsilateral side, beneath the craniotomy 



























Figure 4.8. Lesion size after CCI and DHA treatment. Coronal brain sections from the sham, 
CCI + Veh and CCI + DHA groups. The brain sections were taken from the following locations 
posterior to bregma: -1.5 mm, - 2.0 mm, -2.5 mm and- 3.0 mm. The red arrow heads indicate  











Figure 4.9.  The effect of DHA treatment post-injury on the ipsilateral brain regions as 
compared to the contralateral side. (A) hemisphere, (B) cortex and (C) hippocampus. 
Statistical analysis using one-way ANOVA and post-hoc Bonferroni testing (**p<0.01, 




4.4.4 The effect of DHA treatment on astrocytes in the cortex and the hippocampus 
Reactive astrogliosis is a hallmark of the secondary injury that follows TBI. In the model development 
chapter of this thesis, the amount of reactive astrogliosis correlated with the injury severity. The 
amount of astrogliosis was measured by the percentage increase in the immunolabelling for the 
marker GFAP, within the ipsilateral and contralateral cortex, as well as the contralateral hippocampus 
(Fig. 4.10). 
The increase in contralateral GFAP staining was reported in the previous chapter on model 
development. This phenomenon was also seen in the CCI groups in this chapter, but the DHA 
treatment did not have any impact on the contralateral cortex GFAP staining when compared to the 
vehicle-treated group (Fig. 4.11 B). The CCI + Veh group and the CCI + DHA group had an increase in 
the amount of contralateral cortex GFAP staining of 549.4 ± 240.5 % and 554.0 ± 80.9 % respectively, 
when compared to the Sham group. The Sham group did not show any increase in contralateral  GFAP 
staining compared to the naïve group. 
There was an increase in the amount of GFAP labelling surrounding the impact site on the ipsi lateral 
cortex in the CCI groups. (Fig. 4.11B). The Sham group had a percentage increase compared to naïve 
animals of 343.7 ± 209.7 %. The increase in the percentage of GFAP staining in the CCI groups 
compared to the Sham group was almost 7x fold higher (CCI + Veh, 2245.1 ± 484 %; CCI + DHA, 2424.2 
± 836.3 %). The CCI + DHA group did not show any difference in ipsilateral cortical GFAP staining 
compared to that seen in the CCI + Veh group. The GFAP staining in the CCI + DHA and CCI + Veh 
groups, in both the ipsilateral and contralateral cortices showed increased levels, but also large 
variability as evidenced by the large error bars. 
In the total hippocampus ROI (Fig. 4.11C), the CCI + Veh group had an increase in GFAP compared to 
the Sham group (266 ± 55.3 %). Interestingly, in the hippocampus the CCI + DHA group showed an 
increase in GFAP staining (709.3 ± 220.6 %) that was over double that seen in the CCI + Veh group, 
although this was not statistically significant.  
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In the dentate gyrus ROI of the hippocampus (Fig. 4.11D) the CCI + DHA group (675.9 ± 135.0 %) had a 
statistically significantly (*p<0.05) higher amount of GFAP immunolabelling compared to the Sham 
group (130.3 ± 60.0 %). The CCI+DHA group had almost twice as much GFAP immunolabelling as the 
CCI+Veh group (360.8 ± 119.6 %), but this was not statistically significant.  
The DHA treatment did not affect the GFAP immunolabelling in the cortical ROI; however, the DHA 
treatment appeared to cause an increase in the reactive astrogliosis in the contralateral hippocampus, 





Figure 4.10 The effect of DHA treatment on GFAP expression. Immunolabelling of reactive 
astrocytes with GFAP in the contralateral hippocampus in the sham, CCI + Veh and CCI + DHA 












































Figure 4.11. The effect of DHA treatment on reactive astrogliosis post-injury in the 
cortex and hippocampus. Schematic showing the ROI in the cortex and hippocampus 
that were analysed for GFAP labelling (GFAP+). The percentage increase in GFAP 
labelling compared to naïve tissue in (A) the contralateral cortex, (B) the ipsilateral 
cortex, (C) the contralateral hippocampus and (D) the dentate gyrus of the 
hippocampus. The CCI + DHA group displayed a statistically significant increase in 
GFAP+ compared to the sham group (*p<0.05) in the dentate gyrus. Statistical 
significance was determined using one-way ANOVA and post-hoc Bonferroni test. 
Mean ± S.E.M. N=6 animals per group. 
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4.4.5 The effect of DHA treatment on microglia/macrophages in the cortex and the 
hippocampus 
The numbers of activated microglial/macrophage cells were counted within the same regions of 
interest used to measure astrogliosis; these were identified using labelling for Iba1 (Fig. 4.12).  
In the contralateral cortex and the ipsilateral cortex there was no difference in the number of Iba1+ 
cells between the CCI + Veh and CCI + DHA groups (Fig. 4.13A, B). In the contralateral cortex  the CCI  + 
Veh (110 ± 11) and the CCI + DHA (108 ± 11) groups had an increase in the number of Iba1+ cells 
compared to the Sham group (77 ± 21), but there was no statistical significance. This was also the case 
for the ipsilateral cortex; the CCI + Veh (163 ± 20) and the CCI + DHA (153 ± 16) groups had a higher 
number of Iba1+ cells than the Sham group (146 ± 18), with no statistical significance seen between 
groups. 
As in the cortical ROI, there were no statistically significant differences between the Sham (197 ± 9) ,  
CCI + Veh (261 ± 1) and CCI + DHA (236 ± 22) groups in the values measured in the total hippocampal 












Sham CCI+Veh CCI+DHA 
Figure 4.12. The effect of DHA treatment post-injury on Iba1+ cells. Immunolabelling of 
activated microglia/macrophages with Iba1, identified with red arrows, in the contralateral 







































































































































































Figure 4.13. The effect of DHA treatment on the number of microglia/macrophages in the 
cortex and hippocampus. The number of Iba1+ cells in (A) the contralateral cortex, (B) 
the ipsilateral cortex, (C) the contralateral hippocampus and (D) the dentate gyrus of 




4.4.6 Effect of DHA on neurogenesis in the dentate gyrus of the contralateral hippocampus 
 
The number of immature neurones were counted in the dentate gyrus region of the contralateral 
hippocampus. These immature neurones were identified using co-labelling of the nuclear marker DAPI 
and doublecortin (DCX) (Fig. 4.14),  indicative of neurogenesis (Xuan et al., 2014).  
There was no difference in the number of DCX+ cells in the dentate gyrus between the CCI  + Veh group 
(210 ± 50) and the CCI + DHA group (181 ± 8). The groups that received a CCI injury did have an 
increased number of DCX+ cells in the dentate gyrus, when compared to the Sham group (90 ± 25). 
There were no statistically significant differences between any of the groups. 
 
 
Figure 4.14. The effect of DHA treatment on the number of DCX+ cells in the Dentate Gyrus.  
(A) Schematic of the contralateral hippocampus with the dentate gyrus highlighted in red, in each of  
the four coronal slices analysed. Immunolabelling with DCX, identified with red arrows in the (B) sham 





The results presented in this chapter did not support  the hypothesis formulated in the introduction of  
this part of the work. Acute treatment with DHA post-TBI failed to significantly improve outcome in the 
MWM, reduce lesion size or prevent microglial activation. Instead of reducing reactive astrogl iosis as 
seen in the SCI models studied previously, acute DHA treatment appeared to increase GFAP 
immunolabelling in the contralateral hippocampus. Although there was an increase in the number of  
immature neurones in the dentate gyrus of the contralateral hippocampus in the DHA-treated group 
compared the sham operated group, this increase was equal to that seen post-injury in the injured 
control group, suggesting that there was no modulation by DHA of the increase in neurogenesis due to 
the CCI injury.  
4.5.1 Effect of DHA treatment on motor function and exploratory behaviour 
The predominant aim of the open field testing was the same as it was in the previous chapter, to 
highlight any significant locomotor deficits that may confound the cognitive dysfunction assessed in 
the MWM. The three groups did not show any statistically significant differences from each other in 
the distance travelled and the number of line crossings made over the course of the study. Despite 
there being no statistical differences, there was a trend for the groups that received a CCI to increase 
the distance they travelled and the number of line crossings made over the course of the study.  This 
may be indicative of the CCI injury causing some form of hyperactive behaviour, which has been seen 
in rats following CCI injury (Lewén et al., 1999). It may also be a TBI consequence in human patients; 
akathisia has been reported following TBI and a recent population study has linked paediatric TBI to 
attention deficit hyperactivity disorder (ADHD) (Desai et al., 2010, Silver and Yablon, 1996, Yang et al . ,  
2016). Overall, the DHA treatment had no major impact on the behaviour of the CCI injured mice 
within the open field, thus any behaviours displayed in the MWM maze would not have been  due to a 




4.5.2 Effect of DHA on learning and memory 
The same two-week MWM protocol that was used in the model development chapter was used to 
assess the effect of acute DHA treatment (Fig. 4.1). The acute DHA treatment did not induce any long -
term benefit in this test after CCI. DHA-treated mice failed to demonstrate any sustained increased 
learning capability over the control injured  in the first week (day 15-18) or second week (day 22-25) of  
acquisition training – although in the first week, the DHA-treated animals performed transiently 
better. In the probe trials (day 19 and day 26), the CCI + DHA group did not show any improvement 
over the CCI + Veh group, although in the first probe trial, there was a tendency to perform better.   
Diets deficient in DHA cause animals with no injury to become impaired in cognitive tests, such as the 
Barnes maze (Fedorova et al., 2007, Desai et al., 2014). In a study performed by Moriguchi and 
colleagues, rats fed on an omega-3 deficient diet had slower escape latencies and reduced memory 
function in the MWM. In a subsequent study, the authors found that this dietary-induced impairment 
could be rescued with omega-3 PUFA supplementation (Moriguchi et al., 2000, Moriguchi and Salem, 
2003). Dietary deficiency in DHA also proved to worsen cognitive outcome assessed with the novel 
object recognition test, 7 days  following a CCI injury in mice (Desai et al., 2014). This suggests that 
deficiency in DHA may be related to a worse cognitive outcome. However, these are studies which 
assess dietary manipulations, whereas our study used the acute injection of a very small amount of 
DHA, which is transient in the circulation, so should not affect phospholipid composition. Soon after 
our studies with DHA in TBI were initiated, reports on the effect of the administration of DHA by 
repeated injections in rats with TBI were published (Begum et al., 2014, Harvey et al., 2015). Both of 
these recent studies failed to show any long-term (>7 days) behavioural benefits of DHA 
administration in rat TBI. The only reported neurological benefit was observed in the first week post-
injury in the performance on the animals on beam tasks, which reflect sensorimotor coordination 




4.5.3 Effect of DHA on the brain  
The histology data from the model development chapter showed that with increased severi ty there 
was increased tissue loss and glial activation. This would suggest that treatments that reduced the 
severity of the injury would also be linked to a reduced tissue loss and/or reactive gliosis.  
4.5.3.1 Tissue loss 
The DHA treatment did not appear to reduce tissue loss following the CCI injury in the ipsilateral 
hemisphere, cortex or hippocampus, as assessed 4 weeks post-injury. By this time post-injury, the 
lesion in the ipsilateral hemisphere has become extensive, and the fixed frozen tissue sections were 
fragile, making very accurate determinations of lesion size difficult.  Interestingly, in recent work done 
in our group, the analysis on tissue collected one week post-CCI and processed in thin paraffin-
embedded sections, which were more robust, showed a significant reduction in the lesion size after 
treatment with DHA (Orli Thau-Zuzhman, personal communication). In a SCI model, we recently 
showed that a DHA-enriched dietary preparation (also containing other nutrients) improved functional 
outcome and protected the tissue (Pallier et al., 2015), and in a stroke model, DHA acute treatment 
combined with a fish oil-enriched diet preserved tissue (Pallier et al., 2015, Pu et al., 2016), suggesting 
that longer-term or combined DHA treatments may be more beneficial at reducing tissue loss post-
injury. The effect of high chronic levels of omega-3 PUFAs are investigated in more detail in the 
following chapter. 
4.5.3.2 The effect of DHA on microglia and macrophage responses after injury 
TBI is associated with a complex response of the microglia/macrophages, which has been studied in 
various experimental models. As discussed in the general introduction (section 1.2.2.7) microglial 
activation is a hallmark of TBI secondary injury and these glia can adopt different phenotypes that 
exhibit both detrimental and beneficial effects. The heterogeneity of the microglia extends beyond the 
‘M1-like’ and ‘M2-like’ phenotypes, and microglia can vary in their morphology and also tissue 
distribution (Loane and Kumar, 2016, Loane and Byrnes, 2010, Lawson et al., 1990, Hanisch, 2013) . 
Harnessing the microglia response to provide a neuroprotective effect (i.e. release of growth factors  
such as BDNF, anti-inflammatory cytokines, IL-10 and reduce phagocytosis) or to reduce the 
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detrimental effects (i.e. release of pro-inflammatory cytokines, TNFα and ROS) could provide a 
potential treatment for TBI (Loane and Byrnes, 2010, Loane and Faden, 2010).  
Treatment with DHA has been shown to alter the microglia response to injury; in our group DHA 
reduced microglia activation 4-6 weeks following SCI (Lim et al., 2013b). In an organotypic 
hippocampal culture DHA administration reduced the microglia activation following lipopolysaccharide 
(LPS)-induced inflammation (Chang et al., 2015). 
In our CCI model, DHA treatment did not appear to change the microglia/macrophage response, 
measured by the Iba1 staining 4 weeks post-injury. However, our late time point of 4 weeks may be 
missing potential effects  DHA may have on microglia following TBI in the acute phase, since the 
microglia peak response has been suggested to be at 7 days post-injury (Loane and Byrnes, 2010). 
However, Harvey and colleagues have recently found that DHA treatment following CCI in rats did not 
lead to a reduction in Iba1+ staining at 3, 7 or 21 days post-injury (Harvey et al., 2015). The difference 
between the outcome of DHA treatment in SCI and TBI models on microglia, highlights the subtle 
differences that may exist between the two disease pathologies in terms of microglia response and i ts 
modulation by the fatty acid. 
4.5.3.3 The effect of DHA on astrogliosis after injury 
There was an increase in the amount of reactive astrogliosis in the CCI injured mice, when compared 
to the animals receiving craniotomy only. As mentioned in the first chapter, this latter group did 
demonstrate some GFAP-labelling of reactive astrocytes in the ipsilateral cortex. The reasons for this 
were discussed in the previous chapter (section 1.5.4) and support the concept that a craniotomy is a 
unique injury itself,  separate from the direct focal injury to the brain parenchyma (Cole et al., 2011).  
The CCI injured groups also demonstrated an increase in the reactivity of astrocytes in the 
contralateral cortex, as reported in the previous chapter and similar to observations reported in the 
stroke literature (Patience et al., 2015). There may be multiple explanations for this contralateral 
activation. As discussed previously (section 1.5.3), this could be due to compression of the 
contralateral cortex during impaction, chemotaxic signalling and interhemispheric communication.  
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The DHA treatment did not reduce the amount of reactive astrogliosis in the ipsilateral or contralateral 
cortex. This is in contrast to results seen with DHA in SCI models in our laboratory and others, where 
acute DHA treatment reduced the amount of GFAP immunolabelling surrounding the lesion site in the 
injured cord (Paterniti et al., 2014). Figueroa and colleagues found that DHA pre-treatment in SCI 
improved locomotor function, was associated with tissue sparing and promoted anti -apoptotic 
pathways, without causing a reduction in astrocyte or microglia activation (Figueroa et al., 2012). They 
suggest that the neuroprotective effect of DHA is independent of its anti -inflammatory effects. 
Interestingly, there was an increase in reactive astrogliosis in the contralateral hippocampus of the 
DHA treated mice. The contralateral hippocampus was analysed due to the absence of the 
hippocampus in the ipsilateral hemisphere in the CCI injured mice, but also because the main 
behavioural outcomes measured in our studies are learning and memory, which is predominantly 
controlled by the hippocampus region in the brain (Jarrard, 1993). 
A reduction in reactive astrogliosis is traditionally believed to be indicative of neuroprotection . 
However, more recently the idea that the role of astrocytes following neurotrauma is exclusively a 
detrimental one has been questioned. Astrocytes are involved in several processes in the CNS under 
normal conditions, including maintenance of the BBB, ion homeostasis and synaptic function . Under 
pathological conditions astrocytes can cause further damage through the prevention of axonal 
regeneration and inducing neuroinflammation, but they may also have a beneficial role including BBB 
repair and removal of damaged tissue (discussed further in chapter 6) (Sofroniew and Vinters, 2010, 
Pekny and Pekna, 2016). Myer and colleagues suggested that astrocytes may have an essential 
protective role in neurotrauma, after they found that mice which had all of their astrocytes ablated 
immediately following TBI, had a poorer outcome (Myer et al., 2006). Also a study performed in a rat 
model of stroke injury reported an increase in reactive astrogliosis, cell survival and improved outcome 
following treatment with DHA (Eady et al., 2012a), further suggesting that a DHA associated increase in 
reactive astrogliosis may be potentially beneficial. 
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Astrocytes of the hippocampus may have a different role than those in the cortex. In a study 
performed by Estrada and colleagues in glucose deprived rats, reported an increase in reactive 
astrogliosis in the hippocampus and this was correlated with an increase in the amount of 
neurogenesis seen in the hippocampus (Estrada et al., 2009). As discussed in the introduction, 
increased neurogenesis correlates with improved memory outcome (Kawakita et al., 2006, Drapeau et 
al., 2003, Tanabe et al., 2004). However, in our MWM protocol the CCI+DHA group did not show an 
improved learning or memory function in the MWM performance in the 4 weeks after injury.  
 
4.5.4 DHA treatment does not increase neurogenesis in the dentate gyrus 
The dentate gyrus (DG) is one of the only locations in the adult mammalian brain able to  display 
neurogenesis, apart from the subventricular zone (SVZ) (Drew et al., 2013). Neurogenesis in the 
dentate gyrus is essential for memory function, as proven in studies in which neurogenesis in mice has 
been ablated using irradiation, thereby worsening their performance in the radial arm maze (a spatial  
memory test) (Clelland et al., 2009). The CCI injured mice in our study showed an increase in the 
number of immature neurones in the dentate gyrus of the contralateral hippocampus. Despite this 
increase in neurogenesis, both CCI injured groups performed poorly in the MWM, suggesting that the 
increased neurogenesis of the contralateral hippocampus did not compensate for the loss of 
approximately 75% of the ipsilateral hippocampal tissue.  
The increase in neurogenesis following injury is a phenomenon also seen in stroke models (Türeyen et 
al., 2004, Kuge et al., 2009). Following experimental stroke and TBI, neurogenesis is increased in both 
the subgranular zone (SGZ) of the dentate gyrus and the SVZ (Parent, 2003). The data from these 
studies and our own suggest that increased neurogenesis is a common response to insult to the brain 
tissue. Endogenous neural stem cells (NSCs) of the SGZ may differentiate into neurons to replace those 
lost or damaged following TBI and then incorporate themselves into existing neural circuits (Sun, 
2014). This endogenous neurogenesis following TBI can be manipulated exogenously by 
intraventricular infusion of various growth factors including bFGF, EGF and VEGF and may offer an 
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avenue for potential neuroprotective therapies (Sun et al., 2009, Sun et al., 2010, Lee and Agoston, 
2010).  
The neurogenesis seen in the SGZ of the dentate gyrus in our CCI -injured mice,  may indicate an 
attempt of the NSCs of the DG to replace the hippocampal neurones lost as a result of the trauma 
(Kernie and Parent, 2010, Sun, 2014). The hippocampal neurones are particularly vulnerable to cell 
death following TBI and therefore their replacement by neurogenesis might explain the increased 
number of DCX+ cells in the hippocampus in both of the CCI groups,  in the absence of an improved 
performance in the MWM (Royo et al., 2006) 
DHA treatment has been shown to increase neurogenesis in both in vivo and in vitro studies (Kawakita 
et al., 2006). In our study however, DHA failed to increase the number of immature neurones in the 
contralateral hippocampus when compared to the vehicle treated group, suggesting that in this dosing 
regimen DHA did not promote further neurogenesis compared to the insult-induced neurogenesis.  
4.5.5 Conclusion 
The data produced in this chapter suggest that a single acute DHA treatment at the dose of 500 
nmol/kg, at 30 min after TBI,  does not improve outcome following CCI injury in mice. The treatment 
does not reduce tissue loss, or exert anti-inflammatory effects as measured by microglial/macrophage 
activation and reactive astrogliosis one month after injury. The CCI injury does induce neurogenesis in 
the hippocampus, which reflects the brain insult-induced neurogenesis reported in the literature, but 
this is unaffected by DHA treatment (Parent, 2003). DHA appears to increase the reactive astrocyte 
response induced by injury in the contralateral hippocampus. This indicates that the fatty acid had 
some impact on injury –related events, and raises the issue of the regime/dose administered. We 
hypothesise that further studies could explore a range of doses, to establish if at higher levels of acute 
exposure, the fatty acid displays more effects, in particular more impact on neurological outcome. 
Subsequent studies in this thesis will investigate the effect of prolonged endogeno us production of  
higher omega-3 PUFAs on outcome following CCI and the effect the DHA treatment has directly on 
astrocytes in an in vitro model of focal mechanical injury. 
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4.5.6 Main outcomes 
• Acute DHA treatment does not confer tissue protection in moderate CCI injury 
• Acute DHA treatment amplifies hippocampal reactive astrogliosis 






























5 Controlled cortical impact injury in fat-1 mice 
5.1 Introduction 
As discussed in the main introduction (section 1.4), evidence obtained in various models and using 
various paradigms of administration, suggests that omega-3 PUFAs may have a role in 
neuroprotection. As seen in the previous chapter, an acute injection of the omega-3 PUFA DHA post-
injury does not appear to improve outcome in mice following CCI. This suggests that the single i.v. 
administration of DHA at the 500 nmol/kg dose is not efficacious as an acute treatment strategy. A 
chronic treatment with DHA or mixtures of omega-3 fatty acids containing DHA (such as f i sh oi l )  may 
have beneficial effects in the treatment of TBI. This was suggested by the early studies carried out by 
Bailes and his collaborators; thus, they were the first show that oral supplementation for a month 
post-injury with DHA at the dose of 10 mg/kg/day or 40 mg/kg/day, reduced the axonal dysfunction 
after impact acceleration injury in rats (Bailes and Mills, 2010). In a subsequent publication, a 
supplementation with a similar dose of DHA contained in fish oil, also showed a reduction in caspase -3 
expression after injury (Mills et al, 2011). Our group has recently conducted studies using a transgenic 
mouse line, the fat-1 mice, which have high levels of endogenous omega-3 fatty acids in their body  
tissues (Kang et al., 2004). Our previous studies in spinal cord injury (SCI) and peripheral nerve injury 
(PNI) models employing these fat-1 transgenic mice have shown that higher levels of endogenous 
omega-3 PUFAs conferred neuroprotection in these models of traumatic injury (Gladman et al . ,  2012, 
Lim et al., 2013a). In this chapter, fat-1 transgenic mice were used in our CCI model of TBI, to 
determine whether an endogenous high level of omega-3 PUFAs can confer neuroprotection and 
improve neurobehavioral outcomes after TBI.  
5.1.1 Diet and polyunsaturated patty acids 
Diet composition has an important effect on a person’s health, with fats being vital to a balanced diet. 
Mammals are unable to make sufficient omega-3 and omega-6 PUFAs de novo, therefore PUFAs must 
be obtained from the diet and are referred to as essential fatty acids (as discussed in section 1.4.1) 
(Lee et al., 2016). An essential omega-6 PUFA is linoleic acid (LA), and from this 18-carbon chain PUFA 
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the longer chain n-6 PUFA arachidonic acid (AA) can be synthesised. An essential omega-3 PUFA is the 
18-carbon chain alpha-linolenic acid (ALA), from which the longer chain omega-3 PUFAs 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can be synthesised ( Fig. 1.4) (Gómez 
Candela et al., 2011). In the past 150 years the ratio of omega-6/omega-3 fatty acids in our diets has 
changed from 1:1 to a ratio of 20-25:1 (Simopoulos, 2006, Simopoulos, 2011). Thus, the western diet 
contains an excessive amount of omega-6 PUFAs and is deficient in omega-3 PUFAs. Evolutionarily, 
humans are not genetically adapted to convert these excess omega-6 PUFAs to omega-3 PUFAs, due to 
the absence of the appropriate fatty acid desaturase enzymes. This excessive amount of omega-6 
PUFAs has been linked with several pathologies, including chronic cardiovascular disease, diabetes, 
cancer and rheumatoid arthritis (Simopoulos, 2006). Concurrently, low intake of omega-3 PUFAs has 
been correlated with many disorders and has been linked to cognitive decline in the elderly (Stangl and 
Thuret, 2009, Freemantle et al., 2006).  Dietary supplementation is an effective approach that i s used 
to study the effects of different PUFAs on lipid profiles in vivo. There are several limitations to the 
dietary supplementation approach that may lead to conflicting data and inaccurate results. The aim of  
dietary supplementation is to increase the amount of PUFAs within the tissues of the animals. In order 
to assess the effect of supplementation, a control group has to be put on a diet which is identical  but 
lacking the active ingredient. It is often difficult or impossible to match a control diet with the same 
composition and calorific content as the test diet. Therefore, variations seen between test and control  
may not be due to the active ingredient alone. This has been seen particularly in the testing of omega -
3 fatty acid diet supplementation (Kang, 2007). A further limitation pertaining particularly to the 
testing of the effects of dietary PUFAs is that they are very unstable compounds and can oxidise  very 
quickly. 
 
5.1.2 The fat-1 transgenic mouse 
To solve the problems caused by omega-3 dietary supplementation, Kang and colleagues have 
produced a transgenic mouse that is able to produce high endogenous omega-3 PUFAs from omega-6 
PUFAs (Kang et al., 2004). As previously mentioned, mammals do not have the capacity to convert 
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omega-6 PUFAs into omega-3 PUFAs. However, some lower species such as the round worm 
Caenorhabditis elegans are able to carry out this process, because they express the fat-1 gene which 
encodes the enzyme omega-3 fatty acid desaturase (Lee et al., 2016). It is this fat-1 gene that Kang and 
colleagues have cloned into mice, resulting in the fat-1 transgenic mice (Kang et al., 2007). When 
heterozygous fat-1 mice mate, litters born will contain both heterozygous/homozygous transgenic 
mice and wild-type mice. As these littermates are housed together and fed on the same diet, they wi l l  
generate different fatty acid profiles within their tissues. When fed on a diet containing a high 
concentration of omega-6 fatty acids, the fat-1 mice expressing the omega-3 fatty acid desaturase can 
convert large amounts of the omega-6 fatty acids to omega-3 fatty acids and therefore will have high 
concentration of omega-3 fatty acids and low concentrations of omega-6 fatty acids within their 
tissues. In contrast, their wild-type littermates that do not express the fat-1 gene, will express within 
their tissues low levels of omega-3 fatty acids and high concentrations of omega-6 fatty acids, when 
fed on the same omega-6 rich diet (Kang et al., 2004, Kang, 2007). 
This model of fat-1 transgenic mice has been of great benefit in the field of omega-3 PUFA research. 
Firstly, it eliminates the several difficulties associated with dietary supplementation of omega-3 PUFAs 
such as diet manufacturing, control diet composition, inadequate diet storage and separate housing of 
mice. Secondly, this model shortens the length of feeding time that is usually required in dietary 
supplementation to obtain a change in the fatty acid composition of the tissues. Conversion from 
omega-6 to omega-3 fatty acids can occur as early as the embryonic stage and lasts for the duration of  
the animal’s life. Thirdly, this model creates two distinctly different fatty acid profiles (high omega-3/6 
and low omega-3/6 PUFA ratio) within the same litter. The high levels of omega-3 fatty acids seen in  
fat-1 mice are similar to those seen in mice fed on an omega-3 PUFA enriched diet (Kang et al. ,  2004) . 
Additionally, this model can be genetically crossed with other transgenic lines to evaluate  the effect 
omega-3 PUFAs have in a variety of disease states, such as in recent studies in the Swedish mutation 
human amyloid precursor protein 695 isoform (APP695) mouse used to model Alzheimer’s disease 
pathology (Kang, 2007, Wu et al., 2016a). 
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Since the production of the fat-1 transgenic mouse in 2004, several groups worldwide have utilised 
this model to study the effect that high levels of endogenous omega-3 PUFAs have in a variety of 
diseases including skin and colon cancer, liver disease, rheumatoid arthritis and traumatic injury  and 
more recently, stroke (Table 5.1).  
Table 5.1 Disease models that have utilised the fat-1 mice. 
Disease Model Key Findings Reference 
Skin cancer – 
Malignant melanoma 
Fat-1 mice had a reduction in the growth rate of 
melanoma 
(Yin et al., 2016) 
Colon cancer - colitis-
associated cancer 
Increased apoptosis of tumour cells, reduced 
colonic inflammation and decreased ulceration 
(Han et al., 2016, 
Jia et al., 2008) 
Alcohol-induced liver 
disease 
Down-regulation of: hepatic lipogenesis, 
inflammatory response and oxidative stress 
(Huang et al., 
2015) 
Rheumatoid arthritis  Decrease in: inflammation, ankle swelling, bone 
erosion and cartilage degradation 
(Woo et al., 2015) 
Stroke Improved long-term behaviour outcomes. 
Reduced infarct volume. Increased 
revascularization and angiogenesis and 
neurogenesis following stroke  
(Wang et al., 
2014b, Hu et al., 
2013) 
Alzheimer’s disease Less severe cognitive deficits and sensorimotor 
dysfunction and a reduction in astrogliosis  
(Wu et al., 2016a) 
Parkinson’s disease Positive correlation between higher tissue levels 
of DHA and dopaminergic markers 
(Bousquet et al 
2011) 
Peripheral nerve injury Accelerated functional recovery, reduced muscle 
atrophy and increased axonal survival  
(Gladman et al., 
2012) 
Spinal cord injury Improved locomotor function. Increased 
neuronal survival and a reduction in microglia 
activation 




5.1.3 The fat-1 mouse in CNS disease 
Fat-1 mice have recently been studied in several models of CNS disease (Table 5.1)  with results that 
indicate that high levels of endogenous omega-3 PUFAs confer neuroprotection and improved 
behavioural outcomes (Wang et al., 2014b, Hu et al., 2013, Wu et al., 2016a, Gladman et al., 2012, Lim 
et al., 2013a). 
In models of stroke, Alzheimer’s disease and SCI, fat-1 mice showed a better outcome compared to 
their wild-type littermates. In stroke models, the fat-1 mice had increased revascularisation fol lowing 
cerebral ischemia caused by occlusion of the left middle cerebral artery, as well as improved motor 
function as measured by the rotarod and cylinder behavioural tests (Wang et al., 2014b). In an 
Alzheimer’s disease model, where the Swedish mutation APP transgenic mouse line was crossed with 
the fat-1 mouse, the APP/fat-1 had improved cognitive function, reduced amyloid aggregation, 
reduced neuronal cell death and a decrease in reactive astrogliosis (Wu et al., 2016a). Recently, our 
group conducted compression SCI in fat-1 mice. Following SCI, the fat-1 mice had improved locomotor 
function, decreased microglia activation and a reduction in pro-inflammatory cytokines (e.g. IL-6) (Lim 
et al., 2013a). These beneficial outcomes seen in the fat-1 mouse suggested that the fat-1 mice might 
have an improved neurological outcome after a CCI. If so, this would indicate that prophylactically high 
omega-3 PUFAs may confer neuroprotection in TBI. 
 
5.1.4 Aging and TBI 
In western populations, there has been a shift in the epidemiology of TBI. Generally, the most common 
TBI population are younger men aged < 45 years old. However, due to the increasing aging population, 
a large majority of TBI patients are now much older, with patients over 75 years old having the highest 
incidence of TBI-related hospitalisations (Roozenbeek et al., 2013).  Elderly TBI patients are more likely 
to die as a result of their TBI, are more likely to have pre-trauma co-morbidities, and take a range of 
medications which may increase risk of haematomas (Parekh and Barton, 2010, Roozenbeek et al., 
2013). For example, many elderly patients take the anti -coagulant drug warfarin, which has been 
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linked to severe TBI, a worse outcome and a higher incidence of death (Lavoie et al., 2004). In e lderly 
patients, the risk of worse outcome following TBI is also increased due to cerebrovascular 
atherosclerosis, reduced free radical clearance and moderate cerebral atrophy, associated with aging 
brain tissue (Thompson et al., 2006). Despite some controversy in the literature, there is also evidence 
to suggest that there is a link between TBI and the risk of developing dementia and specifically 
Alzheimer’s disease (Gardner et al., 2014, Fleminger et al., 2003, Helmes et al., 2011).  
Cognitive decline correlates with aging and can therefore slow recovery after TBI (Mahncke et al., 
2006). Elderly patients with pre-trauma dementia or age-related cognitive decline can have additional  
complications for outcome measures, such as the GOS following TBI (Thompson et al., 2006). 
Interestingly, there is evidence to suggest that those individuals whose diets have contained high 
levels of omega-3 PUFAs throughout their life, have reduced cognitive decline in older age (Pusceddu 
et al., 2016, Cederholm et al., 2013). Given that an older age at the time of injury is a factor that leads 
to a worse outcome following TBI, we have also included a study in thi s chapter to investigate the 
impact of a CCI injury in old fat-1 mice and their wild-type littermates. 
5.2 Aims and Hypothesis 
5.2.1 Aims  
• To investigate the effect of high endogenous omega-3 PUFAs in young and aged mice following 
a CCI injury. The behavioural outcome was measured using the MWM and histological 
outcomes included tissue loss, microglial activation and reactive astrogliosis.  
• To investigate the changes in the brain lipid profile of fat-1 mice in the acute phase fol lowing 
CCI injury. 
5.2.2 Hypothesis 
Based on the positive data produced in our group in fat-1 mice in PNI and SCI models, it was 
hypothesised that there would be an improved outcome in fat-1 mice following CCI injury, including 





5.3.1 Young and aged male fat-1 mice 
The animals in this chapter were produced by mating heterozygous fat-1 mice with wild type C57BL/6 
mice. Heterozygous male mice 10-12 weeks old (young adult) and 49-53 weeks old (aged) were fed on 
a high omega-6 PUFA enriched diet in order to maintain the high omega-3: omega-6 ratio of the fat-1 
mice and the high omega-6: omega-3 ratio of the wild-type littermates. The same CCI injury was 
administered to these mice as described in the model development chapter and in methods section 
2.1.2. A one week MWM protocol was used, with a 4-day acquisition trial (day 15 – 18) and a probe 
trial administered 24 hours following the last acquisition trial (day 19) (Fig. 5.1). After perfusion on day 
21 post-injury, brain tissue was stained using toluidine blue and immunostained for GFAP (astrocytic 
marker) and Iba1 (microglia/macrophage marker). Age-matched naïve C57BL/6 male mice were used 
as controls for behavioural and histological testing. 
 
Figure 5.1 Timeline for the testing in the Morris water maze following CCI in the fat-1 mice. 
 
 
5.3.2 Lipid analysis of brain tissue from young adult female mice 
The animals used for lipid analysis were female mice aged 10-12 weeks old, their wild-type littermates 
and naïve controls. CCI injury was conducted and then 24 hours later, the brain tissue was collected for 
lipid analysis. The analysis was carried out using thin layer chromatography and gas liquid 





Fat-1 mice were used to investigate the potential neuroprotective effect high levels of  endogenous 
omega-3 PUFA in tissues had on the outcome following a CCI injury. Young adult (10 -12 weeks)  male 
fat-1 mice and their wild type (WT) littermates were matched with naïve C57BL/6 controls. We 
assessed the effect of the fat-1 gene on cognitive function using the Morris water maze (MWM) and 
on histological markers, i.e. tissue loss, microglial activation and reactive astrogliosis, using to luidine 
blue staining and immunolabelling. The same outcome measures were also used to assess the effect 
the fat-1 gene had in aged (49 – 53 weeks) male mice following CCI. 
In this chapter we also investigated the effect the fat-1 gene had on the lipid profile of the brain tissue 
following CCI injury in young female mice 24 hours following injury. We used thin layer 
chromatography and gas liquid chromatography to establish the changes in fatty acids, with emphasis 
on the omega-6 fatty acids linoleic acid (LA 18:2n-6) and arachidonic acid (AA), and the omega-3 fatty 
acids docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA).  
5.4.1 Behavioural response after CCI injury in young adult male fat-1 mice 
The male mice in this study which were considered young adults were 12-13 weeks old at the time of  
the injury. CCI injury was conducted on mice that expressed the fat-1 gene (termed fat-1 + CCI group)  
and their wild-type (WT) litter mates (termed WT + CCI group) , which were all fed on a high omega-6 
PUFA diet. For behavioural and histological testing, they were matched with naïve 12 week-old 
C57BL/6 male mice, to act as the control naïve group.  
5.4.1.1 Morris water maze – Acquisition and Probe trial 
During the one-week acquisition training protocol (Fig. 5.1), that began on day 15 post-injury, all 
groups demonstrated a decrease in their escape latency (Fig. 5.2; Fig. 5.3A). The naïve group, which 
acted as our control group for this study, had the steepest learning curve. On day 15 the naïve group 
took an average of 53.9 ± 9.6 s to find the platform over the 4 trials, which was reduced to 18.8 ± 7.6 s 
on the final day of the acquisition training on day 18. 
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The fat-1 transgenic and WT groups that received a CCI injury also reduced their escape latencies over 
the acquisition training. The WT + CCI group had an average escape latency of 74.0 ± 4.3 s on day 15, 
which decreased to 40.7 ± 5.4 s on day 18. The fat-1 + CCI group had an average escape latency of 64.3 
± 3.2 s on day 15, which decreased to 36.1 ± 4.9 s on day 18. Despite this decrease in escape latencies 
over the acquisition training, the WT + CCI and fat-1 + CCI animals were still statistically significantly 
slower than the naïve group (day 15: Naïve vs. WT + CCI, ***p<0.001; day 16: Naïve vs. WT + CCI, 
*p<0.05; day 17: Naïve vs. WT + CCI,***p<0.001; Naïve vs. fat-1 + CCI,***p<0.001; day 18: Naïve vs. 
WT + CCI,***p<0.001; Naïve vs. fat-1 + CCI,***p<0.001 -statistical significance was determined using a 
two-way repeated measures ANOVA with post-hoc Bonferroni tests). 
The probe trial was conducted on day 19, 24 hours after the last acquisition training day trial. The 
outcome measures from the probe trial were the same as in previous chapters, in which the time 
taken to the platform zone and the number of entries to the platform zone were analysed (Fig. 5.3B, 
C). The fat-1 gene did not appear to affect locomotor performance as assessed by the analysis of  the 
average swim speed of the young mice in the day 19 MWM probe trial (see appendix 1.1). 
As expected, the naïve control group was the quickest to enter the platform zone during the probe 
trial (18.5 ± 5.9 s). The WT + CCI group (43.8 ± 9.9 s) and the fat-1 + CCI group (32.0 ± 6.3 s) were both 
slower. However, the fat-1 group had over a 10 s improvement in the latency to enter the platform 
zone – but this difference compared to the WT + CCI group was not statistically significant (Fig. 5.3B). 
Compared to naïve control animals, the WT + CCI animals had a decreased number of entries into the 
platform zone. The fat-1 group had a performance which was similar to the naïve control animals,  but 




Figure 5.2. Effect of the fat-1 gene in young males on the performance in the Morris water maze. 













Figure 5.3. Effect of the fat-1 gene in young males on the performance in the Morris water maze 
Acquisition and Probe trial. (A) The average escape latency of the 4 trials conducted on days 15-  18 
post injury during the acquisition training. The WT+CCI had significantly slower escape latencies 
compared to the naïve group on day 15 (###p<0.001), day 16 (#p<0.05), day 17 (###p<0.001) and day 
18 (###p<0.01). The fat-1 + CCI were also statistically slower than the naïve group on day 17 
(&&&p<0.001) and day 18 (&&&p<0.001). There were no statistical differences between the WT + CCI 
and the fat-1 + CCI groups during the acquisition training.  On day 19 the probe trial was conducted; 
(B) the time taken to the platform zone and (C) the number of entries to the platform zone. There 
were no statistical differences between any of the groups in the probe trial measures. Statistical 
analysis of the acquisition training was conducted using a two-way repeated measures ANOVA with 




5.4.1.2 Gross tissue loss after CCI injury in young adult male fat-1mice  
After perfusion of the mice on day 21, the brain tissue was collected and cut into coronal sections. 
Sections from 4 locations (-1.5, -2.0, -2.5 and -3.0 mm posterior to bregma) spanning the area of the 
lesion were analysed using toluidine blue staining. 
The WT + CCI and fat-1 + CCI groups had substantial tissue loss in all three of the measurements 
carried out; the ipsilateral hemisphere, ipsilateral cortex and hippocampus, when compared to the 
contralateral side (Fig. 5.4; Fig. 5.5A-C). The naïve group represented the baseline. The WT + CCI and 
fat-1 + CCI groups had a statistically significant loss of tissue compared to the naive group in the 
ipsilateral hemisphere (*p<0.05), the ipsilateral cortex (**p<0.01) and the ipsilateral hippocampus 
(***p<0.001). The presence of the fat-1 gene did not prevent the tissue loss after CCI as there were no 
statistically significant differences in comparison to the WT + CCI group. 
The ipsilateral hippocampus in both of the CCI groups had the biggest reduction in size, when 
compared to the contralateral hippocampus. The WT + CCI group only had 26.3 ± 3.2 % ipsilateral 














Figure 5.4. Brain sections from young wild type and fat-1 mice stained with 
toluidine blue. 20 µm coronal brain sections from WT + CCI and fat-1 + CCI groups, 
taken from the following locations posterior to bregma: -1.5 mm, -2.0 mm, -2.5 mm 







































Figure 5.5. The effect the fat-1 gene has in young males on tissue loss after CCI. (A) 
hemisphere, (B) cortex and (C) hippocampus. Statistical significance determined using one -
way ANOVA and post-hoc Bonferroni testing (*p<0.05, **p<0.01, ***p<0.001). Mean ± 
S.E.M. N= 3 animals per group. 
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5.4.1.3 Reactive astrogliosis after CCI injury in young adult male fat-1 mice 
The percentage area covered by GFAP immunolabelling was measured in the same ROI as in previous 
chapters, to determine the level of reactive astrocytosis (Fig. 5.6; Fig. 5.7). The CCI injured groups 
showed increased GFAP immunolabelling when compared to the naïve controls. The WT + CCI 
(***p<0.001) and the fat-1 + CCI (***p<0.001) showed a statistically significant increase in the amount 
of GFAP immunolabelling in the ipsilateral cortex when compared to the naïve group (Fig. 5.7B). There 
was also an increase in the GFAP immunolabelling in the fat-1 + CCI group (*p<0.05) compared to the 
WT + CCI in the ipsilateral cortex. In the contralateral cortex, the fat-1 + CCI mice (**p<0.01) had 
increased GFAP immunolabelling when compared to the naïve group (Fig. 5.7A). The WT + CCI group 
had a higher percentage of GFAP immunolabelling compared to the naïve control , but this was not 
statistically significant. 
There was increased GFAP immunolabelling in the hippocampus in the fat-1 + CCI group compared to 
the naïve (*p<0.05) and WT + CCI (*p<0.05) groups (Fig. 5.7C). There were no significant differences 
between the naïve and the WT + CCI groups. There were no differences between the three groups in 
the GFAP immunolabelling in the dentate gyrus (Fig. 5.7D). 
  
Figure 5.6. The effect of the fat-1 gene on GFAP expression in young males. Immunolabelling of 
reactive astrocytes with GFAP in the ipsilateral cortex in the naive, WT + CCI and fat-1 + CCI groups. 














Figure 5.7 The effect the fat-1 gene has in on reactive astrogliosis in the cortex and hippocampus 
in young males. Schematic showing the ROI in the cortex and hippocampus that were analysed for 
GFAP labelling (GFAP+). The percentage increase in GFAP labelling in the WT + CCI and fat-1 + CCI 
groups was compared to young naïve tissue. (A) In the contralateral cortex the fat-1 + CCI (**p<0.01)  
group had an increased amount of GFAP+ labelling compared to the naïve group. (B) In the 
ipsilateral cortex there was increased GFAP+ labelling in the CCI groups (WT + CCI vs. Naïve, 
***p<0.001; fat-1 + CCI vs. Naïve, ***p<0.001; fat-1 + CCI vs. WT + CCI, *p<0.05). (C) In the 
contralateral hippocampus the Fat-1 + CCI showed increased GFAP+ labelling compared to the naïve 
group (*p<0.05) the WT+CCI group also had increased GFAP+ labelling vs. the naïve group (*p<0.05). 
(D) There was no difference in GFAP+ labelling between groups in the dentate gyrus of the 
hippocampus. Statistical significance was determined using one -way ANOVA and post-hoc 




5.4.1.4 Activated microglia/macrophages after CCI injury in young adult male fat-1 mice 
The same ROI used to analyse reactive astrogliosis in the cortex and contralateral hippocampus, were 
used to analyse the number of activated microglia/macrophages in these mice (Fig. 5.8). The lowest 
number of Iba1+ cells was found in the naïve group, in all ROI. In the contralateral cortex the naïve 
group had 20 ± 5 Iba1+ cells, which was statistically fewer than the WT + CCI group 60 ± 12 (*p<0.05) 
and the fat-1 + CCI group 57 ± 6 (*p<0.05) (Fig. 5.9A). In the ipsilateral cortex the fat-1 + CCI (80 ± 17) 
and the WT + CCI (65 ± 7) groups had a higher number of Iba1+ cells compared to the naïve group (29 
± 4) (Fig. 5.9B). Only the WT + CCI group showed a statistically significant increase in the number of 
Iba1+ cell vs.  the naïve group (*p<0.05). 
In the contralateral hippocampus, the two injury groups had a higher number of Iba1+ cells than the 
naïve group (Fig. 5.9C). The WT + CCI group had 201 ± 14 Iba1+ cells and the fat-1 ± CCI group had 224 
± 26 Iba1+ cells, both of these had a statistically significant increased number of Iba1+ cells compared 
to the naïve group which had 125 ± 8 (WT + CCI vs naïve, *p<0.05; fat-1 + CCI vs naïve,**p<0.01). 
 
Figure 5.8. The effect of fat-1 gene on the Iba1 expression in young males. Immunolabelling of 
activated microglia/macrophages with Iba1, in the contralateral cortex in the naive, WT + CCI and fat-1 
















Figure 5.9. The effect the fat-1 gene has on the number of Iba1+ cells in the cortex and 
hippocampus in young males. The numbers of activated microglia/macrophages were 
identified with Iba1+ immunolabelling in the WT + CCI and Fat-1 + CCI groups and was 
compared to young male naïve tissue. (A) In the contralateral cortex the fat-1 + CCI group 
(*p<0.05) and the WT + CCI group (*p<0.05) had an increased no. of Iba1+ cells compared to 
the naïve group. (B) In the ipsilateral cortex there was increased no. of Iba1+ cell s in WT + CCI 
group (*p<0.05) vs naïve group. (C) In the contralateral hippocampus the CCI injured groups 
had increased no. of Iba1+ cells, fat-1 + CCI vs naïve, **p<0.01; WT + CCI vs naive,*p<0.05). (D) 
In the dentate gyrus of the hippocampus, there was no statistically significant difference 
between the groups. Statistical significance was determined using one -way ANOVA and post-




5.4.2 The effect of CCI in aged male fat-1 mice 
The males in this study were 49-53 weeks old at the time of the injury. Mice that expressed the fat-1 
gene and their WT littermates received a CCI injury and were fed on a high omega-6 PUFA diet. For 
behavioural and histological testing, they were matched with naïve 52 week-old C57BL/6 male  mice, 
which acted as the control group.  
5.4.2.1 Morris water maze – Acquisition and Probe trial 
The acquisition training protocol (Fig. 5.1; Fig.5.10) began on day 15 post-injury. The naïve group was 
the only group that demonstrated learning ability (Fig. 5.11A). The naïve group on day 15 had an 
average escape latency of 81.3 ± 5.3 s on day 15, that was reduced to 22.4 ± 4.6 s on day 18. The aged 
WT + CCI group and the aged Fat-1 + CCI group failed to show a significant reduction in escape latency 
over the 4 days of the acquisition training. On day 15 the WT + CCI group had an escape latency of 66.6 
± 6.5 s and on day 18 it had an escape latency of 54.2 ± 3.7 s. The Fat-1 + CCI group on day 15 had an 
escape latency of 68.4 ± 6.3 s and on day 18 it had an escape latency of 55.9 ± 13.2 s. 
The probe trial was conducted on day 19 post-injury, 24 hours after the last acquisition training trial 
(Fig. 5.10; Fig 5.11B, C). The fat-1 gene did not appear to affect locomotor performance as assessed by 
the analysis of the average swim speed of the aged mice in the day 19 MWM probe trial (see appendix  
1.1). The naïve group was able to reach the platform zone quickest with a latency of 29.9 ± 16.2 s, 
whereas the two CCI injured groups took on average over a minute to reach the platform zone (WT  + 
CCI, 63.0 ± 16.7 s; Fat-1 + CCI, 75.9 ± 14.1 s). 
The number of entries made to the platform zone during the probe trial was higher in the naïve mice 
than in the mice that received a CCI injury (Fig. 5.11C). There was no difference between the WT + CCI 
and Fat-1 + CCI groups in the number of visits to the platform zone, which for both groups was fewer 
than 1 visit, meaning that some mice in those groups did not enter the platform zone at all during the 





Figure 5.10. Effect of the fat-1 gene in aged males on the performance in the Morris water maze. 










Figure 5.11 Effect of the fat-1 gene in aged males on the performance in the Morris water maze 
Acquisition and Probe trial. (A) The average escape latency of the 4 trials conducted on days 15-  18 
post injury during the acquisition training. The WT + CCI and the Fat-1 + CCI groups had slower 
escape latencies than the naïve group, but it was not statistically significant. On day 19 the probe 
trial was conducted; (B) the time taken to the platform zone and (C) the number of entries to the 
platform zone. There were no statistical differences between any of the groups in the probe trial  




5.4.2.2 Tissue loss after CCI injury in aged male fat-1 mice 
After perfusion of the aged mice on day 21, the brain tissue was cut into 20 µm thick sections (Fig. 
5.12). Coronal brain slices from 4 locations (-1.5, -2.0, -2.5 and -3.0 mm in reference to bregma) 
spanning the area of the impact lesion and were analysed using toluidine blue staining.  
The aged WT + CCI and aged fat-1 + CCI group had substantial tissue loss in all three of the 
measurements, the ipsilateral hemisphere, ipsilateral cortex and hippocampus, when compared to the 
contralateral side (Fig. 5.13A-C). The aged naïve group did not show any tissue loss on the ipsi lateral  
side. The aged WT + CCI and aged fat-1 + CCI groups had a statistically significant loss of tissue 
compared to the naive group in the ipsilateral hemisphere (**p<0.01), the ipsilateral cortex (**p<0.01) 
and the ipsilateral hippocampus (**p<0.01). The presence of the fat-1 gene did not prevent any tissue 
loss after CCI, and therefore failed to show any statistical difference to the aged WT + CCI group.  
The ipsilateral hippocampus in both of the aged CCI groups had the biggest reduction in  hippocampal 
size when compared to the contralateral hippocampus. The aged WT + CCI group only had 16.7 ± 3.8 % 
ipsilateral hippocampal tissue remaining and the aged fat-1 + CCI group only had 31.5 ± 10.5 % 


















Figure 5.12 Brain sections from aged wild type and fat-1 mice stained with Toluidine 
blue. 20 µm coronal brain sections from WT + CCI and Fat-1 + CCI groups. The brain 
sections were taken from the following location back from the bregma reference: -1.5 















Figure 5.13. The effect the fat-1 gene has in aged males on tissue loss after CCI.  
(A) Hemisphere, (B) cortex and (C) hippocampus. Statistical significance was 
found using one-way ANOVA and post-hoc Bonferroni testing (**p<0.01). Mean 




5.4.2.3 Reactive astrogliosis after CCI injury in aged male fat-1 mice 
The percentage area covered by GFAP labelling was measured in the same ROI as in previous chapters, 
to determine the reactive astrocytosis (Fig. 5.14). The aged naïve group had very little GFAP labelling in 
the contralateral and ipsilateral cortices when compared to the two aged CCI injury groups 
(Fig.5.15A,B). The WT + CCI (*p<0.05) and fat-1 + CCI groups (**p<0.01) showed a statistically 
significant increase in GFAP immunolabelling in the ipsi lateral cortex when compared to the naïve 
group. The two aged CCI injury groups did not show any statistically significant differences to each 
other, although the aged fat-1 + CCI mice had almost 1.5 times as much GFAP labelling (1454.1 ± 268.2 
%) compared to the aged WT + CCI (880.1 ± 44.7 %) GFAP labelling in the ipsilateral cortex. 
The contralateral cortex had a smaller increase in GFAP immunolabelling than the ipsilateral cortex. In 
the contralateral cortex (Fig. 5.15A) the aged fat-1 + CCI group had statistically increased GFAP 
immunolabelling compared to both the naïve (***p<0.001) and aged WT + CCI group (**p<0.01). The 
aged WT + CCI group also had increased GFAP immunolabelling when compared to the naïve group 
(***p<0.001). 
There was increased GFAP immunolabelling in the hippocampus (Fig. 5.15C) in the aged fat-1 + CCI 
injured group compared to the aged naïve (*p<0.05) and the aged WT + CCI (*p<0.05) groups. There 
were no significant differences between the aged naïve and the aged WT + CCI groups. The re were no 
differences between the three groups in the GFAP immunolabelling within the dentate gyrus region of  





Figure 5.14 The effect of fat-1 gene on GFAP expression. Immunolabelling of reactive astrocytes with 
GFAP in the ipsilateral cortex in the naive, aged WT+CCI and aged fat-1+CCI groups. Red arrows 




























Figure 5.15. The effect the fat-1 gene had on reactive astrogliosis in the cortex and hippocampus 
of aged males. Schematic showing the ROI in the cortex and hippocampus that were analysed for 
GFAP labelling (GFAP+). The percentage increase in GFAP labelling in the aged WT + CCI and aged 
fat-1 + CCI groups was compared to aged naïve tissue. (A) In the contralateral cortex the aged WT + 
CCI (***p<0.001) and the aged fat-1 + CCI (***p<0.001) groups had an increased amount of GFAP+ 
labelling compared to the naïve group. The aged fat-1 + CCI group (**p<0.01) also had increased 
GFAP+ vs naïve group. (B) In the ipsilateral cortex there was increased GFAP+ labelling in the CCI 
groups (aged WT + CCI vs naïve, *p<0.05; aged fat-1 + CCI vs naïve, **p<0.01). (C) In the 
contralateral hippocampus the aged fat-1 + CCI showed increased GFAP+ labelling compared to the 
naïve group (*p<0.05) and the aged WT + CCI group (*p<0.05). (D) There was no difference in 
GFAP+ labelling between groups in the dentate gyrus of the hippocampus. Statistical signi ficance 
was determined using one-way ANOVA and post-hoc Bonferroni test. Mean ± S.E.M. Naïve, n=5; 






5.4.2.4 The effect of CCI in aged  fat-1 males – Microglia/macrophage activation 
The same regions of interest (ROI) were used to analyse the number of microglia/macrophages in 
these mice (Fig. 5.16). The lowest number of Iba1+ cells were found in the Naïve group in all ROI. In the 
contralateral cortex (Fig. 5.17A) the naïve group had 27 ± 5 Iba1+ cells, which was statistically fewer 
than the aged WT + CCI group 45 ± 4 (*p<0.05) and the aged fat-1 + CCI group 49 ± 3 (*p<0.05). In the 
ipsilateral cortex (Fig. 5.17B) the aged fat-1 + CCI had the highest number of Iba1+ cells 57 ± 1, which 
was statistically more than the naïve group (*p<0.05). 
In the contralateral hippocampus the two injury groups had a higher number of Iba1+ cells than the 
naïve group (Fig. 5.17C). The aged WT + CCI group had 195 ± 12 Iba1+ cells and the aged fat-1 + CCI 
group had 210 ± 14 cells, both of these had statistically increased number of Iba1+ cells compared to 




Figure 5.16. The effect of fat-1 gene on the no. of Iba1+ cells in aged fat-1 males. Immunolabelling of  
activated microglia/macrophages within the ipsilateral cortex in the aged naive, aged WT + CCI and 







Figure 5.17. The effect of the fat-1 gene in aged males on the number of 
microglia/macrophages in the cortex and hippocampus. Schematic showing the ROI in the 
cortex and hippocampus that were analysed for Iba1+ labelling. The number of Iba1+ cel l s were 
analysed in the (A) contralateral cortex, where the aged WT + CCI (*p<0.05) and the aged fat-1 + 
CCI group (*p<0.05) had an increased number of Iba1+ cells compared to the naïve group. (B) In 
the ipsilateral cortex the aged fat-1 + CCI (*p<0.05) had a higher number of Iba1+ cells compared 
to the naïve group. (C) In the hippocampus the aged WT + CCI (**p<0.01) and the aged fat-1 + 
CCI (**p<0.01) had a higher number of Iba1+ cells compared to the naïve group. (D) There was no 
difference between the number of Iba1+ cells in the dentate gyrus of the hippocampus. 
Statistical significance was determined using one-way ANOVA and post-hoc Bonferroni test. 




5.4.3 The effect of CCI on the brain lipid profile in young adult fat-1 females 
Using thin layer chromatography followed by gas chromatography (section 2.1.8), the fatty acid profile 
of the brain tissue from young adult female fat-1 mice and their wild-type littermates was analysed 
following CCI injury. A naïve group of age- and strain-matched mice were included as the control 
group. The changes in two selected omega-6 fatty acids (LA and AA) and two omega-3 fatty acids (DPA 
and DHA) were expressed as a percentage of the total fatty acids in tissue. We considered separately 
the effect of the diet, of the sham injury (craniotomy) and of the CCI.  Figure 5.18 shows a 
representative chromatogram, annotated for the various fatty acids detected. 
 






5.4.3.1 Effect of the omega-6 enriched diet on the brain lipid profile 
The effect of a high omega-6 diet on the lipid composition of the brain was analysed. A group of  age 
matched C57BL/6 females was compared to WT females fed on the high omega-6 PUFA diet (Fig. 5.19). 
The percentage of omega-6 free fatty acids in the brains of these mice were very similar; both groups 
had less than 1 % LA and both had between 8 – 9 % of AA in their tissue. It may appear that the 
percentage of AA was higher in the WT group; however, due to an early death of a female WT mouse, 
there are only 2 females in this test group and therefore the N number was not high enough to appl y 
statistical analysis. 
In the omega-3 fatty acid analysis, a higher percentage of DPA and a lower percentage of DHA was 
observed in the WT diet fed group when compared to the naïve group fed on a normal murine chow. 



























































Omega-6 PUFAs Omega-3 
PUFAs 
Figure 5.19. The effect a high omega-6 PUFA diet has on the lipid profile of the brain tissue. 
The fatty acids from naïve and WT mice, fed on a control or a high omega-6 PUFA diet, 
respectively, were compared. The omega-6 PUFAs LA (18:2n-6) and AA, and the omega-3 
PUFAs DPA and DHA, were expressed as percentage of total fatty acids. Mean ± SEM. Naïve, 
n=3; WT (no injury), n=2. 
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5.4.3.2 Effect of the fat-1 gene on brain lipid profile 
In this section, we present the data obtained from the two groups of animals fed on the omega -6 rich 
diet. Since the fat-1 group expressed the fat-1 gene, these mice will convert exogenous omega-6 
PUFAs into omega-3 PUFAs, resulting in a higher level of endogenous omega-3 PUFAs in their tissues. 
The WT and fat-1 groups both expressed similar levels of the omega-6 PUFAs LA and AA (Fig. 5.20). 
However, there did appear to be differences in the percentage of the omega-3 PUFAs, DPA and DHA, 
between the WT and fat-1 groups. The WT mice had higher levels of the omega-3 fatty acid DPA (2 %)  
compared to the mice expressing the fat-1 gene (< 1 % of total brain fatty acids). In contrast, the 
omega-3 fatty acid DHA was found at higher concentrations in the fat-1 mice (12 %), compared to the 

























































Omega-6 PUFAs Omega-3 PUFAs 
Figure 5.20. The effect of the fat-1 gene has on the lipid profile of the brain tissue. The 
fatty acids from WT mice and Fat-1 mice, fed on the same high omega-6 PUFA diet, were 
compared. The omega-6 PUFAs LA (18:2n-6) and AA, and the omega-3 PUFAs DPA and 
DHA, were expressed as percentage of total fatty acids. Mean ± SEM. Fat-1 (no injury), 




5.4.3.3 Effect of the fat-1 gene on the lipid profile in the brain following a sham injury 
To determine if the CCI injury had any effect on the fatty acid composition of the brain, brain tissue 
from animals with a sham injury (craniotomy) was analysed (Fig. 5.21). 
The sham injured mice showed no difference in the amount of the omega-6 fatty acid LA in 
comparison to the naive group, regardless of whether they expressed the fat-1 gene. However, some 
differences were observed in the percentage of the omega-6 fatty acid AA. In the sham injured mice, 
there was a decrease in the percentage of AA in both the fat-1 + sham group and the WT + sham 
group, when compared to the uninjured groups, but no statistical difference was observed.  
There were some other differences noted between the percentage brain composition of the omega -3 
fatty acids. The WT + no injury group had the highest percentage of DPA among all the 4 groups, at 2 
%. No statistically significant difference in the percentage of DHA, between the groups was observed. 
Interestingly, the fat-1 + no injury group had the highest percentage of DHA; it was statistically higher 
than the fat-1 with a sham injury (fat-1 + no injury vs. WT + sham, **p<0.01; fat-1 + no injury vs. fat-1 
+ sham, *p<0.05). Thus, the sham injury appears to have caused a reduction in the amount of the 
























































































Figure 5.21 The effect the sham injury has on the lipid profile of the brain tissue. The fatty 
acids from WT mice and Fat-1 mice, fed on the same high omega-6 PUFA diet, and with or 
without a sham injury, were compared. The omega-6 PUFAs LA (18:2n-6) and AA, and the 
omega-3 PUFAs DPA and DHA, were expressed as percentage of total fatty acids.  The 
percentage of the omega-3 PUFA DHA was statistically significantly different between groups. 
The fat-1 with no injury group had an increased percentage of DHA compared to fat-1 with 
sham group (*p<0.05) and the WT with sham group (**p<0.01). The fat-1 with sham group had 
an increased percentage of DHA compared to the WT with sham group (*p<0.05). Statistical 
analysis was performed using a two-way ANOVA with post-hoc Bonferroni tests.  Mean ± SEM. 
WT (no injury), n=2; Fat-1 (no injury), n=3; WT (Sham), n=3; Fat-1 (Sham), n=3. 
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5.4.3.4 Effect of the fat-1 gene had on the lipid profile in the brain following a CCI injury 
 
To assess the effect of the CCI injury on the fatty acid composition, tissue was collected and analysed 
from WT + CCI and fat-1 + CCI mice 24 hours after injury, and analysed alongside sham injured brain 
tissue. 
The percentage of the omega-6 fatty acid AA increased in mice that received a CCI injury whether or 
not the fat-1 gene was present, although this was not statistically significant. 
From the omega-3 fatty acids analysed, the percentage of DHA was increased in the CCI groups when 
compared to the WT + sham group. Of the total fatty acids in the brain tissue, the WT + CCI had 12.1 ± 
0.5% DHA, which was significantly (**p<0.01) more than in the WT + sham group, which had 8.4 ± 
1.4%.   The fat-1 + CCI (12.6 ± 0.7 %) group also had a significantly higher (***p<0.001) percentage of 
DHA than the WT + sham group. Despite not showing any statistical significance, both CCI injured 
groups had an increased percentage of DHA than the fat-1 + sham group. The CCI injury appeared to 
increase the percentage of DHA (>3 %), compared to a sham injury. The WT + CCI group and the fat-1 + 
CCI group have the highest total percentage of DHA among all the groups tested in this chapter. 
The lipid analysis of the brain tissue suggests that there is an increased amount of DHA in the fat-1 
mice, that the sham injury causes a reduction in the percentage of DHA and that a CCI injury increases 





















































































Figure 5.22. The effect the CCI injury has on the lipid profile of the brain tissue. The 
brain lipids from wild type mice with Sham injury, wild type mice with CCI injury, fat-1 
mice with Sham injury and fat-1 mice with CCI injury, were compared. The percentage 
of the omega-3 PUFA DHA was statistically significantly different between groups. The 
fat-1 CCI injury group had an increased percentage of DHA compared to the WT sham 
injury group (***p<0.001). The WT CCI injury group also had an increased percentage 
of DHA compared to the WT sham group (**p<0.01). Statistical analysis was 
performed using a two-way ANOVA with post-hoc Bonferroni tests.  Mean ± SEM. WT 




The studies in this chapter investigated whether high endogenous levels of omega-3 fatty acids due to 
the presence of the fat-1 gene and consumption of an omega-6 enriched diet, conferred 
neuroprotection in mice following CCI injury, in comparison to the impact of injury in wild -type 
littermates with high endogenous levels of omega-6 fatty acids. Furthermore, this aspect of response 
to CCI was investigated in both young and aged fat-1 transgenic male mice.   The measure used to 
assess cognitive outcome was the MWM test, which was performed using a one -week protocol (Fig. 
5.1). To assess the effect of the fat-1 gene on the brain following CCI, the amount of gross tissue loss, 
reactive astrogliosis and activated microglia were measured. Furthermore, in a pilot study focused on 
the acute changes in the brain fatty acid composition 24 h post-injury, we investigated the impact of  
the fat-1 gene and of the CCI on the lipid composition of the brain tissue. 
 
5.5.1 The fat-1 gene did not improve cognitive function following a CCI injury 
Recent experimental and clinical studies have shown that omega-3 PUFA supplementation is 
correlated with improved cognitive outcome (Janssen et al., 2015, Abdel-Wahab et al., 2015, Bauer et 
al., 2014). The group that created the fat-1 transgenic mice have also tested them in the MWM, where 
the adult fat-1 mice exhibited improved acquisition when compared to the WT control mice (He et al . ,  
2009). However, the study that He and colleagues reported used a protocol that included a five -day 
acquisition training phase, which was one day longer than in our study, and the improvement 
observed in their study was only seen on the final day of the acquisition training, therefore rather 
limited. Therefore, it may be suggested that we might have missed any significant improvement due to 
a shorter acquisition phase protocol. Interestingly, the Kang group also performed a probe trial 
following the acquisition training, and failed to see any difference between the fat-1 and WT groups, 
as was also observed in our study. Another study by Wu and colleagues also showed that the presence 
of the fat-1 gene failed to improve performance in the MWM probe trial (He et al., 2009, Wu et al., 
2016a). The data we show in this chapter suggest that the presence of the fat-1 gene does not lead to 
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a robustly improved performance in the MWM, either in the acquisition training or the probe trial, 
following a CCI injury, which is in accordance with the data reported in uninjured fat-1 mice. 
In the young adult male mice of both CCI-injured groups, animals were able to reduce their escape 
latency over the acquisition training, although as expected, not as quickly as the naïve group. This 
reduction in escape latency over the acquisition trial regardless of the moderate CCI injury, has been 
observed in both of the previous chapters. In the young male mice, the fat-1 gene did not improve 
their performance in the acquisition training phase or the probe trial when compared to their WT 
littermates with CCI injury. However, we noted that in the probe trial, when the number of entries in 
the platform zone was considered, young adult fat-1 mice appeared to perform after CCI at the level of 
the naïve mice – albeit with lack of statistical significance for this difference. 
Aging has been linked to a decline in cognitive function, such as impaired memory, in both humans and 
animals (Harada et al., 2013, Rosenzweig and Barnes, 2003). Various diets and dietary supplements 
have been investigated and suggested to have an impact upon cognitive ability in the elderly (Al len et 
al., 2013, Oleson et al., 2016, Singh et al., 2011, Pan et al., 2010), in particular supplementation with 
omega-3 PUFAs preparations (Kiso, 2011, Strike et al., 2016, Pusceddu et al., 2016). However, in a 
study in aged mice that were fed on an omega-3 rich diet, the authors  failed to demonstrate any 
increased cognitive ability in the MWM test, but reported some improvement in the spatial Y-maze 
cognitive test, when compared to age matched controls (Cutuli et al., 2014). In our study, aged mice 
that expressed the fat-1 gene failed to show an improved behavioural performance following the CCI 
in the MWM. The aged naïve group did demonstrate some learning ability by reducing their average 
escape latency over the acquisition training days. However, unlike the young males that received the 
CCI injury, the aged CCI injured males failed to demonstrate any learning capability over the 
acquisition training phase. This data supports the literature that documents a worse outcome after TBI 
in aged patients (Roozenbeek et al., 2013, Thompson et al., 2006). 
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5.5.2 The fat-1 gene did not prevent gross tissue loss 
The presence of the fat-1 gene failed to reduce the brain tissue loss in the ipsilateral hemisphere, 
cortex or hippocampus following CCI injury, whether the mice were young or aged. Interestingly, the 
aged animals did not show any more tissue loss than the young CCI injured mice, although the 
literature would suggest that aged mice would suffer a larger lesion size  following TBI (Kumar et al . ,  
2013). 
5.5.3 The fat-1 gene did not change the microglial/macrophage activation 
The presence of the fat-1 gene did not change the amount of activated microglial/macrophage cells in 
the brain tissue detected several weeks following CCI injury. The CCI injury caused an increase in the 
number of activated microglia/macrophage cells, as was observed in the brain tissue of the CCI injured 
mice in the previous chapters. In the aged mice there was an increase in activated 
microglia/macrophages in both the ipsilateral and contralateral cortices, as well as in the contralateral  
hippocampus. In a recent study by Kumar and colleagues, aged mice were more likely to have 
activated microglia of the detrimental ‘M1-like’ phenotype following a CCI injury when compared to 
young mice (Kumar et al., 2013). They suggested that the increased ‘M1-like’ microglia created an 
increased inflammatory response and contributed to a poorer outcome (Kumar et al., 2013). 
Reduction in the activated ‘M1-like’ microglia in mice has been shown to correlate with an improved 
performance following CCI injury in the MWM (Bedi et al., 2013). In our aged mice, the activated 
microglia in the CCI brain tissue may have had a higher proportion of the ‘M1-like’ phenotype 
compared to the ‘M2-like’ phenotype – this remains to be analysed further, with specific markers (e.g. 
arginase 1 or CD11b) (Cherry et al., 2014, Loane and Byrnes, 2010). This would make the detrimental , 
pro-inflammatory ‘M1-like’ microglia the predominant phenotype in the brain and may have 
contributed to the poor outcome our aged mice had in the MWM test. Recent literature suggests that 
categorising the microglia phenotypes may be more complex than just the ‘M1-like’ and ‘M2-like’ 
phenotypes (Loane and Kumar, 2016). Future studies could establish the predominant microglial 
phenotype in the aged mice at different stages following CCI, in the wild-type and also transgenic mice. 
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5.5.4 The fat-1 gene causes increased reactive astrogliosis following CCI injury 
In the previous chapter, an acute injection of the omega-3 fatty acid DHA correlated with an increase 
in the amount of reactive astrogliosis in the brains of mice 28 days after TBI, despite not exhibiting any 
beneficial (or detrimental) effect on the behaviour of the mice in the MWM task. In this chapter, we 
show that the mice expressing the fat-1 gene also exhibited an increase in reactive astrogliosis in  
selective brain regions, but with no correlation in cognition when compared to the wild-type 
littermates.  
This increase in reactive astrogliosis was seen predominantly in the aged mice, but was also observed 
in the young male mice (only in the ipsilateral ROI). This data is in total contrast with previous studies 
that show that omega-3 PUFAs reduce astrogliosis and neuroinflammation, including studies in our 
group and others that have shown a reduction in astrogliosis following SCI, with acute DHA treatment 
(Zendedel et al., 2015, Paterniti et al., 2014).  
The aged fat-1 mice had increased reactive astrogliosis in both the ipsilateral and contralateral cortex, 
and in the contralateral hippocampus. Increased neuroinflammation, including increased reactive 
astrogliosis, has been associated with the aging brain particularly in the hippocampal region which 
correlates with decreased cognitive function (Lynch et al., 2010, Cowley et al., 2012). This increase in 
reactive astrogliosis in the hippocampus has also been seen in rats following a CCI injury (Sandhir et al., 
2008).  The age-related increase in astrogliosis in these fat-1 aged mice appears to be exacerbated by 
the CCI injury and the presence of the fat-1 gene.  
A direct link between omega-3 administration, either via an acute injection of DHA (chapter 4) or 
increased endogenous levels of omega-3 PUFAs as caused by the presence of the fat-1 gene following 
CCI, and the increased reactive astrogliosis has yet to be analysed in detail and this is the primary aim 




5.5.5 CCI injury altered the lipid profile of the brain tissue 
To characterise the changes in lipids after TBI and in the presence of the fat-1 gene, we investigated in 
a pilot study the brain lipid profiles of the fat-1 mice and their wild-type littermates in response to CCI 
injury. The analysis explored changes following sham injury and CCI injury, at an acute time point,  i .e . 
24 hours post-injury.  
Although we had samples from a limited number of animals, and overall the analysis was 
underpowered, we noted a few trends. The percentage of the omega-3 fatty acid DHA appeared to 
have changed the most with genotype and CCI injury. The wild-type mice fed an omega-6 enriched 
diet, in the absence of the fat-1 gene could not convert this excess omega-6 PUFAs endogenously into 
omega-3 PUFAs, resulting in a lower percentage of DHA when compared to naïve controls. The fat-1 
mice, as expected, had a higher percentage of DHA in their brain lipid profile compared to their wi ld-
type littermates (Bousquet et al., 2011, Wu et al., 2016a)..  
Interestingly, in the sham animals, the fatty acid profile of the fat-1 mice also changed, and a decrease 
in the percentage of DHA was observed. However, following a CCI injury the fat-1 mice had an increase 
in the percentage of DHA measured in tissue. Our data supports observations in the experimental and 
clinical literature, whereby TBI has been shown to decrease the amount of  phospholipids containing 
DHA around the injury site and induce an increase in the amount of DHA as a free fatty acid in 
cerebrospinal fluid (CSF) (Roux et al., 2016, Pilitsis et al., 2003a). In a study employing mass 
spectrometry in the brain of CCI injured rats, there were early changes (24 hours after injury, i .e . the 
same analysis time we present here) in various lipid classes, including the membrane phospholipids ,  
and notably there was a significant reduction in the phospholipid phosphatidylethanolamine (PE) 
containing DHA (Roux et al., 2016). This reduction is a likely consequence of the activation of 
phospholipases after injury, such as phospholipase C (Wei et al, 1982, Dhillon et al, 1999).  The 
activation is extremely rapid, with positive detection at 5 min after injury. This activation of lipases and 
in particular phospholipases, following excessive stimulation in the CNS, was described initially by 
Bazan (1970), and has come to be known as the “Bazan effect” – it reflects the very rapid deterioration 
of the structure of membranes following injury. In a clinical study on TBI patients, a five -fold increase 
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in the amount of DHA detected as a free fatty acid in their CSF when compared to control patients, 
was reported (Pilitsis et al., 2003a).  This study also reported an increase in the amount of AA 
measured as a free fatty acid in the CSF, which although not significant was also increased in our mice 
following CCI injury, irrespectively of WT or fat-1 background. Furthermore, the studies by Pilitsis and 
collaborators correlated moderately favourable GOS scores (>3) with significantly lower levels of  free 
fatty acids in the CSF (Pilitsis et al., 2003a, Pilitsis et al., 2003b). This data suggests that free fatty acids 
would be a useful indicator of TBI severity. Lower levels of PE were also reported 3 months post -injury 
in mouse CCI, in brain tissue and plasma (Abdullah et al, 2014). A very recent study in a closed head 
model of TBI supports these findings and shows that abnormalities in lipids (i.e. decrease in plasma 
phospholipids) are long-lasting and can still be detected 3 months after injury (Emmerich et al ,  2016). 
In our studies, the CCI injury may cause such large destruction of the brain parenchyma and complex 
changes in the fatty acid and phospholipid dynamics, that any neuroprotection conferred by the 
presence of the fat-1 gene and the increased omega-3 PUFAs incorporated into the phospholipid 
membranes, may be insufficient.  
5.5.6 Conclusion 
The data produced in this chapter suggests that the fat-1 gene does not confer neuroprotection 
following a CCI injury. However, the fat-1 gene did appear to cause an increase in reactive astrogl iosis 
particularly in the aged mice. As expected, the aged mice fared worse in the MWM protocol  than the 
young males. The fat-1 mice were shown to have an increased amount of DHA in their brain tissue 
compared to their wild-type littermates, as expected. The CCI injury elicited a further increase in the 
DHA detected in the tissue, early after injury. 
The lack of efficacy of the fat-1 genetic manipulation in providing tissue protection after TBI or in 
improving neurological outcome is markedly different from what we previously re ported after SCI or 
PNI, and different from observations reported in stroke models (Hu et al, 2013), but reminiscent of the 
negative results reported in a mouse model of Parkinson’s disease (Bousquet et al., 2011). In this 
study, using adult mice treated with the toxin methyl-phenyl-tetra-hydropyridine (MPTP), although the 
fat-1 manipulation induced an increase in the tissue omega-3: omega-6 ratio (around 28%), this was 
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not sufficient to confer any neuroprotection. This is in contrast with what the authors had previously 
reported in the same disease model, using chronic oral supplementation with omega-3 PUFA (starting 
before the injury, from 2 to 12 months of age, after which the MPTP exposure occurred) (Bousquet et 
al, 2008). In the latter study, this supplementation regime led to a much larger increase in the omega-
3: omega-6 ratio (92%) and the authors reported neuroprotection in terms of higher dopamine levels 
detected after injury, although no data were provided to show whether this was correlated with a ny 
beneficial neurological outcome. However, it is tempting to conclude that certain forms of injury in the 
CNS may require much larger increases in the omega-3 fatty acid levels than those provided by the fat-
1 background, in order to confer neuroprotection. This hypothesis remains to be tested by carrying out 
future DHA chronic supplementation studies in our CCI model.  
The observations reported in this chapter and the previous chapter also suggest that there is a link 
between DHA and increased reactive astrogliosis following a CCI injury. The following chapter 
investigates the effect DHA has directly on astrocytes in a novel in vitro model of focal mechanical 
injury. 
5.5.7 Main outcomes 
• CCI injury in aged mice leads to a worse outcome in the MWM 
• The fat-1 gene does not confer neuroprotection following CCI injury 
• The fat-1 gene leads to an increased astrogliosis following CCI injury 













6 A novel in vitro model of focal mechanical injury in a 3D 
astrocytic cell culture 
6.1 Introduction 
In this chapter we set-up and optimized an in vitro model of mechanical TBI. We decided to move to an 
in vitro model so that we could focus on the reactions of astrocytes alone following a mechanical 
lesion. In an in vivo model, it is hard to see if the lesion directly causes astrogliosis or whether injury to 
other cells (other glial cells, the BBB or neurones) causes the increase in GFAP expression following CCI 
injury. Also using an in vitro model allowed us to study the morphology of the astrocytes in detail. 
6.1.1 Glial cells 
Glial cells and neurones are the two largest cell populations within the brain and spinal cord. It was 
previously thought that for every neurone in the human brain there were 10-50 supporting glial  ce l l s.  
However, in 2009 this ratio was queried and, using a novel cell counting technique, the ratio of glial  to 
neuronal cells in the human brain was found to be closer to 1:1, therefore represent ing a scaled-up 
primate brain (Azevedo et al., 2009). 
Glial cells are responsible for many functions within the brain, which include maintaining homeostasis 
of the brain environment through neurotransmitter regulation and synapse support, providing myelin 
sheaths for neuronal signalling, and involvement in the immune response during disease. 
There are several subtypes of glial cells in the CNS, namely astrocytes, microglia, oligodendrocytes, and 
ependymal cells. Microglia and astrocytes have already been mentioned in the previous chapters in 
this thesis, with astrocytes displaying a reactive phenotype after injury and an increased GFAP 
expression in the fat-1 mice and mice treated with DHA. Due to this change which was linked to 
treatment with an omega-3 PUFA or a higher level of endogenous omega-3 PUFA, astrocytes are  the 






Astrocytes have been divided into two subgroups based on their morphology and location , since they 
were first described in the 1870s (Parpura and Verkhratsky, 2012). These two subtypes are referred to  




Protoplasmic astrocytes are found in the grey matter and have several thin processes, whereas fibrous 
astrocytes are located in the white matter and have fewer but much l onger processes than the 
protoplasmic astrocytes. These two major subtypes are still valid today, and, in addition, there are 
several smaller populations of other astrocytic subtypes identified since the late 19 th  century. These 




Figure 6.1. Schematic representation of protoplasmic and fibrous astrocyte morphology. 
(A) Fibrous astrocytes found in the white matter have long bi -directional processes. B) Protoplasmic 
astrocytes from the grey matter are highly ramified, with several branches and finer processes.   




Table 6.1. Subtypes of astrocytes based on their location, morphology and structural characteristics. 
(Kettenmann and Verkhratsky, 2011, Şovrea and Boşca, 2013, Sofroniew and Vinters, 2010). 
Subtype Location  Morphology Structural components 
Protoplasmic 
astrocytes 















Radial glia Embryonic brain 
(differentiated into 
Müller cells and 
Bergmann glia) 
Bipolar – ovoid cell body 
with two main processes 
-One process forms 
periventricular endfoot 
-One process forms 
subpial endfoot 
Müller cells Retina – In the sixth 
layer  
Elongated cells with long 
processes that extend along 
the rod and cone cells 
-Form limiting 
membranes that act as 
barriers 
Bergmann glia Cerebellum – Purkinje-
cell and granular layers 
Small bodies with 3–6 long 
processes, that extend 
towards the molecular layer 







Cerebral cortex –  
Layer I, adjacent to the 
pial surface 
(in higher Primates) 
Spherical body with one 
long process (up to 1mm) 
-Subpial endfeet 
 
Pituicytes Posterior pituitary 
gland 





These subtypes of astrocytes can be identified based on their location, morphology and structural 
characteristics. The endfeet of astrocytes are specialized foot-processes that make contact with other 
structures in the brain or ensheath distinct neuronal elements, in order to mediate exchange of 
molecules and neurotransmitters (Parpura and Verkhratsky, 2012). Astrocytic endfeet make contact 
with the brain vasculature (perivascular endfeet), the pia mater of the brain (subpial endfeet), the 
ventricles of the brain (periventricular endfeet) and the nodes of Ranvier of axons (perinodal endfeet).  
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6.1.2.2 Molecular markers 
The most frequently used immunohistological marker for astrocytes is glial fibrillary acidic protein 
(GFAP). This protein is an intermediate filament that is present in the cytoskeleton of astrocytes. A 
recent study published by a group in the Netherlands has identified 10 isoforms of the GFAP protein, 
that are expressed differentially in different brain regions and impose different properties onto the 
intermediate filament network (Kamphuis et al., 2014). The expression of this protein is increased by 
astrocytes in diseased tissue and is often not present at detectable levels in healthy tissue. Astrocytes 
that display an increased GFAP expression are referred to as ‘reactive astrocytes’ or as undergoing 
‘reactive astrogliosis’. 
Despite GFAP being the ‘gold standard’ immunohistochemical marker for astrocytes, GFAP staining has 
its limitations. As mentioned above, GFAP is often not expressed at detectable levels by astrocytes 
unless they have become ‘reactive’ in response to disease or injury (Sofroniew and Vinters, 2010). 
Furthermore, GFAP does not label all of the astrocyte, as it is not present consistently throughout the 
astrocytic cytoplasm and is often not detectable in the cell body. This means that only the thicker 
branches and not the finer processes of the astrocyte are labelled with the GFAP marker. Therefore, 
GFAP labelling may only represent a small amount of the branching, and this can greatly 
underestimate the total astrocytic processes and  cell volume (Sofroniew and Vinters, 2010). In 
addition, GFAP is not exclusively expressed by CNS astrocytes; it is also expressed in the brain by 
ependymal cells from the subventricular zone (SVZ) (Wang and Bordey, 2008). There are several 
peripheral cells that also express GFAP, including keratinocytes, Leydig cells, osteocytes and 
chondrocytes and cells within the pancreas and liver (Wang and Bordey, 2008). 
There are other immunohistochemical markers that have been used to identify astrocytes, which 
include vimentin, S100B, GLT-1, human EAAT2, glutamine synthase, the potassium Kir4.1 channel  and  





Table 6.2. Molecular markers for the identification of astrocytes and astrocytic subtypes. 
The specificity of the molecular marker, the location of the molecular target and the l imitations that 
targeting these markers pose for the identification of astrocytes (Şovrea and Boşca, 2013, Nagelhus et 
al., 2004, Kalsi et al., 2004, Yang et al., 2011, Benner et al., 2013). 
Astrocytic Marker Specificity Location within 
Astrocytes 
Limitations 
GFAP – Glial fibrillary 
acidic protein 
Intermediate filament, 
part of the 
cytoskeleton 
Standard marker for 
astrocytes – Up-
regulated in response 
to CNS injury 
Also present in 
ependymal cells of the 
CNS 
Vimentin Intermediate filament, 
part of the 
cytoskeleton 
Up-regulated in 
response to CNS injury 
Also present in 
ependymal cells 
S100B Calcium binding 
protein 
Present on the cell 
membrane 
Expressed by mature 
astrocytes and NG2-
expressing astrocytes 
Aquaporin 4  Water-selective 
channels 
Present on the 
astrocyte cell 
membrane at the 
endfeet of astrocytic 
processes – Up-
regulated in response 
to CNS injury 
Also present in 
ependymal cells and 
endothelial cells  
Kir4.1 Inwardly rectifying K+ 
channels 
Present on the 
perivascular endfeet of 
astrocytes 
Also present on the 
cell bodies of 
oligodendrocytes 
 
GLT-1 and GLAST (rats) 
or EAAT1 and EAAT2 
(humans) 
Glutamate transporters Distributed along the 
cell membrane  
Other isoforms are 
present in neurons 
Glutamine synthase Enzyme that catalyses 
the conversion of 
glutamate and 
ammonia to glutamine  
Present in the 
cytoplasm of astrocytes 




family, member 1 
(AldhL1) 
Enzyme that catalyses 
the oxygenation of 
aldehydes 
Present in the branches 
rather than cell body  
Low expression levels 
in mature spinal cord 
 
Thrombospondin 4 Thrombospondin 
family of glycoproteins 
Present in astrocytes  
generated in the SVZ  




Transgenic mice that express a fluorescent reporter protein under promoters of astrocytic markers 
such as GFAP or GLT-1 can also be a useful tool to identify astrocytes in vivo (Nolte et al., 2001, de Vivo 
et al., 2010). They can be used to identify astrocytes using fluorescence microscopy within living brain 
slices and fixed tissue preparations. As an investigative tool , these mice can be extremely valuable; 
however, it is important to confirm the staining with additional immunolabelling with another 
astrocyte marker (Wang and Bordey, 2008). 
6.1.3 The physiological roles of astrocytes 
Astrocytes have many functions which contribute to general homeostatic mechanisms in the CNS. 
They play key roles within the blood-brain barrier (BBB), the maintenance of the extracellular 
environment, synapse formation and function, metabolic support and the regulation of blood flow.  
6.1.3.1 Blood-brain barrier and blood flow 
 
Figure 6.2. Schematic of the blood brain-barrier (BBB). Detailing the microvasculature of the BBB, 
including the basement membrane, endothelial cells, pericytes, astrocyte endfeet and neurons. 
 
The blood-brain barrier (BBB) refers to the specialized structure of the brain’s microvasculature, which 
comprises endothelial cells, basement membrane, pericytes and astrocyte endfeet (Fig. 6.2)(Zlokovic,  
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2008). The function of the BBB is to help maintain the brain microenvironment by preventing 
potentially harmful substances from the blood entering the brain tissue. The endfeet of astrocytes can 
ensheath the brain microvasculature, make contact with the neuronal cell membrane or encapsulate 
the synaptic cleft. In this way, the astrocytes act as a bridge between the neurones and the 
vasculature. Astrocytes help mediate the permeability of the BBB as well as the vasodilation or 
vasoconstriction of the neurovasculature through the release of mediators such as prostaglandins (e.g. 
PGE2) and nitric oxide (Alvarez et al., 2013, Sofroniew and Vinters, 2010). 
6.1.3.2 K+ homeostasis 
Astrocytes help maintain ion homeostasis in the extracellular space, particularly the K + concentration. 
Neurotransmission leads to K+ ions building up in the extracellular space, which, if not rectified, can 
lead to depolarization and hyperexcitability of neurones (Wang and Bordey, 2008). Inwardly rectifying 
K+ channels (Kir) and sodium potassium pumps (Na+/K+ ATPases) on the astrocyte cell membrane help 
to buffer this increase in extracellular K+(Wang and Bordey, 2008). Mice with a conditional  knock -out 
of the Kir4.1 channel show motor impairment, body tremor and an increased mortality rate (Neusch et 
al., 2001). 
6.1.3.3 Neurotransmitter uptake 
A key function that astrocytes are responsible for is the uptake of the excitatory neurotransmitter 
glutamate from the synaptic cleft. After neurotransmission glutamate needs to be cleared, as an 
excess can lead to excitotoxicity and trigger neuronal cell death. Astrocytes remove the extracel lular 
glutamate through uptake via the excitatory amino acid transporters (EAAT). There are currently f ive 
types of EAAT identified in the human brain, and the EAAT1 and EAAT2 types are expressed by 
astrocytes (the rodent equivalents are GLAST and GLT-1, respectively)(Bak et al., 2006, Palacín et al., 
1998). GLAST transporters are found in both astrocytes and oligodendrocytes, whereas GLT-1 are 
found in much higher levels in astrocytes as opposed to any other types of brain cells (Rothstein et al . ,  
1994, Robinson and Jackson, 2016). The GLT-1 transporters are responsible for the bulk of the 
glutamate clearance in the brain and the deletion of these transporters results in seizures and 
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premature death (Tanaka et al., 1997). The deletion of the GLAST transporter causes minimal 
abnormalities in the motor coordination (Watase et al., 1998). 
The glutamate accumulated by astrocytes is converted to glutamine by the enzyme glutamine 
synthase, and then transported back to the pre-synaptic terminal in a process known as the glutamate-
glutamine shuttle (Bak et al., 2006). This uptake of glutamate by  the astrocytes prevents excitotoxicity 




Figure 6.3. Schematic representation of the glutamate-glutamine shuttle at a glutamatergic synapse. 
Glutamate (Glu, blue filled circles) is released from the presynaptic terminal into the synaptic cleft. 
Glutamate diffuses across the cleft and binds to receptors of the postsynaptic membrane. Excess 
glutamate in the cleft is taken up by the astrocytes through the excitatory amino acid transporters 
(EAAT) and converted to glutamine (Gln) using free ammonia (NH4+). This conversion is catalysed by 
the enzyme glutamine synthase (GS). The glutamine is then returned to the presynaptic neuron, where 
it is converted back to glutamate by phosphate-activated glutaminase (PAG), with the release of 
ammonia (NH4+). 
 
6.1.3.4 Synaptic function 
Astrocytes are involved in both the formation and maintenance of synapses. Around 60% of synapses 
are ensheathed by astrocytic processes (Bernardinelli et al., 2014). Astrocytes play an important role in 
synaptic transmission, and have been suggested to be as integral to the synapse as the pre - and post-
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synaptic neuron terminals; this is referred to as the ‘tripartite synapse’ (Bernardinelli et al., 2014) .  As 
part of the ‘tripartite synapse’, astrocytes can regulate synaptic function, plasticity and transmission. 
Astrocytes can respond to the release of neurotransmitters from the neurones, and can, themselves, 
release ‘gliotransmitters' into the synapse (Harada et al., 2015). Astrocytes exhibit several types of 
receptors including glutamatergic, GABAergic, adrenergic, purinergic, serotonergic, muscarinic and 
peptidergic receptors (Porter and McCarthy, 1997).  
It has been shown that neuronal activity can evoke rises in intracellular calcium (Ca2+) within astrocytes 
and that these increases in intracellular calcium can propagate to adjacent astrocytes and even back to 
neurons (Parpura et al., 1994, Hamilton and Attwell, 2010, Charles et al., 1991, Cornell -Bell et al., 
1990). The term ‘gliotransmission’ has been used to describe this phenomenon, whereby these 
astrocytes and neurones can communicate with each other. These Ca2+ waves can provoke the release 
of gliotransmitters, such as glutamate (Bernardinelli et al., 2014). The release of astrocytic glutamat  
can alter neuronal excitability (Hamilton and Attwell, 2010). Other gliotransmitters include several 
neuroactive molecules that can bind to receptors on neurones, including D-serine, adenosine, GABA 
and  the cytokine tumour necrosis factor-α (TNF-α) (Perea et al., 2009).  
Astrocytes can promote synaptogenesis through the release of other factors such as cholesterol, which 
has been hypothesised to aid synaptogenesis by increasing the number of lipoproteins in neurones 
which are used to create synaptic vesicles (Mauch et al., 2001, Göritz et al., 2002). Astrocytes can also 
control neurotransmission by altering the density of post-synaptic receptors, including the up-
regulation of AMPA receptors and down-regulation of GABAA receptors, through the release of  TNFα  
(Stellwagen and Malenka, 2006, Kettenmann and Verkhratsky, 2011, Chung et al., 2015) . 
6.1.3.5 Metabolic support 
Astrocytes provide metabolic support to the neurones by acting as a glycogen store, which provides 
energy during periods of high neuronal activity or hypoglycemic conditions (Brown and Ransom, 2007). 
Astrocytes also provide neurones with the glutamate precursor glutamine, as neurones do not have 
the ability to synthesise glutamate.  As previously mentioned, glutamate released into the synaptic 
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cleft is uptaken into the astrocytes through EAAT1 and EAAT2 transporters and converted to glutamine 
via the glutamate-glutamine shuttle (Fig. 6.3). This glutamine is non-toxic and can be released back 
close to the pre-synaptic terminal. The pre-synaptic terminal can then convert this glutamine back into 
glutamate (Bak et al., 2006).  
 
6.1.4 Brain pathology 
6.1.4.1 Reactive astrogliosis 
Under pathological conditions, astrocytes undergo a noticeable change in their morphology and a 
corresponding increase in the expression of the intermediate filament GFAP (Baldwin and Scheff, 
1996). This astrocytic response is known as “reactive astrogliosis” (Sofroniew and Vinters, 2010) . The 
main morphological changes include hypertrophy, increase in number, thickness and length of the 
cytoplasmic cell processes, overlapping of the processes and proliferation. The term ‘reactive  gl iosis’  
(or astrogliosis) has been used as an umbrella term to describe any evidence of these changes seen in 
astrocytes. Recently however, Sofroniew and colleagues have suggested that there are categories or 












A) Astrocytes under normal conditions 
• Low levels of GFAP expression 
• No overlapping 
• Little or no proliferation 
B) Mild to moderate astrogliosis 
• Higher levels of GFAP expression 
• No overlapping 
• Little or no proliferation  
 
 
C) Severe diffuse reactive astrogliosis 
• High levels of GFAP expression 
• Overlapping of processes 
• Proliferation 
• Extension of processes 
D) Severe astrogliosis and the glial scar 
• High levels of GFAP expression 
• Substantial overlapping 
• Proliferation 
• Reorganisation of the tissue 
architecture – Formation of a compact 
glial scar surrounding an area of CNS 
tissue damage 
 
Figure 6.4. Schematic representations of the gradations of reactive astrogliosis. 
(A) The characteristics of astrocytes under normal physiological conditions are the  expression of  low 
levels of GFAP and the maintenance of individual domains. (B) Mild to moderate astrogliosis is 
associated with higher expression levels of GFAP and maintenance of individual domains.  This type of  
reactive astrogliosis can occur after mild TBI or in areas distal to the lesion, and it can also occur i n mild 
infections. (C) Severe diffuse reactive astrogliosis occurs after a more severe TBI, in which astrocytes 
proliferate, become highly ramified, and overlap, losing individual domains.  (D) Severe astrogliosis with 
glial scar surrounds a focal lesion after TBI. The glial scar forms a compact barrier preventing axonal 
regeneration. It contains highly ramified astrocytes and newly proliferated astrocytes. This type of 
reactive astrogliosis causes reorganisation of the tissue architecture, with the glial scar persisting for a 




6.1.4.2 Glial scar formation 
The glial scar as depicted in figure 6.4D, is a barrier of primarily newly proliferated astroc ytes, which 
have elongated processes that intertwine with adjacent astrocytes at the lesion edge. This thick gl ial  
scar acts to protect the remaining healthy tissue from the damaged tissue of the primary injury site, 
mediates inflammatory responses and instructs wound healing (Burda et al., 2016). The glial scar 
contributes to the tissue reorganization that occurs following severe TBI. Originally thought to protect 
healthy tissue by providing a physical barrier against the injured tissue, the glial scar has now been 
shown to produce inhibitory molecules to provide a molecular barrier as well (Fitch and Silver,  2008) . 
Heavily glycosylated proteins, known as proteoglycans, are released by astrocytes and have an 
inhibitory effect on axonal growth. The biggest group of proteoglycans up-regulated and re leased by 
astrocytes of the glial scar are the chondroitin-sulphate proteoglycans (CSPGs), which are  extremely 
inhibitory to axonal growth (Silver and Miller, 2004). In spinal cord injury (SCI), the physical and 
molecular barrier of the glial scar prevents axonal regeneration across the lesion, thus making the glial 
scar and CSPGs a major target for SCI treatment. 
There may be a specific molecular trigger for the formation of the inhibitory glial scar structure. The 
candidates for this function include the cytokines transforming growth factor β (TGFβ) and interferon-γ 
(Silver and Miller, 2004). In an experiment in rats with a brain lesion, TGFβ-1 and TGFβ-2 were 
attenuated with antibodies, which caused glial scar formation to be significantly reduced (Moon and 
Fawcett, 2001). The introduction of interferon-γ caused an increase in proliferation of human 
astrocytes in vitro and increased glial scarring in brain lesioned adult mice (Yong et al., 1991). 
6.1.4.3 Molecular triggers of astrogliosis 
The molecular triggers for reactive astrogliosis are numerous and include: large polypeptide growth 
factors, cytokines, neurotransmitters and reactive oxygen species (Sofroniew and Vinters, 2010). 
Reactive astrogliosis can also be induced through deprivation of glucose, hypoxia, and the exposure to 
molecules linked with neurodegenerative diseases such as β-amyloid, which is associated with 
Alzheimer’s disease (Sofroniew, 2009). Molecular triggers can be released by a number of CNS cell 
types including neurons, microglia, oligodendrocytes, endothelial cells, leukocytes and other 
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astrocytes. These triggers may be released by cells at the primary lesion site and trigger a chain 
reaction of reactive astrogliosis in the tissue surrounding the lesion and in more distal locations.  
 
Figure 6.5. Examples of main triggers of reactive astrogliosis. 
There are numerous molecular triggers (e.g. cytokines, growth factors, neurotransmitters, small 
molecules released at the time of a TBI, molecules released during oxidative stress and molecules 
associated with neurodegenerative diseases). Environmental changes that can trigger reactive 
astrogliosis include hypoxia and glucose deprivation, and the action of mechanical forces. Adapted 
from (Burda et al., 2016, Sofroniew and Vinters, 2010). 
 
6.1.4.4 Mechanical triggers of astrogliosis 
Molecular triggers are not the only mechanisms by which reactive astrogliosis can be ini tiated, since 
the force of the injury can also induce a phenotypic change in astrocytes. The processes and 
mechanisms by which a mechanical force exerted during a TBI can have a harmful effect on CNS cel l s 
are still largely unknown. There have been in vitro studies in co-cultures that showed reactive 
astrogliosis and glial scar formation after a mechanical stretch (Wanner et al., 2008). Some 
mechanisms have been proposed, including mechanical forces prompting plasmalemmal instabil ity, 
which causes disruption to the cytoskeleton (Singleton and Povlishock, 2004). Another mechanical 
trigger worth considering is that plasmalemmal instability may activate mechanosensitive ion channels 
on the astrocyte cell membrane and trigger the phenotypic changes associated with reactive 
astrogliosis (Burda et al., 2016). Candidates for these mechanosensitive ion channels include the 
transient receptor potential cation channels, TRPV4 and TRPC1 (Maneshi et al., 2015).  
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6.1.4.5 Time course of reactive astrogliosis 
The time course of reactive astrogliosis following TBI is dependent on numerous factors, such as the 
severity of TBI, location of TBI and the type of injury. After focal lesions, astrocytes in the immediate  
tissue surrounding the injury site display a fast response to the TBI. Studies in vivo have shown that 
following TBI, astrocytes up-regulate GFAP expression and some populations have al ready begun to 
proliferate by 24 hours post-injury (Susarla et al., 2014). The same study by Susarla et al., reported 
further proliferation of astrocytes at 7 days post-impact and maintenance of high levels of GFAP 
expression and proliferation in astrocytes at 28 days post injury (Susarla et al., 2014). Several  patient 
studies have shown continued high levels of GFAP immunoreactivity in the brains of TBI patients from 
6 months to 22 years post-injury (Levin et al., 2014). 
6.1.4.6 The role of astrocytes following traumatic brain injury 
Many central nervous system (CNS) disorders are associated with reactive astrogliosis, including 
Alzheimer’s disease, encephalitis, epilepsy, multiple sclerosis, Parkinson’s disease, amyotrophic lateral  
sclerosis, Huntington’s disease, several psychiatric disorders, brain tumours, stroke and 
cerebrovascular disease, as well as CNS trauma including TBI.  For the purpose of this thesis the 
astrocytic response in TBI will be the main focus of discussion. 
TBI triggers reactive astrogliosis and at the site of impact in a focal lesion a glial scar will form. In tissue 
distal to the lesion and throughout the brain tissue, there may be mild to moderate astrogliosis; this i s 
dependent upon the severity of the TBI. This is demonstrated in the first results chapter in this thesis.  
It is also worth noting that the level of the GFAP-breakdown product (GFAP-BDP) in the serum of  TBI 
patients correlates with the severity of their TBI, as measured by GCS and CT scans (Papa et al., 2012). 
Whether reactive astrogliosis contributes to the damaging secondary injury sequelae following TBI, or 
offers some beneficial and protective support to the remaining healthy tissue, is a matter that is still 
largely unresolved. It has been common knowledge for almost a century that reactive astrogliosis 
inhibits axonal regeneration, since it was first reported by Ramon y Cajal (Ramo\n y Cajal, 1928). 
Therefore, targeting astrogliosis has been explored as a therapeutic strategy for CNS trauma treatment 
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(McGraw et al., 2001).  Moon et al., showed that removal of glial cells with ethidium bromide following 
transection of the nigrostriatal tract, allowed axons to regenerate by up to 4 mm (Moon et al., 2000). 
This rapid growth was lost at day 7 post-lesion, when glial cells returned to the site of the lesion to 
form a glial scar. Another study employed transgenic mice that expressed herpes simplex virus 
thymidine kinase (HSV-TK) specifically in astrocytes, so that newly divided reactive astrocytes could be 
ablated using the anti-viral drug ganciclovir (Bush et al., 1999). Ablation of these astrocytes resulted in 
the increased axonal growth following a forebrain stab injury. It is worth noting that alongside the 
axonal growth, ablation of astrocytes also resulted in prolonged increased leukocyte infiltration and a 
sustained BBB leakage (Bush et al., 1999).On the other hand, a study employing this same transgenic 
mouse model by Myer and colleagues, showed that a moderate CCI injury in these transgenic mice led 
to significantly more cortical tissue loss (60%), than the CCI in wild-type mice (18% cortical tissue loss) 
(Myer et al., 2006).These examples demonstrate that reactive astrogliosis may exhibit both damaging 
and protective effects following a TBI. 
Table 6.3. A summary of the potentially beneficial or damaging roles of astrocytes following TBI. 
 
 
In table 6.3, inflammation is listed as being both a potentially beneficial and  damaging role for 
astrocytes following a TBI. It has been shown that astrocytes can secrete several molecules with both 
pro- or anti-inflammatory properties (Farina et al., 2007). Pro-inflammatory mediators released by 
astrocytes include cytokines (e.g. TNF-α), ROS and nitric oxide (NO), all of which elicit an inflammatory 
response from other astrocytes (Avila-Muñoz and Arias, 2014, Sofroniew, 2014). Anti-inflammatory 
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interleukins released from astrocytes include IL-6 and IL-10 (Sofroniew, 2015). These conflicting 
actions may not happen simultaneously but instead may occur at different phases following a TBI.  
 
6.1.5 3D modelling in vitro 
Various in vitro models have been summarised in the general introduction (section 1.7). In vivo 
modelling allows for the analysis of a whole system response to a TBI, i.e. both the tissue response and 
the pathophysiological changes, and the neurobehavioural consequences. The complexity of the 
pathophysiological response can make it difficult to distinguish the individual roles of various 
molecular mechanisms or cell types following a TBI. In vitro models of TBI have been developed to 
address this problem as well as to provide a model in which many factors can be tightly controlled, 
including the extracellular environment, and the  administration of various agents (Morrison et al., 
1998). 
Traditional in vitro models utilise cell cultures that are grown on flat plastic or glass surfaces in a 2D 
monolayer. Under such conditions, cells adhere to the surface and only contact adjacent cells at their 
border (Antoni et al., 2015). This 2D arrangement in vitro is very different to the arrangement of  ce l l s 
in vivo; they are unable to lie on top of each other, to make multiple contacts with other cells or, in the 
case of astrocytes, extend their processes in a third dimension. Three -dimensional (3D) cell culture 
systems have been developed to address these limitations and to make the in vitro environment more 
relevant to the in vivo situation.  
Typically, 3D culture systems comprise of a hydrogel matrix in which the chosen cell population ( from 
immortalised cell lines to primary cells) are placed (Fig. 6.6). The cells within these gels are able to 
make contacts with other cells, proliferate, migrate, respond to stimuli and change morphology, which 





Figure 6.6. Schematic representation of cells in in vitro cultures. 
 (A) Conventional 2D monolayer culture and (B) a 3D cell culture system. 
 
6.1.5.1 Astrocytes in a 3D cell culture 
Astrocyte cell cultures have been used in in vitro studies to investigate astrogliosis and glial scar 
formation. These studies have been predominantly conducted in 2D monolayer cultures (Wanner et 
al., 2008, Polikov et al., 2006). Within a 2D culture system astrocytes exhibit a high level of astrogliosis 
without stimulus (East et al., 2009, Wang et al., 2015). This high baseline astrogliosis does not 
accurately reflect the in vivo situation and therefore makes it difficult to use GFAP up-regulation as an 
endpoint measurement in an in vitro model that would attempt to mimic TBI. 
Astrocytes have been put into a 3D culture system, where the environment is closer to that of  the in 
vivo situation; such studies revealed that when grown in a 3D collagen gel, astrocytes exhibit a far less 
reactive phenotype when compared to a 2D monolayer culture . They exhibit a less reactive 
morphology and a lower level of activation markers (East et al., 2009). This 3D cell culture system was 
also exposed to the cytokine TGFβ1, which is known to trigger astrogliosis in vivo. Astrogliosis was thus 
simulated in the 3D gels and, by day 15 post-stimulation, astrocytes exhibited high GFAP, vimentin and 
aquaporin 4 (AQP4) expression (East et al., 2009). This astrocyte cell culture system offers a novel way 
to investigate therapeutic strategies targeted at astrogliosis, and could be used to develop a novel  in 
vitro model mechanical injury relevant to TBI. This 3D astrocyte culture developed in the group led by 







Primary astrocyte cultures were prepared from P2 GFP+ rat cortices. Astrocytes were dissociated and 
expanded for 2 weeks before being placed in 3D collagen gels (Fig. 6.7). The GFP gene was expressed 
ubiquitously in the culture, which had been established as 95% astrocytes (East et al., 2009). The 
induction of the lesion was carried out using the computer-controlled pneumatic Hatteras PinPoint 
Precision Cortical Impactor™ and then cultures were fixed at 24 hours, 5 days and 10 days post-impact. 
DHA (1 µM) or vehicle treatment was applied to cultures at the time of the impact. Cells were then 
labelled with GFAP, as an index of reactive astrogliosis within the cultures. The volume of GFP and 
GFAP per cell was measured in the peri-lesion ROI and in ROI distal to the lesion, using confocal 
microscopy and 3D image analysis software (Volocity), to assess the amount of reactive astrogliosis. 
The number of astrocytes in the peri-lesion and distal from the lesion ROI was also measured. 




Figure 6.7 Timeline of the in vitro studies. Astrocytes were extracted 10-14 days prior to lesion and 
were placed in a 3D collagen gel 24 hours before lesion. DHA or vehicle was added to the gel  di rectly 





Figure 6.8. Experimental setup for the 3D astrocytic culture. (A-A’) 3D astrocytic gel cultures were 
generated in 12-well plates. (B-B’) Using a computer-controlled mechanical device, a mechanical 
impact was induced onto the gel. (C) An image of the gel post lesion (arrow indicates region of lesion) . 




6.3  Aims and hypothesis 
6.3.1 Aims 
The primary aim of this chapter is to develop and optimise a novel model of focal mechanical injury 
using the 3D astrocyte cell culture system. The pneumatically driven rigid impactor used in previous 
chapters to cause a CCI injury in vivo, was employed in this study to cause an impact injury to the 3D 
collagen gels. The main aim of this injury was to induce reactive astrogliosis in the astrocytes, as was 
seen in the astrocytes in vivo after CCI TBI. 
Alongside the development of a novel in vitro model of TBI, the omega-3 PUFA DHA was tested, to 
identify any direct effects it had on astrocytes in culture after injury. In previous chapters, mice that 
received a CCI injury with DHA treatment or transgenic mice with the fat-1 gene, exhibited reactive 
astrocytes with higher levels of GFAP expression. 
In summary, the aims of work of in this chapter were: 
-To optimise a model of focal mechanical impact injury in vitro. 
-To assess any direct effect DHA had on astrocytes after a mechanical impact.  
 
6.3.2 Hypothesis  
The hypothesis of this chapter is that a mechanical impact to a 3D astrocyte culture system will trigger 
reactive astrogliosis within the astrocytes at the lesion site and those further away from the lesion site. 
We hypothesised that the reactive astrogliosis will be evident by a distinct change in the morphology 





6.4.1 Effect of a mechanical injury on the cellular volume of astrocytes in the perilesional 
regions of interest 
Astrocytes in the perilesional region of interest (Peri -ROI) showed no significant differences in the 
levels of GFP expression between the lesion-only, lesion + Veh and lesion + DHA (1 µM) compared to 
the control group in the 3D cultures, at 24 h post lesion (Fig. 6.9E). Furthermore, there was no 
difference within the 4 groups in GFP expression at 5 days and 10 days post-impact (Fig. 6.9E). 
However, the level of GFAP staining in the peri -ROI was significantly higher per cell in the lesion -only 
(*p<0.05) and the lesion + Veh groups (*p<0.05), compared to the control group, on day 5 post- injury 
(Fig.6.9F). Interestingly, the lesion + DHA group also had higher levels of GFAP staining, but i t was not 
statistically significant when compared to the control group on day 5. 
On day 10 post-injury, the lesioned only and the lesion + Veh group, had higher levels of GFAP labelling 
per cell when compared to the control group, although the effect was not statistically significant (Fig.  





Figure 6.9 The effect of lesion and DHA treatment on GFP expression and GFAP immunostaining in 
the perilesional ROI.  (A, A’& A’’) Control non-lesioned group, (B, B’& B’’) lesion-only gels, (C, C’& C’’)  
lesion + Veh group, (D, D’& D’’) lesion + DHA group, at 1d, 5 d and 10 days post lesion, respectively. (E)  
GFP expression per cell and (F) GFAP expression by cell, the lesion + Veh and lesion-only groups at day 
5 had statistically higher (*p<0.05) GFAP expression compared to the control group. Repeated 
measures two-way ANOVA with post-hoc Bonferroni testing used for statistical testing. Scale bar = 300 





6.4.2 Effect of a mechanical injury on the cellular volume of astrocytes in the distal lesion 
regions of interest 
Astrocytes in our in vivo studies showed an increase in GFAP immunolabelling in areas distal to the 
lesion site, termed the unlesioned site in figure 6.10. To determine if this novel in vitro model reflected 
this distal increase of astrogliosis observed in vivo, astrocytes in ROI distal to the lesion (Distal-ROI) site 
were also analysed for GFP and GFAP volume per cell.  
The GFP defined volume per cell  showed no statistically significant differences between the groups or 
the time points post-lesion. The GFAP defined volume per cell analysis also showed no statistically 
significant differences between the groups or time points. However, there was a trend  that showed 
that at each time point post-injury, the lesioned groups had an increased volume of GFAP per ce l l ,  in 





Figure 6.10. The effect of lesion and DHA treatment on GFP expression and GFAP immunostaining in 
the ROI distal to the lesion. (A, A’& A’’) Control non-lesioned group, (B, B’& B’’) lesion-only gels, (C, 
C’& C’’) lesion-Veh group, (D, D’& D’’) lesion+ DHA group, at 1d, 5 d and 10 days post lesion, 
respectively. (E) GFP expression per cell and (F) GFAP expression by cell. Scale bar = 300 µm. Means ± 






6.4.3 The number of astrocytes in the perilesional regions of interest 
Over the course of the study, all of the groups saw an increase in the number of astrocytes in the Peri -
ROI. Despite seeing increasing numbers of astrocytes over the study, the control group still had the 
lowest number on day 10 (day 10; Control, 25 ± 3; lesion-only, 41 ± 9; lesion + Veh, 28 ± 2; lesion + 
DHA, 34 ± 2). 
Despite being no statistically significant differences observed between any of the groups, there was a 
higher number of astrocytes at day 5 and day 10 in the lesion + only (Fig. 6.11) (day 5, 37 ± 7; day 10, 
41 ± 9) group when compared to the control non-lesioned group (day 5, 25 ± 3; day 10, 41 ± 9). 
6.4.4  The number of astrocytes in the regions distal from the lesion site 
The number of astrocytes in the Distal-ROI in the lesion-only and the lesion + Veh group increased 
almost two-fold between day 1 post-lesion (day 1; lesion-only, 43 ± 9; lesion + Veh, 43 ± 8) and 10 days 
(day 10; lesion-only, 22 ± 3; lesion + Veh, 21 ± 3) post-lesion. The lesion + DHA group had an increase in 
the number of astrocytes between 24 hours (15 ± 3) and day 5 (30 ± 3) post-lesion, but then decreased 
again by day 10 (25 ± 4) post-lesion (Fig. 6.12). 
The lesion-only group, as well as the lesion + Veh group, displayed significantly (*p<0.05) higher 
numbers of astrocytes at day 10 when compared with the control group (Fig. 6.12). There was also a 
significantly higher (*p<0.05) number of astrocytes at day 10 in the lesion-only group as well as the 




Figure 6.11. Effect of Impact and DHA treatment on the number of astrocytes in the perilesional ROI 
at 1 day, 5 days and 10 days post-lesion.  (A-D) Representative images from all 4 groups. (E) 
Quantitative analysis of the number of astrocytes in the perilesion area, from all 4 groups. The graphs 
were reduced to 2 group comparison for clearer comparison; (F) Control vs. lesion-only, (G) Control vs.  
lesion + Veh (H) Control vs. lesion + DHA (I) lesion vs. lesion + Veh (J) lesion vs. lesion + DHA and (K) 






Figure 6.12. Effect of Impact and DHA treatment on the number of astrocytes in the distal to the 
lesion ROI at 1 day, 5 days and 10 days post lesion. (A-D) Representative images from all 4 groups. (E)  
Quantitative analysis of the number of astrocytes distal to the lesion, from all 4 groups. The graphs 
were reduced to 2 group comparison for clarity;  (F) Control vs. lesion (day 10, *p<0.05), (G) Control vs. 
lesion + Veh (day 10, *p<0.05) (H) Control vs. lesion + DHA (I) lesion vs. lesion + Veh (J) lesion-only vs. 
lesion + DHA (day 10, *p<0.05)and (K) lesion + Veh vs. lesion + DHA (day 10, *p<0.05). Repeated 
measures two-way ANOVA with post-hoc Bonferroni testing used for statistical testing. Data are 




6.4.4.1 A summary of the impact injury in 3D gels as an in vitro model of astrogliosis after a 
mechanical focal injury 
This is a novel in vitro model to model the reactive astrogliosis that occurs similarly to that following a 
focal TBI. The ability of this model to induce reactive astrogliosis in response to a mechanical injury can 
be seen when comparing the control and lesion-only group data (Fig. 6.13). 
The analysis of cell counts shows that the number of astrocytes in the Peri -ROI (Peri-ROI; Control,  19 ± 
2; lesion-only, 23 ± 3) and the distal-ROI (distal-ROI; Control, 17 ± 2; lesion-only, 22 ± 3) at day 1 post-
lesion is not significantly different between control non-lesioned group and the lesion-only group. 
However, by day 5 post-lesion the lesion-only group had a much higher number of astrocytes, 
although non statistically significant, in the Peri-ROI (Peri-ROI; Control, 25 ± 3; lesion-only, 37 ± 7)  and 
distal-ROI (distal ROI; Control, 25 ± 4; lesion-only, 35 ± 5) vs. the control group. The number of 
astrocytes continued to increase in the distal-ROI until day 10, when the difference reached 
significance (*p<0.05; Control, 25 ± 3; lesion-only, 43 ± 9) when compared to the control group (Fig. 
6.13B). 
The GFP volume per cell did not show any significant difference between the control group and the 
lesion group at day 1 and 5 days post-lesion. At day 10 post-lesion, there was a more obvious, but non-
significant, increase in the GFP volume per cell in the lesion-only group compared to the control group, 
in both the Peri-ROI and distal ROI (Fig. 6.13C, D). 
The difference in GFAP volume per cell was more apparent. In the Peri -ROI the GFAP volume per ce l l 
was considerably higher in the lesion-only group compared to the control group, with a significant 
difference (*p<0.05) observed at 5 days post-lesion. In the distal-ROI the GFAP volume per cell is 
largest in the lesion group at day 5 post-lesion (Fig. 6.13F). At day 5, in the lesion group there was a 
significant (*p<0.05) increase, which represented almost 3-fold more GFAP per cell than that in the 
control group.  At the 1 day and 10 day time points, the lesion group had a higher volume of GFAP than 





Figure 6.13. Effect of impact on a 3D astrocyte culture in the perilesional and away from lesion ROI, 
at 1 day, 5 days and 10 days post-impact. Number of astrocytes in (A) the perilesion ROI and (B) the 
distal to the lesion ROI. GFP volume per cell in (C) the perilesion ROI and (D) the distal to the lesion  
ROI. GFAP volume per cell in (E) the perilesion ROI and (F) the distal to the lesion ROI. *p<0.05.  Mean  




6.4.5 Effect of a mechanical injury on the morphology of astrocytes 
The astrocytes in the lesion group displayed a much more ramified morphology, compared to those in 
the control group. Nevertheless, within each region of interest there are astrocytes that exhibit severe 
astrogliosis that are highly ramified, as well as astrocytes that display mild astrogliosis that have very 
few processes. In order to assess the percentage of astrocytes that displayed a highly ramified or less 
reactive phenotype, we used a quantitative analysis which showed that the distribution of  astrocyte  
process number was altered after lesion (Fig. 6.14).  
The control group showed a narrower range in the number of astrocytic processes, at every time 
point, in both the Peri-ROI and distal-ROI, when compared to the lesion only group. Furthermore, for 
the majority of astrocytes assessed, there were fewer than 5 processes per an astrocyte (>50%).  
Interestingly, the lesion only group showed a far greater range of astrocyte process number, especially 
at day 5; in both the Peri-ROI and distal-ROI astrocytes have the greatest range, with a small 
percentage of astrocytes having over 30 processes (Fig. 6.14). At all time points and ROI, the lesion 






Figure 6.14. Population analysis of the effect of impact on the number of processes per astrocyte in 
the perilesional and away from lesion ROI. At 1 day, 5 days and 10 days post-impact. (A, B & C) 
Perilesion ROI in Control group, the (D, E & F) Impact only group and distal from lesion ROI  (G, H & I)in 
the Control and (J, K & L)Impact only group,  at 1 day, 5 days and 10 days, respectively. Mean ± S.E.M. 




6.4.6 Effect of the lesion on astrocytes at the lesion site 
In the in vivo CCI model, astrocytes at the edge of the lesion site formed a thick and complex barrier,  
i.e. a glial scar (chapter 3, Fig 3.23F). Interestingly, in this in vitro model of mechanically induced injury, 
astrocytes immediately adjacent to the lesion site also appeared to form a structure similar to that of  
the glial scar (Fig. 6.15). The processes of the astrocytes at 1 day post-lesion in the lesion only group 
appeared to align themselves along the lesion edge. By day 5 post-impact, astrocytes at the lesion 
edge were highly ramified and establishing several contacts with processes from surrounding 
astrocytes. By day 10 post-impact the astrocytes were highly ramified, aligned with the lesion edge, 
and had several contacts, overlapping to form a barrier similar to the glial scar observed in vivo. 
 
 
Figure 6.15. Glial scar formation in 3D astrocytic culture. (A) GFP- expressing cells express low GFAP 
immunostaining in astrocytic 3D cultures in the absence of lesion at 10 days in culture.  (B-D) GFP- 
expressing cells express increasing levels of GFAP immunostaining in astrocytic 3D cultures after a 













6.5.1 A 3D culture as an in vitro model of focal mechanical injury 
6.5.1.1 Astrogliosis 
The primary aim of this study was to develop a novel in vitro model of a focal mechanical injury in a 3D 
astrocyte cell culture system.  Reactive astrogliosis was used as an outcome measure to evaluate  the 
efficacy of this model in inducing a quantifiable response after impact. To determine reactive 
astrogliosis, the level of GFAP immunolabelling was measured and the changes in the astrocyte 
morphology were observed. 
6.5.1.2 GFAP expression 
A hallmark of reactive astrogliosis is an up-regulation of the intermediate filament GFAP. In this study, 
the astrocytes in the control group had low GFAP immunolabelling. Due to the astrocytes being in a 3D 
collagen gel the baseline immunoreactivity was similar to that observed in healthy brain ti ssue. The 
impacted group had an increased amount of GFAP volume per cell when compared to the control 
group at all 3 time points after injury. This increase in GFAP indicates that the astrocytes in the 
lesioned gels had changed to a reactive phenotype. Therefore, this suggests that a mechanical injury at 
the chosen setting induced by the HatterasTM impactor to the 3D gel was sufficient to elicit reactive 
astrogliosis and is therefore a valid in vitro model of focal mechanical injury. 
The increase in GFAP volume per cell was seen in both the Peri-ROI and the distal-ROI. In the previous 
in vivo studies reported here, reactive astrogliosis was seen very distal to the lesion as well as 
perilesionally after injury. The astrocytes within this cell culture model appeared to have a similar  
response to the in vivo response after injury. The astrocytes in the distal -ROI displayed the greatest 
GFAP volume per cell at 5 days after injury. This delayed reaction could possibly be indicative of 
astrocyte-astrocyte communication through release of molecular mediators such as growth factors 
(e.g. TGFβ) and cytokines (e.g. IL-6 and TNFα) (Sofroniew and Vinters, 2010, Sofroniew, 2009). 
Interestingly, the significant increase in GFAP was diminished by day 10. As astrocytes are able to 
move through the collagen gel, those that become reactive may have migrated towards the lesion site. 
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It has been previously reported that  astrocytes are able to migrate from different areas in the brain to 
the lesion site, 2-4 weeks after injury in vivo (Benner et al., 2013). 
6.5.1.3 Changes in morphology 
In combination with an increase in GFAP immunostaining, marked morphological changes were 
observed during development of reactive astrogliosis in this cell culture study. These changes included 
hypertrophy of the cell body, increase in the number of processes, thickening of the processes and 
elongation of the processes. Qualitatively, the astrocytes in the lesioned group exhibited these 
changes and also displayed several process-process contacts between astrocytes. The astrocytes in the 
control non-lesioned group maintained a less ramified morphology and kept their individual domains, 
non-over-lapping with other cells. 
Changes in morphology proved difficult to quantify in detail, due to astrocytes within each ROI 
displaying a range of different morphologies, which may be representative of diffe rent astrocyte 
subtypes present in the 3D culture. However, it was possible to analyse the number of processes 
detected per astrocyte, to determine a change in astrocytic overall morphology. The data showed that 
within the control groups, a large percentage of astrocytes had fewer than 5 processes, while 
astrocytes in the lesioned group had a higher percentage of astrocytes, with over 5 processes, and 
some displaying upwards of 30 processes. This highly ramified phenotype would be described as 
severe astrogliosis according to Sofroniew and Vinters (Sofroniew and Vinters, 2010). The marked 
change in the morphology of the astrocytes in the lesioned gels provides further evidence to support 
this in vitro model as a viable model of a focal mechanical injury, relevant to focal TBI.  
6.5.1.4 Change in astrocyte number 
It has been observed that astrocytes migrate and proliferate in response to TBI in vivo (Sofroniew and 
Vinters, 2010, Wang and Bordey, 2008, Susarla et al., 2014). In this in vitro study the number of 
astrocytes also changed according to the group, ROI and time point after injury. The control group 
showed no increase in astrocyte numbers over the time course of 1-10 days. In contrast,  the number 
of astrocytes in the lesioned group was higher than in the control group at 5 days and 10 days post 
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lesion. The lesion group may be displaying an increase in astrocyte number due to astrocyte 
proliferation. If proliferation was occurring in the Peri -ROI, this would suggest this was a severe 
reactive astrogliosis (Fig. 6.3), and it may be that this was driven by the need to produce more 
astrocytes to contribute to the formation of the glial scar. It is worth mentioning that the cell  number 
in the Peri-ROI plateaued after day 5; this could be due to a limited capacity of proliferation being 
reached, or maintenance of the rate of proliferation with an increased amount of migration out of the 
ROI and towards the lesion edge. The cell number in the distal -ROI of the lesion group continued to 
increase up until day 10. This again may indicate proliferation. In a study conducted by Susarla and 
colleagues, proliferation of GFAP+ immunopositive cells was seen at day 1, 3, and 7 post - injury, with 
the highest rate of proliferation at 3 days post-injury, in a mouse model of CCI  (Susarla et al., 2014) . If  
the increase in our cell count data was due to proliferation, it would correlate with the in vivo data 
published by Susarla et al., and may explain the plateau in cell number, as seen at day 10 in our Peri -
ROI.  
Astrocytes could also be migrating from the outer areas of the gel towards the centre of the gel, 
towards the lesion site, and this could explain the increased cell numbers seen in the ROI. If migration 
occurred towards the lesion site this would indicate that the astrocytes can sense the location of  the 
lesion site, possibly via release of chemicals such as cytokines from the lesion site, al though there i s 
limited data in the literature to suggest a particular mediator. Interestingly, blocking ATP signalling via 
the P2Y nucleotide receptor on astrocytes has been shown to reduce migration of astrocytes in vitro 
(Wang et al., 2005). 
6.5.1.5 Topography of the reactive astrocytes 
Astrocytes in the Peri-ROI and distal-ROI exhibited reactive astrogliosis, and this suggests that there i s 
some form of communication between the astrocytes at different locations with reference to the 
impact zone. The main focus of many biological investigations is the identification of a molecular 
mediator or mediators that may be released from a reactive astrocyte , that could elicit a reactive 
phenotype in another astrocyte. This list of potential mediators is long and includes cytokines, 
neurotransmitters, growth factors and ROS (Sofroniew, 2009, Sofroniew and Vinters, 2010). Al though 
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these mediators can be released by numerous CNS cell types, the high purity of our astrocyte  cul ture  
suggests such mediators identified within this cell culture system would be attributed to astrocytes 
(East et al., 2009). A further study that could be carried out to implicate a molecular mediator as the 
propagator of reactive astrogliosis would be to take the media from a lesioned gel exhibiting high 
levels of reactive astrogliosis and introduce it to a non-lesioned gel to see if a reactive phenotype could 
be induced. If reactive astrogliosis was primarily propagated by mol ecular mediators, it could be 
hypothesised that in this in vitro model the astrocytes within the lesion site may be damaged and their 
cell membranes are leaky or ruptured, therefore release of the initial wave of mediators would start 
the chain reaction of reactive astrogliosis in the surrounding astrocytes. Mediators of reactive 
astrogliosis may also be released by astrocytes under stress in a controlled manner, via exocytosis 
(Hamilton and Attwell, 2010, Singh et al., 2015). In this model, at the earliest time point of 24 hours, 
the gel at the lesion site was destroyed, creating a void similar to that observed in the in vivo tissue 
after CCI injury.  
The astrocytes in the gel could also be changing to a reactive phenotype in response to the mechanical 
force exerted by the impact. This has been referred to as mechanopathogenesis in a recent review by 
Burda et al. on astrocytes and TBI (Burda et al., 2016). The benefit of the 3D collagen cell culture 
system is the creation of a structure in which the impactor can penetrate. It also allows the inertial 
forces caused by the impaction to radiate out from the impaction site to be experienced by cells within 
the gel, similar to the cells distal to the impact in the brain after TBI. How astrocytes convert this 
mechanical stress into a change in phenotype is still widely unknown, although some mechanisms 
have been described, which include disturbing the cytoskeletal intermediate filaments or activation of  
mechanosensitive ion channels, such as TRPV4 or TRPC1 (Burda et al., 2016, Bowman et al., 1992, 
Maneshi et al., 2015). This force-induced reactive astrogliosis could be working in tandem with 




6.5.1.6 Glial scar formation 
An important outcome from this study is the evidence of a glial scar-like structure formation at the 
lesion-edge of the gels. By day 5 in the lesioned gels, astrocytes at the edge of the lesion si te  became 
highly ramified and their domains began to overlap. By day 10 post lesion, the processes of the 
astrocytes intertwined and formed a thick barrier, similar to the glial scar described by Sofroniew 
(Sofroniew and Vinters, 2010). The formation of this scar-like structure provides further evidence to 
support this model as a good in vitro model of focal mechanical injury, with direct relevance to TBI. If  
the time course of this study were longer, a denser and more complex scar may form and this could be 
a useful in vitro model to investigate the glial scar formation after traumatic impact. 
 
6.5.2 DHA had no effect on GFAP expression or the morphology of astrocytes after impact  
The groups that received a lesion and vehicle or DHA treatment failed to show any significant 
differences between each other or the impact only group, with regards to GFAP volume per ce l l .  This 
failure to see any change in astrocyte reactivity after exposure  to DHA was a somewhat unexpected 
finding. The data in the previous thesis chapters showed an apparent increase in reactive astrogl iosis 
after DHA treatment or in the fat-1 gene. This in vitro study suggests that any effect DHA may have on 
astrogliosis may be through an indirect mechanism that may involve other CNS cell types. Despite not 
showing any significant differences, there is a noticeable decrease in the GFAP volume per cell 10 days 
post lesion in the DHA group compared to the other lesioned groups, in both the Peri-ROI and distal -  
ROI. This decrease conflicts with the in vivo data and contributes to the concept that the effect DHA 
has on astrocytes in vivo may be via an indirect mechanism and that were not be reproduced in vitro .  
Triggers of astrogliosis can be released by all CNS cell types, including microglia, oligodendrocytes, 
neurones, pericytes and endothelia cell of the BBB. These molecular mediators of astrogliosis include 
growth factors (e.g. TGFβ), cytokines (e.g. IL-6), Toll-like receptor ligands, glutamate, ATP and ROS 




6.5.2.1 DHA treatment and astrocyte numbers 
The day 10 post lesion observation that the DHA treated group had a decrease in the GFAP volume per 
cell coincides with the observation that at day 10 there was a decrease in the cell number in the distal -
ROI. There was a significantly lower number of astrocytes in the distal -ROI when compared to the 
lesion with vehicle group, or the lesion only group. The number of astrocytes at day 10 was simi lar to 
the control group. This data appears to suggest that DHA may be preventing astrocyte proliferation in 
these ROI, assuming that proliferation was the reason for the cell number increase seen in the lesion 
group. 
It is worth noting that the administration of DHA to the cultures was directly into the media and at the 
time of the lesion. The addition of DHA to the culture media could affect cell signalling as DHA can act 
as a ligand to retinoid X receptors (RXR) as well as acting on ion channels such as TREK-1 (de Urquiza et 
al., 2000, Wu et al., 2013, Begum et al., 2012). However, as DHA was only administered once,  it may 
have been oxidised or metabolised soon after administration without eliciting an effect. Given that the 
media of the cultures was changed every third day, we would presume that at 10 days post- lesion, i f  
degraded DHA is absent from the media. The DHA group at 1 day and 5 days post-lesion behaved 
similarly to the lesion only group in the number of cells present, whereas at 1 day it had the highest 
GFAP volume per cell. The data may show that the DHA had a delayed effect that was not seen until 
day 10, indicating a longer mechanism of action of DHA. This is not surprising since a single  bolus i .v.  
injection of DHA can induce neuroplasticity in an in vivo model of SCI (Liu et al., 2015). Another 
consideration is that the cells in the DHA group were not being protected from the lesion, but i n fact 
were dying or dead. In either case, further in vitro studies are required to elucidate the effect DHA is 
having on astrocytes.  
6.5.3 Limitations 
The many benefits of the 3D collagen cell culture system are detailed in the introduction of this 
chapter. The 3D system does have some limitations that are worth considering. Firstly, the tension 
created in the collagen gel at the boundaries of the system causes a high level of baseline reactive 
astrogliosis, similar to that seen in the 2D astrocyte cultures. Recording this baseline reactive 
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astrogliosis as an impact elicited response can be avoided by establishing the ROI far from the edge of  
the culture dish and by starting the z-stack analysis at 30 µm from the top of the gel, as was carried out 
in this study. 
The 3D gel culture system eradicates for the most part the baseline reactive astrogliosis which is 
present in 2D astrocyte cultures, but the 3D nature of the gels makes the imaging of these astrocytes 
difficult (East et al., 2009). A confocal microscope was used in this study for imaging these gels after 
fixation. As revealed by the cell count data, there is an increase in the number of astrocytes after 
impact at day 5 and day 10. Astrocyte migration could be a reason for this increase. Live cell imaging is 
a technique commonly used to monitor cell migration, however in 3D culture systems cells are able  to 
travel in multiple directions and therefore in and out of focus, making individual cells difficult to track.  
Limitations of GFAP staining are covered in the introduction and need to be considered when looking 
at the GFAP data from this study. GFAP immunolabelling does not label all of the branching and f iner 
processes, therefore the true extent of the ramification of the reactive astrocytes may not be visible in 
the images. 
The astrocytes in this culture came from the cortex of rat pups, so there may be potential differences 
between astrocytes derived from an immature versus an adult brain. However, the behaviour of  the 
astrocytes in these cultures has exhibited similarity with the astrocytic behaviour observed in the 
previous chapters in in vivo experiments performed in mice. The species difference may have 
interfered with the DHA experiment outcomes. Cortical astrocytes are only a subpopulation of the 
astrocytes from the brain and therefore only partially representative of the behaviour of the total 






In summary, this novel in vitro model of focal mechanical injury within a 3D astrocyte culture system is 
a viable model, with clear endpoints that reflect the in vivo reactive astrogliosis seen following TBI. 
This novel model can be used as an investigative tool for the analysis of reactive astrogl iosis and the 
screening of potential therapies targeted at astrocytes or the glial scar. 
 
6.5.5 Main outcomes 
• Astrocytes in lesioned gels had higher levels of GFAP volume per cell compared to control  
• Astrocytes in lesioned gels displayed a much more ramified morphology compared to control  
• In the lesioned gels there was an increase in astrocyte numbers on day 5 and day 10 post 
lesion compared to control non-lesioned cultures 





















7 General discussion 
Traumatic brain injury (TBI)  is one of the leading causes of death and disability worldwide, in 
particular in men aged below 50 year-old (Maas et al., 2008). TBI is a condition with substantial 
heterogeneity and can significantly impact upon a patient’s quality of life because of long -term motor, 
sensory and cognitive dysfunction. Currently there are no effective treatments for TBI,  and there i s a 
worldwide effort to understand better what can be improved in terms of diagnosis and of definition of  
relevant outcomes, through initiatives such as TRACK-TBI (Yue et al., 2013) and CENTRE-TBI (Maas et 
al., 2015). Although several experimental neuroprotective therapies have been taken to clinical trials, 
they have been unsuccessful. In this thesis, an animal model of TBI was optimised in mice, and then 
used to assess omega-3 PUFAs as a potential neuroprotective treatment. Omega-3 PUFAs (and in 
particular the long-chain DHA) are a class of compounds which have elicited much interest and 
research over the last decade in a variety of models of disease. Previous to the beginning of this work, 
data from our group and others, showed a clear therapeutic or prophylactic potential of DHA in 
traumatic injury in the PNS and CNS (for SCI) (King et al., 2006, Huang et al., 2007, Ward et al., 2010, 
Lim et al., 2013b, Lim et al., 2013a, Liu et al., 2015, Paterniti et al., 2014, Figueroa et al., 2012). The 
results reported in this thesis in a specific animal model of TBI , however, did not provide strong 
evidence to support omega-3 PUFAs as an effective treatment for TBI or protection against TBI. We 
will conclude this thesis with final comments on various issues raised by this work, in the general 
context of neurotrauma and neuroprotection. 
7.1 Modelling TBI in vivo 
The first results chapter of this thesis details the characterization and optimisation of a CCI injury in 
mice, with outcome measures that reflect the cognitive dysfunction and pathophysiological  changes 
seen in human TBI. The CCI injury caused severity-dependent deficits in the MWM test, gross brain 
tissue loss, and reactive astrogliosis and activated microglia within the injured brain. The main aim of  
the first chapter was to establish the parameters of the injury that would provide reproducible 
outcomes. A unilateral injury above the parietal lobe at the velocity of 3 m/s, dwell time of 100 ms, tip 
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diameter of 3 mm, set at 20o, with an impact depth of 2.2 mm, was finally chosen as an injury severe 
enough to cause behavioural deficits and histological changes, but not to lead to major behavioural 
disruption and impairment in mice. This injury paradigm was then used in the following chapters to 
investigate the efficacy of an acute single bolus DHA treatment and the neuroprotective potential of  
the fat-1 gene. 
The work in the model development chapter did reveal some interesting consequences of the CCI 
injury. Firstly, we noted the activation of glial cells on the contralateral side of the brain. Originally, the 
contralateral cortex was to be used as a control for the injured ipsilateral side. This phenomenon 
highlights the global impact a CCI injury has on the brain, despite the model being traditionally used to 
replicate a focal localized injury. This extended pathology has been reported in the stroke l i terature, 
i.e. increased reactive gliosis is observed on the contralateral side to the occlusion side (Patience et al., 
2015). While our studies were proceeding, a report was published by Niesman, showing 
neuroinflammatory responses both ipsilaterally and contralaterally after CCI in mice, at 7 days post-
injury, supporting the concept of a bilateral response to unilateral trauma. Furthermore, a 
contralateral response after injury in terms of tau pathology, has also been reported in the 3xTg model  
of Alzheimer’s disease (Tran et al., 2011, Niesman et al., 2014). In agreement, this phenomenon was 
also observed throughout the rest of the in vivo chapters in this thesis, regardless of treatment or 
genetic manipulation.  Possible explanations for this contralateral increase in glial cell activation were 
discussed in the first results chapter, which include: contralateral compression against the skull at the 
time of injury, chemotaxic signalling, migration of activated glial cells, or communication of damage to 
the contralateral side through interhemispheric functional connectivity of large brain networks  such as 
the cortico-cortical connections. This concept of global dysfunction seen in animals is supported by 
observations in humans after TBI, showing global network dysfunction (Sharp et al., 2014). 
Another finding from the first results chapter was the detrimental effect the sham injury had on mice, 
particularly on their performance in the MWM test. A sham injury control could be expected to have 
an outcome more comparable to a naïve control. However, due to the invasive nature of the sham 
injury in the case of an open skull model of TBI (craniotomy) , there were behavioural and 
272 
 
pathophysiological consequences. This observation suggests that comparison of CCI injured groups to 
naïve groups alone may confound results and their interpretation, especially in the earlier period after 
injury, as the pathology seen in the injured animals may be a cumulative result of both the negative  
consequences of the surgical sham-injury and the direct brain impact-linked injury. Therefore, in order 
to elucidate the effect a treatment has on the focal brain injury alone, CCI injured animals using an 
open-skull approach, should be whenever possible compared to a sham-operated group, especially for 
the analysis of the early events after injury. The importance of using a sham control in studies with the 
CCI model is reiterated in a paper published by Cole and colleagues (Cole et al., 2011). It is interesting 
to note that there is evidence that different mouse strains respond differently to sham surgery, with 
some strains (e.g. FVB/N and 129/SvEMS) presenting a persistent impairment in cognition induced by a 
sham operation (Fox et al, 1999). Interestingly, in this study the authors also show that somewhat 
paradoxically, the resilience to CCI in the FVB/N strain is higher than in 129/SvEMS or C57BL/6 mice. In 
all three of the in vivo chapters of this thesis, our CCI injury paradigm was robust enough to cause a 
deficit in learning and trigger secondary injury mechanisms, which was independent of the age of  the 
mice or their strain (CD1 and C57/BL6). The possible strain-dependent variation in the response to 
injury was mentioned above, and it has been documented in mice and also in rats  (Fox et al., 1999, Tan 
et al., 2009).  However, the use of this CCI model also revealed some of its limitations. Firstly, there 
was the extensive tissue loss at the site of the lesion. In time, the injury resulted most commonly in 
destruction of almost half of the ipsilateral hemisphere beneath the site of the injury and almost the 
entire ipsilateral hippocampus. This level of tissue loss is not comparable to the tissue pathology of 
human TBI patients, or at least those that survive the injury (Marklund and Hillered, 2011). Secondly, 
in our model we replaced the skull bone flap after the injury. Although we did not secure the bone flap 
in its place, this may not be sufficient enough to overcome the damaging effects from secondary brain 
swelling. The model is not reflecting well the surgical  decompressive craniectomy which is used in the 
clinic to reduce ICP in TBI patients (De Bonis et al., 2010). In conjunction with this, anaesthetics have 
been shown to confer neuroprotection, or in the case of the anaesthetic drug used in our studies, 
ketamine, can cause increased neuronal cell death in the hippocampus of rats following TBI (Statler et 
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al., 2006). However, since ketamine is provided in prehospital care as a safe and effective option, we 
tried to relate our animal model to the clinical setting (Porter, 2004). 
In addition to the limitations of the actual CCI surgery, the outcome measures used in  this study have 
their disadvantages. The MWM, despite it being commonplace in the TBI literature, has limitations, 
such as the sensitivity of the test to the surrounding environment (D'Hooge and De Deyn, 2001). 
Despite keeping the experimenter, testing room and extra maze cues consistent in all the studies, 
environmental factors (such as noise, olfactory cues and housing details), which are sometimes beyond 
the experimenter’s control, might have affected in some instances the performance of the mice in the 
MWM test – and affected differently the different groups. In our MWM protocol, the acquisition 
training was the most sensitive part of the protocol, since it could differentiate between the severities 
of the injuries, as shown in the first results chapter. However, in the probe trial, one of the two 
measures used to assess memory function was the number of visits to the platform zone. This measure 
may not have been robust enough to differentiate between test groups, due to the low frequency of  
visits to the zone. It is important to note that we chose a cognition test because of the importance of  
cognition and memory impairment after TBI, but this is only one of the possible choices; further 
studies could explore other equally relevant aspects, such as fatigue or depression, which could reflect 
for example damage to the pituitary (Zaben et al., 2013).  
7.2 Effect of DHA and of the fat-1 genotype in CCI 
In order to assess the effect of the injury severity, treatment with DHA or genotype on the outcome 
and secondary injury mechanisms following CCI injury, we measured behaviours and also chose to 
focus in the tissue on the amount of activation detected within the astrocytes and microglia cell 
populations, bilaterally. Data from previous SCI studies, whether injury was induced by hemisection or 
compression, carried in our group and others, showed that acute i.v. treatment with DHA or the 
presence of the fat-1 gene caused a significant reduction in the reactivity of these glial cell types 
(Paterniti et al., 2014, Lim et al., 2013a). The results we present in this thesis do not show such 
reduction after acute treatment with DHA in contusion TBI. One potential explanation may be due to 
274 
 
the timing of the examination of the tissue post-injury, as there are complex polyphasic temporal 
cellular changes which are linked to the neuroinflammatory response after CNS injury  (Bowes and Yip, 
2014). The brain tissues from the studies presented in this thesis on the model optimisation/severity 
variation and the DHA treatment were obtained at 28 days, and the tissue from the mice in the fat-1 
studies was obtained at 21 days post-injury. This means that the immunohistochemical data gathered 
in this thesis were from relatively delayed time points after injury (comparable though to the SCI time 
line examined previously). However, the general levels of activation in both astrocytes and microgl ia 
can vary at different time points following TBI, and the predominant microglial phenotype also 
changes at different time points post-TBI (Loane and Byrnes, 2010, Woodcock and Morganti-
Kossmann, 2013). Any relevant transient changes in glial cells at earlier time points post - injury were 
missed, as we focused on a late evaluation of the brain tissue. In particular, DHA treatment or the fat-1 
background may have influenced earlier events affecting the glial populations. Interestingly, in a 
recent study in our group using acute DHA after thoracic SCI induced by contusion, it was also noticed 
that there was a time-dependent response of microglia (analysed using the Iba1 marker): DHA 
increased the microglia response to injury by 7 days, but in the tissue collected 28 days after injury, 
there was no difference between control injured and DHA-treated animals (Dr Ping Yip, personal 
communication). Finally, in the months preceding submission of this thesis, our group completed 
another DHA study in this CCI model, at the same dose of DHA shown in this thesis, and examined the 
tissue both 7 days after injury and 28 days after injury, to have a better grasp of the time line of 
events. In this latter study, there was a very significant decrease in the Iba1 perilesional post-injury 
reactivity at 7 days, after treatment with DHA, but this effect was not seen any more at 28 days (Dr Orli 
Thau-Zuchman, personal communication), which confirms the observations in contusion SCI.  These 
time-dependent changes in the impact of DHA on the Iba1 positive cells were seen in paral le l with a 
significant improvement in sensorimotor neurological dysfunction after injury (as assessed by a 
modified neurological score), which was already significant by 7 days and maintained at 28 days. 
Therefore, it is difficult using this general marker for microglia/macrophages, to establish a simple 
correlation between neurological outcome and the microglia/macrophages detected in tissue. 
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Microglia are cells that actively reshape circuits in development and disease, and it is necessary to be 
able to differentiate the various subtypes (Wake et al., 2013). Future work using histological  markers 
for the different subtypes of microglia, and also markers which allow the assessment of the functional  
activity of the microglia (e.g. phagocytic activity), will help elucidate these post-injury changes. For 
example, in a recent PET imaging study in our group, using the 18-kDa translocator protein (TSPO) as a 
marker of activated microglia, we showed that acute DHA post-injury decreases the activation of  this 
specific microglia population, at 7 days post-SCI (Tremoleda et al., 2016). 
Concerning the astrocytes, in the model development chapter we showed that there was increased 
reactive astrogliosis with increasing injury severity, and this correlated with a poorer performance in 
the MWM. An amplified reactive astrogliosis was also seen in CCI injured mice after DHA treatment 
and in those possessing the fat-1 gene, compared to their respective control groups. However, the 
further increase in reactive astrogliosis seen in these latter mice did not correlate with poorer 
performance in the MWM. These results suggest that increased astrogliosis may not always  and 
necessarily correlate with decreased cognitive function. This is in direct conflict with the literature that 
suggests that the beneficial effects of omega-3 PUFAs are causally linked to a reduction in the glial 
inflammatory reaction (Zendedel et al., 2015, Orr et al., 2013). Astrogliosis has been associated with 
poor recovery in SCI, but in the context of injury in the brain, Harris  and colleagues, have shown that 
the reduction of the glial scar by administration of chondroitinase ABC, and the subsequent increase in 
peri-contusional axonal sprouting, do not lead to robust neurological improvement  (Harris et al., 
2010). However, our observations do suggest a link between DHA and reactive astrogliosis following a 
CCI injury. The nature of this link remains elusive. In a manner similar to what we saw in terms of 
microglia activation, it is likely that the astrocytic response evolves in a complex manner post-injury. At 
very early times after injury, the glial scar may limit the injury but then become a neutral by -stander or 
even play a beneficial role. Indeed, in the recent repeat study in our group on acute DHA treatment in 
CCI, which is mentioned above, it was seen that DHA reduced markedly the ipsilateral perilesional 
GFAP reactivity at 7 days – but this effect was no longer seen at 28 days (Dr Orli -Thau-Zuchman, 
personal communication).  Amplification of the astrocytic response contralaterally may have a positive 
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impact on the reported plasticity of the contralateral hemisphere after a focal TBI, which may lead to 
at least a partial recovery of function (Axelson et al., 2013). There is clear recognition of  the posi tive 
role of astrocytes in the active remodelling of synapses and consequent brain plasticity ( Jones et al . ,  
1996). Astrocytes have gradually emerged in the last decade as key regulators of behaviour (Oliveira et 
al., 2015), which confirms their important roles in the “tripartite synapse” (Perea et al., 2009). They are 
also the only brain cells capable of synthesizing DHA (Moore, 1993). Disruption of intracellular calcium 
signalling in astrocytes (Petravicz et al., 2014) or disruption of the “lactate shuttle” (which provides 
lactate formed through anaerobic glycolysis in astrocytes and delivered to neurons) (Newman et al . ,  
2011) can lead to significant spatial memory disruption. The ablation of astrocytes in the prefrontal 
cortex leads to significant cognitive impairment (Lima et al., 2014), while the engraftment of larger, 
human astrocytes into the murine hippocampus, enhances hippocampal LTP and hippocampal -
dependent learning (Han et al., 2013). Interestingly, in contrast with a tendency to amplify astrogliosis, 
no amplification of the strong neurogenesis seen post-CCI was detected at 28 days after treatment 
with DHA, as reflected through use of a marker of immature neurones. 
Due to the complexity of the secondary injury mechanisms following TBI, characterizing in detail a l ink 
between omega-3 PUFAs and reactive astrogliosis in vivo could be difficult. In order to simplify this 
investigation, a novel in vitro model of reactive astrogliosis in a 3D culture was developed. 
7.3 In vitro model of TBI 
Our novel in vitro model of TBI was able to reproduce reactive astrogliosis and even a “glial scar” 
formation using only a single mechanical insult, within a 3D culture of astrocytes. The main benefits of  
a 3D culture system are described in the introduction of the final results chapter. Astrocytes are highly 
reactive and in a 2D culture system they exhibit an increased baseline level of GFAP expression, due to 
the stress of being restricted to growing in only one plane (East et al., 2009). In contrast, astrocytes in 
a 3D cell culture system exhibit much lower levels of GFAP and a reduced ramified morphology, 
therefore reflecting the unreactive astrocytes seen in normal uninjured brain tissue (East et al., 2009) . 
To replicate the CCI injury in an in vitro model, after we optimized the in vivo model in mice, the same 
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impactor used to create the lesion in vivo was also used to create a focal mechanical lesion  in the 3D 
cell culture. The 3D structure of the culture system was more similar to brain tissue architecture than a 
2D system, and allowed for mechanical destruction by impaction. At the start of this work we were 
uncertain as to whether a mechanical insult would elicit reactive astrogliosis in astrocytes in cul ture. 
Reactive astrogliosis has been elicited in in vitro models through hypoglycaemia, hypoxia, or 
inflammation - through the introduction of lipopolysaccharide (LPS)(East et al., 2009). Surprisingly, our 
in vitro impaction model not only elicited reactive astrogliosis at the site of the lesion, but also distal to 
the lesion site. The reactive astrogliosis increased over the time course of the study. One of  the most 
exciting observations following the injury was the appearance of a glial scar-like structure at the edge 
of the lesion. The development of this model allowed us to investigate the direct effect DHA had on 
astrocytes following an injury. In this study, the DHA-treated cultures did not have a significantly 
different response post-impact compared to injured vehicle-treated cultures. Therefore, it was not 
possible to further study the correlation between DHA and the modulation of increased reactive 
astrogliosis post-CCI. One possible explanation for the lack of significant effect may be l inked to the 
DHA concentration used or the protocol of administration. DHA used at a higher concentration (10 
µM) has been shown in acute experiments to inhibit the endoplasmic reticulum stress response and 
subsequent cell death in a 2D astrocyte culture submitted to oxygen-glucose deprivation ( i schaemia 
model) (Begum et al., 2012). The authors also showed that a similar protective effect was obtained 
with a metabolite of DHA which was an isomer of neuroprotectin D1. Interestingly, DHA has also been 
shown to increase the gap junction coupling in astrocytes and also decrease aspartate uptake 
(Champeil-Potokar et al., 2006, Grintal et al., 2009).  
An obvious question that arises from this in vitro data is whether the increase in astrocyte number in 
the lesioned gels is due to migration of astrocytes from distal regions or proliferation of the astrocytes 
at the site of the lesion. The data from the in vivo studies shows increased reactive astrogliosis on the 
contralateral side 4 weeks after injury. Utilizing this novel in vitro model and labelling the astrocytes 
for proliferation markers or by employing time lapse microscopy, will allow in future to better 
characterize the mechanisms underlying the response of astrocytes to injury. The exact composition of 
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the scar formation, and its similarities with the scar formed in vivo – in particular enrichment in axon-
inhibiting chondroitin sulfate proteoglycans such as NG2 (Chen et al., 2002), also remains to be 
determined. 
This 3D astrocyte model could also be used in combination with other CNS cell types such as neurones, 
microglia and oligodendrocytes, to see how the focal mechanical injury affects mixed cultures.  
 
7.4 Omega-3 PUFAs and their potential in the treatment of TBI 
Several therapies have shown promise in animal models in terms of neuroprotection in TBI. However, 
no treatment has been successfully translated into the clinic. Therefore, there is a significant 
translational block in the development of new neuroprotective treatments in TBI. Despite using a 
similar dosing regimen of DHA to the regimen that conferred neuroprotection in models of SCI and 
employing the fat-1 transgenic mice as an investigative tool, the data in this thesis did not point 
towards omega-3 PUFAs being a viable neuroprotective treatment for TBI – at least for the type of 
injury and mode of administration considered.  
Evidence has accumulated which allows us to compare the data reported so far with DHA in three 
models of acute injury to the CNS: SCI, TBI and stroke, which have strong similarities in the  
pathophysiology of secondary injury. While our group has carried out numerous studies in models of  
SCI, where we have shown the significant neuroprotective potential of DHA, the group led by Bazan 
has published extensive data supporting the neuroprotective potential of acute single administration 
of DHA in stroke models, in adult or aged rats (Belayev et al., 2005, Belayev et al., 2009, Eady et al., 
2012b). In these various studies, the i.v. fatty acid bolus was ei ther administered at the onset of 
reperfusion or up to 3 h post-ischaemia onset. Interestingly, in one of their studies, the authors 
showed an increased astrocyte density in the lesioned hemisphere at 7 days compared to controls 
(Eady et al., 2012a). In a subsequent study, in which the authors used a formulation of DHA bound to 
albumin, the post-injury administration time window was extended up to 7 h post-ischaemia (Eady et 
al., 2012b). However, in this study as in previous studies, the neurological score improvement was only 
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monitored in the first 7 days, raising the question whether the improvement was long-lasting. Albumin 
has the potential to mobilize PUFAs and facilitates the delivery of DHA to the injured brain tissue  
(Rodriguez de Turco et al., 2002). It is interesting to note that in their most recent studies this group 
show that while the sensorimotor improvement induced by DHA post-ischaemia can still be  seen at 3 
weeks after injury, the cognitive improvement is transient and lost by 3 weeks (Hong et al., 2014). The 
group led by Bazan have suggested that the improvement seen after a bolus of DHA in stroke models is 
due to the formation of the metabolite neuroprotectin D1 (Mukherjee et al., 2007, Bazan, 2005, Eady 
et al., 2012a). However, it cannot be ruled out that other metabolites of DHA – and there is a wide 
array of possibilities of such pro-resolving and potentially protective mediators (Serhan and Chiang, 
2008), could also play a role in the observed effect; thus, Harrison and colleagues, have shown that an 
aspirin-triggered epimer of neuroprotectin D1 (Harrison et al., 2015), AT-resolvin D1, reduced motor 
and cognitive deficit (Rotarod and novel  object recognition test) at 7 days after a fluid percussion 
injury in mice; it is important to note though that the administration of the resolvin was initiated 
before the injury and continued daily during the 7 days post-TBI. Under these conditions, AT-resolvin 
D1 had not effect on microglial immunoreactivity post-injury. 
The neuroprotective effect of an intraperitoneal administration of the long chain omega-3 PUFAs in 
models of neonate hypoxia-ischaemia was first reported by Williams, using the post-natal P10 mouse 
Rice-Vannucci model of hypoxia-ischaemia, with a time window for efficacy of 2 h post-ischaemia; the 
authors reported that this protective effect was seen after a DHA-containing emulsion and not EPA 
emulsion (Williams et al., 2013). In a very recent follow-up study, the group showed that 8 weeks after 
the intraperitoneal administration of a DHA-emulsion, first immediately after injury, and then a 
repeated injection at 1 h, the animals had a tendency to show better learning in the MWM and also a 
partially improved performance in the memory trial, in parallel with a reduced tissue loss 
(Mayurasakorn et al., 2016). Overall, all these observations suggest that there may be some potential  
for DHA administration in stroke/hypoxia-ischaemia, in the adult, aged and also immature brain. 
Concerning the prophylactic potential of omega-3 PUFAs: the data reported by Desai and col leagues, 
suggest that deficiency in the PUFAs can worsen outcome, but to this date, no clear indication has 
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emerged that DHA has a significant long-lasting efficacy in TBI (Desai et al., 2014). While this 
dissertation was completed, Shi and colleagues published data which showed that the fat-1 cortical 
neurones in culture had a better response to the stress of oxygen-glucose deprivation and that pre-
treatment of cultures from wild-type animals with DHA, also improves resilience in this model  (Shi et 
al., 2015). Furthermore, in the same study, the authors induced very limited focal cortical ischaemia 
and reported protection of the tissue and improved sensorimotor outcome 2 weeks post-injury in fat-1 
mice. Very recently, the authors showed in a model of more extensive damage, induced by transient 
middle cerebral artery occlusion in mice, that only a combination of intraperitoneal injections of  DHA 
and sustained oral supplementation, leads to significant tissue protection, increased angiogenesis and 
improved spatial memory in the MWM (Pu et al., 2016). 
 
7.5 Conclusion  
To date, there has been much promise raised by positive experimental observations using DHA or i ts 
metabolites and striking improvement reported on a single TBI case history basis, after treatment with 
very large doses of omega-3 PUFAs added to enteral feeding (Lewis et al., 2013). However, much more 
research work is necessary to establish whether significant and sustained efficacy can be induced by 
treatment with this type of compound post-TBI. Although there is some indication in the literature of  
secondary injury TBI mechanisms which could be alleviated by omega-3 PUFAs, it is still not clear which 
critical cellular targets, i.e. specific receptors, are the key drivers of the effects observed, and whether 
DHA would act more as a parent drug (therefore the efficacy is linked to specific metabolites) or as the 
intrinsic active compound. Furthermore, there is a need to try more varied regimes of admini stration 
(e.g. time window, duration and dose) which remain clinically relevant, and explore the long-term 
outcome, in several models of TBI. Considering that omega-3 PUFAs have a major potential to 
contribute to the resolution of persistent inflammation post-trauma, it will be important to design 
studies to understand better the impact of the treatment with these compounds on the systemic 
response to injury, e.g. the changes in the immune system which occur after trauma in general and TBI 
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in particular, and which are also long-lasting (Schwulst et al., 2013, Hazeldine et al., 2015). Finally, 
there is also much promise in the concept of using omega-3 PUFA in combination with rehabil itation 






















Appendix  1.1 - The average swim speed during the MWM probe trial for the young and 
aged fat-1 mice 
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